

Synthesis and pharmacological characterization of conformationally restricted retigabine analogues as novel neuronal Kv7 channels activators

Carmine Ostacolo, Francesco Miceli, Veronica Di Sarno, Piera Nappi, Nunzio Iraci, Maria Virginia Soldovieri, Tania Ciaglia, Paolo Ambrosino, Vincenzo Vestuto, Anna Lauritano, Simona Musella, Giacomo Pepe, Manuela Giovanna Basilicata, Michele Manfra, Diego Romano Perinelli, Ettore Novellino, Alessia Bertamino, Isabel M. Gomez-Monterrey, Pietro Campiglia, and Maurizio Tagliatalata
J. Med. Chem., **Just Accepted Manuscript** • DOI: 10.1021/acs.jmedchem.9b00796 • Publication Date (Web): 09 Dec 2019

Downloaded from pubs.acs.org on December 16, 2019

Just Accepted

“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

Synthesis and pharmacological characterization of conformationally restricted retigabine analogues as novel neuronal Kv7 channels activators

Carminé Ostacolo,^{†,‡} Francesco Miceli^{¶,‡}, Veronica Di Sarno^{‡,‡}, Piera Nappi[¶], Nunzio Iraci[‡], Maria Virginia Soldovieri[§], Tania Ciaglia[‡], Paolo Ambrosino[¥], Vincenzo Vestuto[‡], Anna Lauritano[¶], Simona Musella[⊥], Giacomo Pepe[‡], Manuela G. Basilicata[‡], Michele Manfra[□], Diego Romano Perinelli[□], Ettore Novellino[‡], Alessia Bertamino[‡], Isabel M. Gomez-Monterrey[‡], Pietro Campiglia^{‡,}, Maurizio Tagliatela^{¶,*}.*

[†] Department of Pharmacy, University Federico II of Naples, Via D. Montesano 49, 80131, Naples, Italy

[¶] Department of Neuroscience, Reproductive Sciences and Dentistry, University Federico II of Naples, Via Pansini, 5, 80131, Naples, Italy

[‡] Department of Pharmacy, University of Salerno, Via G. Paolo II 132, 84084, Fisciano, Salerno, Italy

[§] Department of Medicine and Health Science V. Tiberio, University of Molise, Via F. de Sanctis, 86100, Campobasso, Italy

[¥] Department of Science and Technology (DST), University of Sannio, Via Port'Arsa 11, 82100, Benevento Italy;

[□] Department of Science, University of Basilicata, Via dell'Ateneo Lucano 10, 85100 Potenza, Italy

[□] School of Pharmacy, University of Camerino, Via Gentile III da Varano, 62032, Camerino (MC), Italy

[⊥] European Biomedical Research Center (EBRIS), Via Salvatore de Renzi, 3, 84125 Salerno (SA), Italy

ABSTRACT

Kv7 K⁺ channels represent an attractive pharmacological targets for the treatment of different neurological disorders, including epilepsy. In this paper, 42 conformationally restricted analogues of the prototypical Kv7 activator retigabine have been synthesized and tested by electrophysiological patch-clamp experiments as Kv7 agonists. When compared to retigabine (0.93±0.43 μM), the EC₅₀s for Kv7.2 current enhancements by compound **23a** (0.08±0.04 μM) was lower, whereas no change in potency was observed for **24a** (0.63±0.07 μM). In addition, compared to retigabine, **23a** and **24a** showed also higher potency in activating heteromeric Kv7.2/Kv7.3 and homomeric Kv7.4 channels. Molecular modeling studies provided new insights into the chemical features required for optimal interaction at the binding site. Stability studies evidenced improved chemical stability of **23a** and **24a** in comparison with retigabine. Overall, the present results highlight that the N5-alkylamidoindole moiety provides a suitable pharmacophoric scaffold for the design of chemically-stable, highly-potent and selective Kv7 agonists.

INTRODUCTION

Epilepsy is one of the most common neurological disorders affecting approximately 1% of the worldwide population. Although several classes of antiepileptic drugs are available for clinical use, about one third of patients do not benefit from currently-available medications; thus, drugs with novel mechanisms of actions might significantly reduce this figure.¹

The K_v7 (KCNQ) subfamily of K⁺ channels comprises five members, each showing a distinct tissue distribution and physiological roles.² K_v7.2 and K_v7.3 are the most abundant K_v7 subunits in the central and peripheral nervous system; heteromeric channels composed of K_v7.2 and K_v7.3 subunits are thought to underlie a K⁺ current, named M-current (I_{KM}), whose activation reduces neuronal excitability by driving the membrane potential to values close to the equilibrium potential for K⁺ ions, thus limiting repetitive firing and causing spike frequency adaptation. The critical role exerted by I_{KM} in controlling neuronal excitability is also highlighted by the observation that mutations in the genes encoding for K_v7.2 and K_v7.3 are responsible for a wide spectrum of epileptic diseases ranging from Benign Familial Neonatal Seizures to severe epileptic encephalopathies, and that drugs acting as Kv7 activators are potent anticonvulsants in humans.³ Retigabine is the proptotype Kv7 activator, recognizing a hydrophobic pocket located in the pore domain;⁴ within this cavity, H-bond interactions are established between the carbamate group of retigabine and a tryptophan residue in the channel pore (W236 in Kv7.2, W265 in Kv7.3).⁵ Retigabine has been approved as an add-on treatment for drug-resistant partial onset seizures with or without secondary generalisation in people aged 18 or older, and has been on the market since 2011; however, because of a low benefit/risk ratio, clinical use of retigabine has been declining over the years, leading to its discontinuation in 2017. Several drawbacks are likely responsible for the limited clinical efficacy of retigabine which can be summarized as follows: a. Poor selectivity for Kv7 subtypes. Indeed, activation of Kv7.4/5 channels expressed in genitourinary smooth muscle cells seems responsible for one of the most frequently-reported side effect, namely urinary retention; b. Short half-life. Retigabine is metabolized by phase-II enzymes (acetylation and N-glucuronidation), with little involvement of the cytochrome P450

1
2
3 system. Consequently, retigabine has fast clearance kinetics ($t_{1/2} \sim 6-8$ hours), and requires three-
4 times-a-day dosing;⁶ c. Poor brain penetration. Because of its limited lipophilicity (Log P= 3.08), the
5 brain-plasma concentration ratio of retigabine is rather low, thus requiring posological schemes at
6 relatively high doses;⁷ d. Chemical instability. One of the main clinical concern over retigabine is its
7 tendency to cause retinal and muco-cutaneous blue-gray discoloration;⁸ although the mechanism for
8 this toxic effects remains poorly understood, one hypothesis is that light exposure may cause
9 photodegradation and oxidation of retigabine's aniline ring, which may lead to dimer formation,
10 partly in conjunction with melanin, which would be responsible for the abnormal pigmentation light-
11 exposed tissues.⁹ To possibly overcome some of these limitations, we have designed and synthesized
12 a small library of 42 novel conformationally-restricted retigabine derivatives, and characterized some
13 of these compounds with respect to: potency, selectivity, chemical stability, and in vitro
14 pharmacokinetics. In addition, molecular modeling studies were performed to identify the chemical
15 features required for optimal interaction between the syntetized compounds and Kv7 channels.
16 Noteworthy, in view of the previously-mentioned removal from the market of retigabine, and of the
17 even more recent withdrawal of the marketing authorization for flupirtine, the precursor of retigabine
18 used as a non-opioid analgesic, several naturally-occurring or synthetic small molecules with
19 heterogeneous chemical scaffolds acting as Kv7 activators have been recently described.¹⁰ In
20 particular molecules bearing indoline and indole scaffolds and acting as Kv7 activators have been
21 previously described in a patent by Valeant Pharmaceuticals;¹¹ nonetheless, a comprehensive
22 description of their structure-activity relationships and a detailed pharmacological characterization of
23 these molecules in terms of pharmacodynamics, metabolism and photostability is lacking.
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

RESULT AND DISCUSSION

Design and Chemistry

A new library of structural analogues of the Kv7 agonist retigabine was synthesized introducing a conformational restriction of retigabine (**I**) scaffold aimed at increasing the potency and the metabolic and photochemical stability by blocking the labile 4-NH₂ and removing the 2-NH₂ of benzene-1,2,4-triamine scaffold.¹² By this strategy, indoline (**A**), indole (**B**) and tetrahydronaphthalene (**C**) derivatives were designed and synthesized (Figure 1). Moreover, the designed structures allow extensive and chemically accessible modifications to investigate structure-activity relationships. The indoline derivatives (series **A**, Figure 1) were designed maintaining the substituted benzyl group at the N-1 position while varying the nature of both the R1 chain and the linker X on the amino group at position C-5. At this position, we have chosen a series of linker groups characterized by different electrostatic potential, electron density distribution, and N-X rotation energy profiles, such as amide, sulphonamide, urea, thiourea and guanidine, which could mimic the retigabine pattern HB acceptor-HB donor-aromatic ring (Figure S1 and Table S1).





Figure 1. Structures of retigabine and its newly synthesized analogues


The first series of indoline analogues was synthesized according to the following scheme 1.

Scheme 1: Synthesis of 1-(4-fluorobenzyl)-5-substituted indoline derivatives **4a-b**, **5a-b**, **6**, **7**, **8a-i** and **9a-c**.




Starting from 5-nitroindoline (**1**) a reductive amination at the N-1 led to the corresponding 1-(4-fluorobenzyl)-5-nitroindoline (**2**) that, upon continuous flow hydrogenation to the corresponding amine (**3**), was used in the next steps. Reaction of **3** with ethyl or menthyl chloroformate in alkaline media gave the corresponding carbamate derivatives **4a** and **4b**. Urea derivatives **5a** and **5b** were prepared by one-pot reaction of **3** with triphosgene and 2,2-dimethylpropan-1-amine or cyclohexylamine, using DIPEA as base. On the other hand, treatment of **3** with CS₂ and 2,2-dimethylpropan-1-amine using TEA as base lead to the thiourea analogue of **5a** 1-(1-(4-fluorobenzyl)indolin-5-yl)-3-neopentylthiourea (**6**). Derivative **6** was converted to the corresponding carbodiimide by reaction with HgO and then reacted with NH₄OH to give the guanidine derivative **7**. Finally, coupling of intermediate **3** with different sulfonyl chlorides at the presence of DBU led to the sulfonamide derivatives **8a-i**, while coupling with acyl chlorides using DIPEA as base led to the amide derivatives **9a-c**. A second series of indoline analogues, investigating the influence of N-1 substituents on the pharmacological activity, was synthesized according to schemes 2 and 3.

Scheme 2: Synthesis of 1-benzyl-5-cyclohexanesulfonamido indoline derivatives **13a-g**.




5-nitroindoline (**1**) or 2-methyl-5-nitroindoline (**10**) were derivatized by reductive amination using differently functionalized aldehydes, giving intermediates **11a-f**. Continuous flow hydrogenation of these intermediates led to the amines **12a-f** that were converted to the corresponding cyclohexylsulfonamides (**13a-f**). Due to the lability of the 4-bromo-2-nitrobenzyl group to the hydrogenation conditions, final product **13g** was obtained using a different synthetic approach. The N-1 position of 5-nitroindoline (**1**) was protected as tert-butoxycarbonyl derivative obtaining the intermediate tert-butyl 5-nitroindoline-1-carboxylate (**10b**). The nitro group of compound **10b** was reduced to the corresponding amine (**11g**) and coupled with cyclohexane sulfonyl chloride, as previously described, before removal of the Boc protecting group by trifluoroacetic acid (TFA). The intermediate **12g**, thus obtained, underwent to reductive amination using 4-bromo-2-nitrobenzaldehyde. Functionalization of the N-1 was also attained by reaction of **1** with 4-chlorobenzoyl chlorides, 2-(4-chlorophenyl)acetyl chloride and 1-(2-bromoethyl)-4-fluorobenzene to give intermediates **14a-b** and **17** (Scheme 3). These intermediates were reduced by continuous flow hydrogenation and converted to the corresponding sulfonamides **16a-b** and **19** by coupling with cyclohexanesulfonyl chloride (scheme 3).

Scheme 3: Synthesis of 1-acyl-5-cyclohexanesulfonamido (**16a-b**) and 1-alkyl-5-cyclohexanesulfonamido (**19**) indoline derivatives.




Indole analogues (**B**, figure 1) were synthesized according to scheme 4. Intermediate **20b** was obtained starting from 4-hydroxybenzaldehyde, that reacted with methoxymethyl chloride (MOMCl) to give 4-(methoxymethoxy)benzaldehyde (**19a**). The protected aldehydes was reduced to the corresponding alcohol (**20a**) using NaBH₄ and then subjected to iodination affording 1-(iodomethyl)-4-(methoxymethoxy)benzene (**20b**). Nucleophilic displacements of **20** or commercially available 4-substituted benzyl halides by 5-nitroindole in strong basic medium provided the nitro intermediates **21a-d**, which were reduced to the corresponding substituted amino indole derivatives **22a-d**, as previously described. Coupling of these intermediates with acyl chlorides afforded the final alkyl amide derivatives **23a-b**, **24a** and **25a**. Removal of the methoxymethyl group from derivative **23b** by TFA led to **24b**. On the other hand, reaction of amine intermediates **22a-d** with cyclohexanesulfonylchloride gave final sulfonamides **23c**, **23d** and **26a**, while reaction with 2-cyclohexylethane-1-sulfonyl chloride (**20d**) led to the sulfonamide derivative **27a**. For the synthesis of **28a**, intermediate **22a** was reacted with chloroacetyl chloride and then subjected to nucleophilic displacement by n-butylamine. Alkylation of the secondary amine on the side chain by reductive amination with formaldehyde gave final product **29a**.

Scheme 4: Synthesis of 1-benzyl-5-amido (**23a-25a**, **23b-24b**, **28a-29a**) and 1-benzyl-5-cyclohexanesulfonamido (**23c-23d**, **26a-27a**) indole derivatives.



Tetrahydronaphthalene analogues (**C**, figure 1) were synthesized as depicted in scheme 5. Reaction of **30** with heptanoyl chloride and DIPEA, gave the amide intermediate **31**, which was reduced to the tetrahydronaphthol derivative **32** using NaBH₄ as reducing agent. Intermediate **32** was subjected to a modified Wittig reaction by formation of the corresponding phosphonium salt, followed by reaction with 4-(trifluoromethyl)benzaldehyde, giving the geometric isomers **33a** and **33b**.¹³ Saturation of the double bond in **33a** and/or **33b** using ammonium formate and Pd/C as catalyst gave final compound **34** as racemic mixture.

Scheme 5: Synthesis of (R,S)-N-(5-(4-(trifluoromethyl)benzyl)-5,6,7,8-tetrahydronaphthalen-2-yl)heptanamide (**34**).



Effects of the retigabine derivatives on Kv7.2 channels expressed in CHO mammalian cells.

To assess the effects of these novel retigabine derivatives on Kv7.2 currents, and to identify compounds more active than retigabine we performed whole-cell patch-clamp electrophysiological experiments in mammalian CHO cells transiently transfected with Kv7.2 cDNA. The effect of the synthesized compounds was investigated at a single concentration (10 μ M), using a ramp protocol in which Kv7.2 currents were activated by a 3-second voltage ramps from -80 to +20 mV. We used 10 μ M of each compound given that this concentration exerts maximal efficacy in the case of retigabine, the comparator drug (see below). Moreover, most drug screening efforts performed in search of novel Kv7 modulators use a 10 μ M compound concentration.¹⁴

Ramp-evoked currents were analysed by measuring the currents at -40 mV (a membrane potential value close to the activation threshold) and at 0 mV (a membrane potential value at which Kv7.2 conductance is almost completely saturated), and the effect of each compound was expressed as the ratio between current amplitude in the presence (A_2 , B_2 , I_{drug}) and absence (A_1 , B_1 , I_{CTL}) of the drug at these two membrane voltages (Figure 2 a-b, Table S2). Measuring drug effects at both -40 mV and 0 mV membrane potential values allowed to formulate distinct predictions on the potential effects of these compounds. In fact, the reference compound retigabine is described as a Kv7 activator because it exerts two main effects on Kv7.2 channel function: one is a leftward shift in the activation gating, the other being an increase in the maximal current at more depolarized potentials where conductance is saturated. Therefore, drug-induced current enhancement at -40 mV, a membrane potential value close to the current activation threshold, is likely to result in membrane hyperpolarization and

inhibition of action potential firing. On the other hand, drug-induced current enhancement at 0 mV, may reduce sustained neuronal depolarization during trains of action potentials and cause spike frequency adaptation. Therefore, measurements performed at both membrane potential values are likely to predict different profiles of mechanism of actions of a Kv7 activator. Using this method, drugs showing $I_{\text{drug}}/I_{\text{CTL}} > 1$ are considered as enhancers, drugs whose $I_{\text{drug}}/I_{\text{CTL}}$ is < 1 are blockers and drugs whose $I_{\text{drug}}/I_{\text{CTL}}$ is $= 1$ are considered ineffective.




Figure 2. Effect of synthesized compounds on Kv7.2 current in comparison with retigabine. a-b. Representation of the ratio between current amplitude in the presence (A_2 , B_2) and absence (A_1 , B_1) of each of the indicated compounds ($10 \mu\text{M}$) calculated at 0 mV (a) and at -40 mV (b). The inset shows the protocol used to evaluate drug activity on Kv7.2 currents. Current scale, 400 pA; time scale, 0.2 s. Histograms are colored according to the following scheme: blue represents available Kv7 activators, such as retigabine (RET) at 1 and $10 \mu\text{M}$, Flupirtine (FLU) at $10 \mu\text{M}$, and ICA27243 (ICA43) at $10 \mu\text{M}$; red represents indoline derivatives, yellow represents indole derivatives and green represents tetrahydronaphthalene derivatives. Each data point is expressed as the mean \pm standard error of the mean (SEM) of at least 3 cells recorded in at least 2 independent transfections; the precise number of cells included in the analysis for each compound is specified in Table S2. * indicates values significantly different ($p < 0.05$) from retigabine ($10 \mu\text{M}$).

The effect of each newly synthesized compounds was compared to that of retigabine.¹⁵ In this cellular assay, retigabine showed a ratio $I_{\text{drug}}/I_{\text{CTL}}$ at -40 mV of about 6, whereas at 0 mV the $I_{\text{drug}}/I_{\text{CTL}}$ ratio

1
2
3 was about 2 (Figure 2, a-b), suggesting that retigabine is more active at negative potentials than
4 positive potentials, as previously described.^{15,16} In order to further validate our screening assay we
5 also evaluated the effects of a lower concentration (1 μ M) of retigabine, as well as those of two
6 additional Kv7 activators, namely flupirtine (FLU) and ICA-27243 (ICA43), two compounds
7 showing lower and higher activity, respectively, than retigabine on Kv7.2 channels when the three
8 compounds were compared at the 10 μ M concentration.¹⁷ The results obtained suggest that our
9 screening assay is able to discriminate compounds with different activity on Kv7.2 currents, both at
10 -40 mV and 0 mV (Figure 2).

11
12 Of the 42 compounds tested at the single concentration of 10 μ M, seven (**8a**, **13a**, **13d**, **13g**, **23a**, **23c**,
13 and **24a**) were able to increase Kv7.2 currents more than retigabine ($p < 0.05$) at 0 mV; among these,
14 only two (**23a** and **24a**) also increased Kv7.2 currents more than retigabine at -40 mV ($p < 0.05$)
15 (Figure 2 A-B). Given that activity at both -40 mV and 0 mV is predictive of a wider spectrum of
16 pharmacological effects on neuronal excitability needed for novel anticonvulsant/analgesic
17 compounds acting as Kv7 activators, **23a** and **24a** were selected for further analysis.

18
19 To compare the kinetics of onset and offset of the Kv7.2-activating effects and the potency of the two
20 most active compounds **23a** and **24a** with those of retigabine, time-course experiments at increasing
21 drug concentrations (0.01-10 μ M) were performed. As shown in figure 3a and 3b, retigabine dose-
22 dependently increased Kv7.2 currents with a fast ON kinetics; indeed, upon application of 10 μ M of
23 retigabine with a fast solution exchange apparatus, maximal steady-state levels were achieved in about
24 10 seconds. Similarly, currents returned to basal values after about 10 seconds upon retigabine
25 removal from the bath. By contrast, the kinetics of onset and offset of both **23a** and **24a** appeared
26 significantly slower. In particular, upon exposure to 10 μ M **23a**, more than 200 seconds were needed
27 to reach maximal steady-state current levels; little (if any) current recovery was observed upon 10
28 μ M **23a** removal from the perfusion solution for at least 200 seconds. Similar, although slightly faster
29 onset and recovery kinetics were observed upon exposure and removal, respectively, of 10 μ M **24a**.
30 It seems likely that the slower wash-in and wash-out kinetics shown by **23a** and **24a** when compared

1
2
3 to retigabine may be ascribed to the enhanced hydrophobicity of both newly-synthesized compounds,
4 whose logPs were 6.83 and 5.58, respectively, both values significantly higher than that of retigabine
5 (logP of 3.08). Given the higher hydrophobicity of **23a** and **24a** when compared to that of retigabine,
6
7 the self-aggregating propensity of all three compounds was further evaluated using pyrene
8
9 fluorescence spectroscopy measurements.¹⁸ The results obtained, shown in Figure S2, revealed that
10
11 the ratio of the pyrene fluorescence intensity peaks at λ 372 nm (I) and λ 383 nm (III) for **23a** and **24a**
12
13 decreased as a function of drug concentration (1-100 μ M), indicating an increase of hydrophobicity
14
15 in the microenvironment sensed by the probe; these data are consistent with the hypothesis that **23a**
16
17 and **24a** show the typical behaviour of amphiphilic self-assembling molecules forming
18
19 supramolecular aggregates (micelles) in the nanometric range. By contrast, no change in the pyrene
20
21 I/III fluorescence ratio was observed in the presence of retigabine. These findings suggest that the
22
23 slow ON/OFF kinetics of compounds **23a** and **24a** (with the respect to those of retigabine) may
24
25 correlate with their increased hydrophobicity. Although we don't know yet whether this physico-
26
27 chemical property translates into significant changes in distribution and metabolism in vivo, and
28
29 whether it represents a potential hurdle for in vivo application, it should be mentioned that one of the
30
31 major limitation of retigabine is its rather poor brain penetration and short half-life, requiring 3 times-
32
33 a-day administration.⁷ Both these pharmacokinetic drawbacks might be improved by the increased
34
35 hydrophobicity shown by **23a** and **24a**.
36
37

38
39 The EC₅₀s of **23a** and **24a** on Kv7.2 current activation (calculated as described in the Methods section
40
41 and depicted in Fig. 3C) showed that **23a** was about 12 times more potent than retigabine, while no
42
43 statistically-significant difference was observed between retigabine and **24a** (Figure 3D).
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 3. Effect of retigabine, 23a and 24a on ramp-evoked Kv7.2 current. **a.** Representative whole-cell current traces from Kv7.2 channels activated by the indicated ramp protocol recorded in control conditions and upon exposure to 0.01-10 μM retigabine (RET), **23a** and **24a**. **b.** Time courses of Kv7.2 current potentiation by retigabine (RET), **23a** and **24a**. The steady-state amplitudes of the peak currents at -40 mV were plotted as a function of time. The bars on top of the plot indicate the duration of drug application. Current scale, 200 pA; time scale, 0.2 s. **c.** Protocol used to calculate ΔV ($V_2 - V_1$) at 20% of current peak value for controls (V_1) and after RET exposure (V_2). **d.** Dose-response curve for RET-, **23a**-, and **24a**-induced ΔV shift.

The voltage ramp-protocol used in the previously-described experiments did not allow us to precisely define the effect of the drugs on the steady-state properties of the Kv7.2 current; therefore, in the next experiments, we compared the effect of 0.03 μM retigabine and **23a** on Kv7.2 channels activated by constant voltage pulses (Figure 4 a-b). While 0.03 μM retigabine failed to enhance maximal Kv7.2 currents and to modify their voltage-dependence, the same concentration of **23a** doubled Kv7.2 maximal conductance (Figure 4c) and caused a leftward shift of about 18 mV in the half-activation voltage ($V_{1/2}$) of Kv7.2 currents (Figure 4); in fact, the $V_{1/2}$ values were -20.1 ± 1.2 mV, -24.4 ± 1.8 mV and -38.2 ± 2.0 mV for control (Ctl), 0.03 μM RET, and 0.03 μM **23a**, respectively (Figure 4d).




Figure 4. Effect of retigabine and **23a on Kv7.2 currents activated by constant voltage pulses.** a-b. Representative macroscopic current traces recorded from a CHO cell expressing Kv7.2 homomeric channels in response to the indicated voltage protocol before (left) and after (right) application of 0.03 μM RET (a) or **23a** (b). Current scale, 100 pA; time scale, 0.2 s. c. Kv7.2 current/voltage curves before and after application of 0.03 μM RET or **23a**. d. Normalized Kv7.2 conductance/voltage curves before and after application of RET or **23a**. Continuous lines represent fits of the experimental data to a double Boltzmann distribution.

1
2
3 Small molecules can activate Kv7 channels through different molecular mechanisms. Among these,
4 retigabine activates Kv7.2 channels by recognizing a hydrophobic pocket located between the
5 cytoplasmic parts of the S5 and the S₆ transmembrane domains in the open channel configuration;
6
7 within this cavity, an H-bond is established between the carbamate group of retigabine and the
8 aromatic side chain of a tryptophan present at the intracellular end of the S₅ helix (W236 in the Kv7.2
9 sequence). Substitution of this tryptophan with smaller and less hydrophobic leucine largely prevents
10 the ability of retigabine to activate neuronal Kv7 subunits.^{5b, 5c} By contrast, a second group of
11 compounds, belonging to benzamides (ICA-27243 and ICA-069673) appears to recognize a pocket
12 located in the voltage sensing domain (VSD; region between the S₁ and the S₄ transmembrane
13 domains).¹⁹ In particular, two specific amino acid positions in the S₃ segment of the Kv7.2 VSD (A181
14 and F168) seem to be relevant to confer current sensitivity to activation by benzamides.^{19b}

15
16 To define the structural determinants for Kv7.2 current enhancement by **23a** and **24a**, and in particular
17 whether these molecules required the presence of W236 in S₅ or of F168 in S₃, we examined the effect
18 of **23a** and **24a** on retigabine-insensitive Kv7.2 W236L and on ICA-insensitive Kv7.2 F168L mutant
19 channels. Application of 10 μM **23a** or **24a**, similarly to retigabine, failed to enhance Kv7.2 W236L
20 currents; whereas ICA-27243 strongly activated Kv7.2 W236L currents (Figure 5 a-b). By contrast,
21 application of 10 μM of retigabine, of **23a** or of **24a** increased Kv7.2 F168L currents, whereas ICA-
22 27243 was ineffective. These results strongly suggest that W236 exerts a critical influence on
23 retigabine, **23a** and **24a** binding within the pore hydrophobic pocket (Figure 5 c-d). Consistent with
24 this hypothesis, **23a** (similarly to retigabine itself) failed to affect homomeric Kv7.1 currents where
25 the 236 position is naturally occupied by a leucine residue (Figure S3).
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 5. The W236 residue in Kv7.2 exerts a critical influence on **23a** and **24a** ability to activate Kv7.2 currents. **a-b.** Representative traces of whole-cell ramp-evoked currents from Kv7.2 W236L (**a**) and Kv7.2 F168L (**b**) channels upon application of 10 μM retigabine (RET), ICA 27243 (ICA43), **23a** and **24a**. **c.** Quantification of the effects of the indicated compounds on Kv7.2, W236L and Kv7.2 F168L currents; data are expressed as the ratio between current amplitude at -40 mV in the presence and absence of 10 μM drugs ($I_{\text{DRUG}}/I_{\text{CTL}}$). Each data point is expressed as the mean \pm standard error of the mean (SEM) of at least 3 cells recorded in at least 2 independent transfections. * indicates values significantly different ($p < 0.05$) from respective controls.

Characterization of the selectivity profile for channels formed by different Kv7 subunits.

Considering that I_{KM} is mainly formed by heteromeric assembly of Kv7.2 and Kv7.3 subunits, in subsequent experiments we evaluated the activity of **23a** and **24a** on Kv7.2/Kv7.3 heteromeric currents. Similarly to Kv7.2, **23a** and **24a** dose-dependently (0.01-10 μM) increased Kv7.2/Kv7.3 currents. Similarly to Kv7.2, **23a** and **24a** were more potent in activating homomeric Kv7.4 channels, whereas

only **24a** was more potent than the reference compound in activating homomeric Kv7.5 channels (Table 1).

In conclusion, the selectivity profile for **23a** was $Kv7.2=Kv7.4=Kv7.2/Kv7.3>Kv7.5>>Kv7.3>>Kv7.1$; while for the **24a** was $Kv7.4>Kv7.5=Kv7.2=Kv7.2/Kv7.3=Kv7.3>>Kv7.1$.

Table 1. EC₅₀ and induced ΔV shift of retigabine and compounds **23a** and **24a** over different Kv7 channels.

Target channel	ΔV (mV) ^a			EC ₅₀ (μ M)		
	RET	23a	24a	RET	23a	24a
Kv7.2	-25.37 \pm 1.23	-29.47 \pm 2.03	-30.01 \pm 3.81	0.93 \pm 0.43 (12)	0.08 \pm 0.04 ^S (15-20)	0.63 \pm 0.07 (6-9)
Kv7.2/Kv7.3	-26.81 \pm 1.93	-25.45 \pm 2.91	-20.00 \pm 2.48	1.72 \pm 0.41 (8)	0.21 \pm 0.14 ^S (6-8)	0.34 \pm 0.06 ^S (9-10)
Kv7.3	-39.88 \pm 5.13 (30 μ M)	-26.25 \pm 4.60 (30 μ M)	-21.40 \pm 6.18* (30 μ M)	3.90 \pm 1.70 (6)	10.5 \pm 6.00 [†] (7-9)	0.92 \pm 0.64 (6)
Kv7.4	-15.19 \pm 1.97	-32.85 \pm 2.97**	-24.43 \pm 5.39	1.98 \pm 0.84 (7)	0.10 \pm 0.02 ^S (6-7)	0.08 \pm 0.20 ^S (6)
Kv7.5	-21.95 \pm 5.40	-25.6 \pm 4.9	-19.7 \pm 3.6	0.80 \pm 0.24 (3)	1.07 \pm 0.12 (4)	0.35 \pm 0.14 (4)

The number of recordings is indicated in brackets. ^a All three drugs were used at 10 μ M concentration, unless otherwise indicated;

* p<0.05 vs ΔV of RET on Kv7.3 channels; ** p<0.05 vs ΔV of RET on Kv7.4 channels; ^S p<0.05 vs EC₅₀ of RET; [†] p<0.05 vs EC₅₀ of **23a** on Kv7.2 channels

Molecular Modeling

We used pharmacophore modelling to get insight into the chemical features of our novel Kv7 channel activators. In particular, using Phase ²⁰ on an active set (composed by molecules showing more than 4 I_{drug}/I_{ctl} at -40 mV) and on an inactive set (Table S3), we obtained the pharmacophore model A (Figure 6a).




Figure 6. Pharmacophore models developed on the basis of our novel Kv7 channel activators. Pharmacophore features are color-coded as follows: Hydrophobic (HY – cyan), Aromatic (Ar – orange), Hydrogen Bond Donor (HBD – green), Hydrogen Bond Acceptor (HBA – red). Panel a) Model A with compounds **24a** and **8a** depicted in magenta and cyan sticks, respectively. Panel b) Model B with compound **24a** depicted in magenta sticks. Panel c) Model C with compound **8a** depicted in cyan sticks. Panel d) Model D with compounds **24a** and **8a** depicted in magenta and cyan sticks, respectively. **Retigabine** is depicted as reference, in every panel, in green sticks.

The model is composed by 5 pharmacophore features, a hydrogen bond acceptor (HBA), a hydrogen bond donor (HBD), a hydrophobic region (HY1) and two aromatic regions (Ar1 and Ar2). Despite the evident influence of the R1 substituent (see figure 1) on the activity, model A does not present any feature focused on these substituents. We thought this may be due to the different geometries of the sulfonamide and amide moieties of the molecules belonging to the active set. We thus developed two separate models for amides and sulfonamides. Removing the sulfonamide derivatives from the active set we obtained model B (Figure 6b). On the opposite, by keeping sulfonamides only we obtained model C (Figure 6c).

As evident from their superposition (Figure S4), the two models share features Ar1, Ar2, HY1, HBA and HBD, with almost identical coordinates (RMSD=0.51Å). We superimposed models B and C to

1
2
3 model A to get model D, (Figure 6d) that inherits Ar1, Ar2, HY1, HBA and HBD from model A,
4
5 HY2 from model B and HY3 from model C. The hydrogen bond interaction with W236, whose
6
7 importance has been proven for other channel modulators^{5a} as well as for **23a** in this study, is
8
9 represented in the models by the HBA feature. The finding of the two additional hydrophobic
10
11 locations HY2 and HY3 could explain the great variety of substitutions tolerated at position 5, as well
12
13 as the possibility of linking the HY2/3 substituent at 5-NH₂ with geometrically different linkers.
14
15

16
17 Indeed, despite the most potent molecules herein reported have an amide HBA-HBD moiety, the
18
19 sulfonamide one is of great interest for this and for future investigations. It can mimic the HBA-HBD-
20
21 Ar pattern of model D in different conformations and address the substituent at position 5 toward
22
23 HY2 or HY3, due to its larger HBA surface and to the rotation/energy profile of the bond connecting
24
25 HBA and HBD (Figure S1). For instance, compounds **8a** and **23a** are able to fit, in different
26
27 conformations, both HY2 and HY3 (Figure 7). The sulfonamide derivative docks the substituent
28
29 preferentially into HY3 (Figure 7b) but in a slightly higher energy conformation ($\Delta E_{\text{intra}} = 1.49$
30
31 kcal/mol) the substituent can be addressed towards HY2. (Figure 7a) On the opposite, the amide
32
33 compound **23a** preferentially addresses its aliphatic chain toward HY2, (Figure 7a) but, in another
34
35 low energy conformation ($\Delta E_{\text{intra}} = 1.10$ kcal/mol), due to the flexibility of the n-hexane moiety, the
36
37 chain can fit into HY3. (Figure 7b).
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60





Figure 7. Compounds **23a** (green sticks) and **8a** (cyan sticks) fitting feature HY2 (panel a) and HY3 (panel b). Pharmacophore features are color-coded as follows: Hydrophobic (HY – cyan), Aromatic (Ar – orange), Hydrogen Bond Donor (HBD – green), Hydrogen Bond Donor (HBD – green).

HY2 and HY3 could probably indicate a whole, larger and flexible pocket on Kv7.2, where more flexible compounds could bind in different conformations, interacting with more protein residues. This may be achieved by the flexibility of the substituent in the case of **23a**, or of the sulfonamide linker in the case of **8a**. Homology modeling of the Kv7.2 219-325 region is in agreement with the existence of two hydrophobic sites separated by W236, this critical residue appears indeed surrounded, on two sides, by several hydrophobic residues that could be the counterpart of HY1 and

1
2
3 HY2/3 on the channel protein (Figure 8). Addressing the binding mode of our inhibitors, and their
4 optimization by structure-based studies, is our next goal, although previously reported studies^{5a, 21}
5
6
7 have already provided very interesting clues on the binding mode of retigabine and other Kv7
8
9 channels modulators.
10



46 **Figure 8.** Kv modulators binding region modeled by homology with the CryoEM structure of Xenopus
47 KCNQ1 channel (PDB id: 5vms). W236 (magenta sticks) is surrounded by several hydrophobic residues (cyan
48 sticks) that could host chemical features HY1 and HY2/3.
49
50
51
52
53
54
55
56
57
58
59
60

Structure-activity relationship analysis

Compounds **5a**, **6**, and **7** show the activity rank that would be expected on the basis of their potential hydrogen bonding strength with the W236 side chain, with the urea moiety of **5a** showing higher efficacy than the guanidine of **7** and the thiourea of **6**.

The compounds bearing non-branched substituents at 5-NH₂ give clues about the HY2/3 feature. While in the amide series a six membered chain gives an optimal activity (**23a**, **23b**, **24b**), in the sulfonamide series, it does not (**8e**). Substitutions of a methylene group of **23a** by nitrogen, as in compounds **28a** and **29a**, increase hydrophilicity of the chain that would fall into HY2 and result detrimental to the activity. Compounds with longer (**25a**) or bulkier (**8f-8g**) chains show a loss in activity that could be due to steric clashes with the target protein. Even the substitution of the cyclohexyl substituent of **8a** with an aromatic ring (**8b**), is detrimental to the activity. Interesting SAR clues are also evidenced for the substituents at N-1 position. Derivatization of the N-1 by acyl groups, with its subsequent change in geometry and misfitting of HY1, is responsible for a markedly reduced activation of the channel (compounds **16a** and **16b**). On the other side, N-1 benzyl derivatives are among the most active compounds (compounds **8a**, **23a-d** and **24a-b**), while the substitution of the benzyl moiety with a phenylethyl group is not tolerated (compound **19**). Both electron-withdrawal and electron-donating groups were used to decorate N-1 benzyl moiety. In accordance with previous reports, electron-withdrawal substituents exert positive effects on the channel activation (compounds **13g**, **23a**, **24a**).^{9a} Nevertheless, we found that also some electron-donating groups such as hydroxy and alkoxy groups are suitable substituents in the para position of the N-1 benzyl moiety (compounds **13d**, **23b**, **23d** and **24b**). In addition, we found some differences in efficacy between the indoline and the indole series when some specific para substituents were used to decorate the N-1 benzyl group. For instance, the p-trifluoromethyl group is effective in improving efficacy for the indole series (compound **23a**) while penalizing the activity for the indoline series (compound **13c**). At the opposite, the p-methoxy substituent is responsible for a remarkable increase in efficacy in the indoline series (compound **13b**) when compared to fluorine, but decreases efficacy in the indole series (compound

1
2
3 **23d**). These differences are actually difficult to be explained by the data we collected so far; synthesis
4
5 of more derivatives and future target-based study could provide further clues. It can be speculated
6
7 that in our model, the N-1 benzyl moiety falls within the AR2/HY1 region, thus an electron
8
9 withdrawing group might be able to improve hydrophobic interactions in these regions. On the other
10
11 side, N-1 benzyl substituents, might be also involved in more specific interactions in the HY1 region,
12
13 such as hydrogen or halogen bonds, justifying the apparent conflicting results. However, the para
14
15 position appears to be the preferred position for the N-1 benzyl substituents. Multiple substitution in
16
17 different positions are well tolerated, but do not significantly influence efficacy (derivatives **13a-b**,
18
19 **13c-e** and **13g**).

20
21
22
23 Retigabine and its conformationally restricted analogues **4a** and **9a** are able to fit six out of the seven
24
25 chemical features required by the pharmacophore model. Despite this, the activity of retigabine is
26
27 significantly higher. This may be explained by the lack of a primary amine in compounds **4a** and **9a**,
28
29 corresponding to the 2-NH₂ of retigabine, that probably exerts supplementary interactions at the
30
31 receptor site that **4a** and **9a** do not properly compensate with additional hydrophobic interactions at
32
33 HY2/3 as the most potent compound of these series do.

34
35
36
37 Finally, tetrahydronaphthalene derivatives **33a**, **33b** and **34**, were totally inactive when tested over
38
39 Kv7.2 channels. Considering that these molecules bear the substituents conferring enhanced efficacy
40
41 in the A and B chemotypes, the lack of activity has to be attributed to the tetrahydronaphthalene
42
43 scaffold. This hypothesis is consistent with molecular modeling data showing that the different central
44
45 core and the double bond of **33a** and **33b** indeed hamper the fitting within the Ar2-HY1 region.
46
47
48
49
50

51 **Photostability assays**

52
53 Retigabine chemical photoinstability is a well-known characteristic of the molecule, likely leading to
54
55 some important adverse events observed during chronic long-term therapy, such as blue-gray
56
57 discoloration of skin, mucosae, and, possibly, retina^{8,9a,22}. Two main impurities, corresponding to
58
59 C5-C5 and C5-N retigabine dimers, likely obtained by oxidative self-coupling of two quinone diimine
60

1
2
3 tautomers, have been found in retigabine batches.²³ Retigabine dimer formation, which is favoured in
4 aqueous media under UV radiation,²³ is responsible for the change in color of retigabine aqueous
5 solutions from colourless to red/dark blue when left on air, and for the previously mentioned retinal
6 and muco-cutaneous side effects.^{8,9a} More recently, phenazinium, phenazine and benzimidazole
7 dimers of retigabine with high melanin affinity have been identified by matrix-assisted laser
8 desorption/ionization imaging mass spectrometry in corneal tissue.²⁴ Given these premises, all
9 synthesized derivatives were subjected to photostability assays. Initially, an UV quartz cuvette
10 containing an aqueous solution of retigabine (100 µg/mL) was irradiated in a black-box UV analyzer
11 at wavelengths of 254 nm (UV-B) and 365 nm (UV-A) for 6 hours. At predetermined intervals (2, 4
12 and 6 hours) aliquots were withdrawn and analyzed by HPLC. The molecule showed high
13 photostability under these experimental conditions with negligible degradation after 6 hours (about
14 5%, data not shown). By contrast, exposure to visible light led to a remarkable and significant
15 photodegradation of retigabine; as a matter of fact, about 47,33±4,03% of retigabine was degraded
16 after 6 hours of drug exposition to artificial daylight lamp. Quantitatively similar results were
17 obtained upon direct exposure of retigabine to natural solar light (43.5±4.3% degradation at 6 hours).
18 We then decided to further investigate the photodegradative behaviour of retigabine by analysing the
19 corresponding by-products. As shown in figure S5 the HPLC profile of photodegraded retigabine
20 batches is mainly characterized by the presence of two additional peaks with a retention time of 5.98
21 and 14.39 minutes. Running HPLC/MS analysis of these peaks we were able to detect the mass
22 spectra only for the late eluting peak (14.39 minutes), putatively identified as the retigabine adduct
23 ethyl (2,4-bis((4-fluorobenzyl)amino)phenyl)carbamate (Figure S6). The peak eluting at 5.98
24 minutes was undetectable by mass spectrometry, in accordance with a previous report showing the
25 occurrence of non-identified retigabine impurity at shorter retention times.²² Thus, we decided to
26 analyse the unknown peak using a GC/MS method, leading to the identification of 4-
27 fluorobenzaldehyde as the main by-product in retigabine photodegradation (Figure S7). The result
28 was further confirmed by comparison with the HPLC trace of pure 4-fluorobenzaldehyde (Figure S8)

and is consistent with a photooxidative C-N bond cleavage mechanism widely described in literature.²⁵ The proposed mechanism justifies the reason why visible light is more effective in inducing retigabine photodegradation^{25c} and corroborate the hypothesis concerning the molecular structure of the peak eluting at 14.39 minutes. Considering that Groseclose and Castellino²⁴ found that the typical absorbance of retigabine photoinduced dimers is 550 nm, we decided to set the same wavelength for the UV detection, evidencing some additional byproducts with a retention time between 7.00 and 10.00 minutes. HPLC/MS/MS analysis of the most abundant peak lead to the putative identification of a dimer with a mass peak of 601.2357 m/z and a serie of MS/MS peaks roughly corresponding to some of the previously reported phenazinium dimers (Figure S9).²⁴ Thereafter, the most active synthesized derivatives, namely derivatives **8a**, **13a**, **13d**, **23a** and **24a**, were subjected to the photostability assay. Results obtained are reported in Table 2.

Table 2: Photoinduced degradation of retigabine and its analogues under solar lighting. Results are expressed as percentage of degradation±SD

Derivative	Time (h)		
	2	4	6
Retigabine	9.65±6.93%	25.16±7.31%	47.33±4.03%
8a	45.29±7.35%	86.87±10.54%	≥99%
13a	33.46±6.50%	81.72±1.12%	≥99%
13d	37.51±7.25%	84.66±4.12%	≥99%
23a	1.36±0.89%	5.82±2.05%	9.15±2.91%
23c	6.46±1.78%	15.78±1.97%	23.11±1.84%
24a	0.96±0.64%	6.62±2.17%	8.45±1.99%

Our results indicate that the N-(1-benzyl)indolin-5-yl)sulfonamide derivatives **8a**, **13a** and **13d** are even less stable than retigabine. At 6h degradation is almost complete and only traces of the starting molecules are detectable by HPLC analysis. This is likely due to the sulfonyl activation of the *p*-quinone diimine intermediate²⁶ representing the starting product in the degradative pattern for retigabine-like by-products. We performed HPLC/MS analysis for derivative **8a** to further investigate

1
2
3 the photodegradation pattern for this series of indolin-5-yl sulfonamides (Figure S10), but no
4
5 significant mass peaks were identified. On the other side, GC/MS analysis revealed, also for **8a**, the
6
7 presence of 4-fluorobenzaldehyde as the main photooxidation by-product, evidencing a similar
8
9 photogradative pathway with retigabine (Figure S10). Increased photostability was attained turning
10
11 to the N-(1-(4-fluorobenzyl)-1H-indol-5-yl)sulfonamide scaffold, as for **23c**, probably due to the
12
13 improved delocalization of the π -electrons of the indole ring. Finally, derivatives **23a** and **24a**,
14
15 obtained by replacement of the sulfonamide with a carboxamide moiety, were the most photostable
16
17 retigabine analogues, showing less than 10% of degradation after the 6 hours time-course.
18
19
20
21
22
23

24 **In vitro metabolism**

25
26 In vitro metabolism assays were performed using the S9 fraction of human liver microsomes as
27
28 model. Compounds **23a** and **24a** were selected for this study due to the potency and efficacy shown
29
30 as Kv 7.2 agonists and to their inherent photostability. The phase I metabolism of these derivatives
31
32 was initially investigated, in comparison with retigabine. In our assay, only a very small extent
33
34 (3.11±0.21%) of retigabine undergoes phase I metabolism, a result consistent with available data.⁶
35
36 Instead, derivative **23a** was found to undergo extensive (48.71±2.47 %) phase I metabolism. This is
37
38 likely due to the fact that indole moiety is naturally prone to cytochrome metabolism²⁷, and the long
39
40 and lipophilic side chain further decrease the metabolic stability of the compound.²⁸ In fact, when
41
42 the lipophilicity of the side chain is decreased, as for derivative **24a**, an improved Phase I metabolic
43
44 stability is attained (17.30±1.74% of degradation). Next, retigabine and the more stable to Phase I
45
46 metabolism **24a** underwent to UDP-glucuronosyltransferases (UGT) and N-acyl transferase (NAT)
47
48 activity evaluation. Retigabine was metabolized in 11.41±2.73% in UGT activity assays and in
49
50 12.68±1.94% in NAT activity assays, in agreement with the literature^{12b,29}. Compound **24a** displayed
51
52 increased stability in both assays, being metabolized by 7.42±1.81% in UGT activity assays and
53
54 3.41±0.62% in NAT activity assays. Collectively, these results highlight a good in vitro metabolic
55
56
57
58
59
60

1
2
3 stability for compound **24a**, especially during Phase II metabolism, making **24a** a potential candidate
4
5 for *in vivo* metabolic and pharmacokinetic studies.
6
7

8 9 **CONCLUSIONS**

10
11 Activation of Kv7 channels effectively suppresses neuronal hyperexcitability, a common feature of
12
13 different neuropsychiatric disorders such as epilepsy,³⁰ neuropathic pain,³¹ amyotrophic lateral
14
15 sclerosis³² and many others.³³ For these reasons, identification of Kv7 channels modulators showing
16
17 improved pharmacokinetic and pharmacodynamic properties over existing compounds represents an
18
19 attractive research topic in medicinal chemistry; this issue is even more pressing in the light of the
20
21 recent market withdrawal of retigabine and flupirtine, the only two clinically approved drugs acting
22
23 as Kv7 activators. In fact, the analgesic flupirtine was found to cause drug-induced liver injury in rare
24
25 but fatal cases, whereas prolonged use of the antiepileptic retigabine led to muco-cutaneous and retinal
26
27 discoloration. Several efforts have been previously made in search for the structure-activity
28
29 relationships regulating retigabine binding and actions at Kv7.2 and Kv7.3 channels. Results obtained
30
31 so far describe the retigabine binding site as a central hydrophilic core flanked by two hydrophobic
32
33 pockets. The most important chemical interaction evidenced is represented by a hydrogen bond
34
35 between the carbamate group of retigabine as donor and a specific, highly conserved, triptophan
36
37 residue (W265 in Kv7.3, W236 in Kv7.2) as acceptor. This H-bond has been considered as critically
38
39 responsible to confer retigabine its ability to control Kv7 channel gating^{5a, 21, 34} and is the reason why
40
41 retigabine is inactive over cardiac Kv7.1 channels, in which this specific triptophan is substituted by
42
43 a leucine residue. Previous investigations also provided evidence that the use of electron-withdrawing
44
45 group in the para position of benzylamino substituents at C-4 of retigabine is able to increase potency
46
47 and efficacy over Kv7.2/7.3 heterotetramers,^{9a} while introduction of a fluorine atom in position 3 of
48
49 the benzene-1,2,4-triamine core modulated selectivity among Kv7 channel subtypes.³⁵ Nevertheless,
50
51 a systematic investigation of the structural determinants required for Kv7 channel modulation is still
52
53 missing. In the present paper we have investigated the Kv7-opening ability of a series of constrained
54
55
56
57
58
59
60

1
2
3 retigabine analogues carrying specific substitutions in critical positions, thus generating a
4 pharmacophore model. Our results further highlight the pivotal role of the H-bonding with W236 in
5 Kv7.2 channel activation, but also reveal the possibility of using H-bond donor groups different from
6 carbamate, such as amide and sulfonamide. It is worth of note that the replacement of the benzyl
7 group at the N-4 position of retigabine (N-1 position in our derivatives) is hardly tolerated. When
8 different substituents are used, the efficacy of the compound is always decreased in our series.
9
10 Moreover, we found that the N-1 benzyl moiety tolerate multiple substitutions, regardless of the
11 electron-withdrawing or electron-donating properties of the substituents. Previous results have led to
12 the hypothesis of the existence of a narrow hydrophobic pocket accommodating the N-1 benzyl
13 moiety exerting a specific interaction in the para-position. In addition, by the present data we may
14 suppose the existence of a larger hydrophobic pocket (HY2 and HY3 region of the pharmacophore
15 model), able to accommodate a wide range of hydrophobic substituents. Notably, some substituents
16 at the position C-1 of retigabine (corresponding to the C-5 position in our derivatives) were also
17 studied by Kumar et al.,^{9a} who demonstrated that while lipophilic isopropyl chain improved potency
18 by about 2/3 times, more hydrophilic substituents were not tolerated, suggesting the existence of a
19 hydrophobic pocket. In agreement with this hypothesis, our results also highlight that changes in
20 lipophilicity at C-5 also modify the kinetics of onset and offset of Kv7.2 channel activation; in fact,
21 when compared to retigabine (log P=3.08), more lipophilic **23a** (logP=6.83) and **24a** (logP=5.58)
22 both displayed slower kinetics. These results are in good agreement with recently published studies
23 concerning flupirtine analogues.³⁶ Mostly important, we found that the type of substituents in position
24 C-5 of the indole series influences selectivity between Kv7.2 and Kv7.3 channels. In particular, long
25 and flexible carbon chains as in derivative **23a** are required for Kv7.2 selectivity. Furthermore, both
26 indole derivatives **23a** and **24a** showed selectivity for Kv7.4 channels. Finally, we found that some
27 of the most active derivatives show a dramatic improvement in photostability in comparison with
28 retigabine. Further investigations are needed to optimize metabolic properties of synthesized
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 compounds, but the preliminary results obtained seem highly promising for the development of a new
4
5 class of Kv7 channel modulators.
6
7
8
9

10 **Experimental section**

11
12 **General.** All reagents and solvents used were purchased from Sigma-Aldrich (Milan, Italy), unless
13
14 otherwise stated. Reactions were carried out with magnetic stirring in round-bottomed flasks unless
15
16 otherwise noted. Moisture-sensitive reactions were conducted in oven-dried glassware under nitrogen
17
18 stream, using freshly distilled solvents. Pre-coated glass silica gel plates (F254, 0.25 mm, VWR
19
20 International) were used for TLC analysis of reaction mixtures, while crude products were purified
21
22 by an automated flash chromatography system (Isolera Spektra one, Biotage, Uppsala, Sweden)
23
24 coupled with an APCI mass detector (Dalton 2000, Biotage), using pre-loaded silica gel cartridges
25
26 (SNAP KP-Sil, Biotage). Continuous flow hydrogenation reactions were conducted using the H-cube
27
28 hydrogenation reactor (ThalesNano, Budapest, Hungary) equipped with pre-loaded Pd/C 10%
29
30 cartridges (30 mm, ThalesNano). NMR spectra were recorded on Varian Mercury 400 MHz and on
31
32 a Bruker Avance 400 MHz and 300 MHz apparatus, at room temperature. Chemical shifts were
33
34 reported in δ values (ppm) relative to internal Me_4Si , for ^1H and ^{13}C NMR, and CClF_3 for ^{19}F NMR.
35
36 J values were reported in hertz (Hz). ^1H -NMR and ^{19}F NMR peaks were described using the following
37
38 abbreviations: s (singlet), d (doublet), t (triplet) and m (multiplet). HR-MS spectra were recorded by
39
40 LTQ-Orbitrap-XL-ETD mass spectrometer (Thermo Scientific, Bremen, Germany), equipped with
41
42 an ESI source. Analytical RP-HPLC analysis of final products was performed to confirm $\geq 95\%$ purity
43
44 using the instrumentation and the UHPLC PDA conditions described below.
45
46
47
48
49
50
51
52
53

54 **General procedure A: reductive amination reaction.**

55
56 Reductive aminations were performed following the procedure previously described,³⁷ using 5-
57
58 nitroindoline (**1**), 2-methyl-5-nitroindoline (**10**) or tert-butyl 5-nitroindoline-1-carboxylate (**10b**)
59
60

1
2
3 as starting materials and commercially available aldehydes. Briefly, to a solution of the aldehyde (1.0
4 eq) in DCM:CH₃COOH (5:1 v/v) 2.0 equivalents of **1**, **10** or **10b** were added and the mixture was
5
6 warmed to reflux for 1.5h. After addition of 1.8 equivalents of sodium triacetoxyborohydride the
7
8 mixture was refluxed for further 3-5h. After cooling to room temperature, aqueous solution of NaOH
9
10 (1N) was added. The organic layer was separated and further extracted with NaOH 1N. After drying
11
12 over Na₂SO₄, the organic phase was concentrated *in vacuo*. Intermediates thus obtained were purified
13
14 by flash chromatography using linear gradients of n-hexane/ethyl acetate as mobile phase.
15
16
17
18
19
20

21 **General procedure B: Continuous flow hydrogenation.**

22
23 Reduction of 5-nitroindoline and 5-nitroindole derivatives was achieved by continuous flow
24
25 hydrogenation using the H-Cube hydrogenator and commercially available Pd/C 10% cartridges as
26
27 catalyst. Starting material was dissolved in a mixture of THF/CH₃OH (1:1, v:v) at a final
28
29 concentration of 0.1M and was pumped at a flow rate of 1.0 mL/min. Temperature was set at 30°C
30
31 while the hydrogen inlet pressure was set at 10 bar. After completion, the reaction solution was
32
33 evaporated *in vacuo* and the obtained products used in the following step without further purification.
34
35
36
37
38
39

40 **General procedure C: Synthesis of sulfonamides**

41
42 Indolin-5-amino and 1H-indol-5-amino intermediates (1.0 eq) were dissolved in dry DCM under a
43
44 nitrogen positive pressure. To this solution 1.2 equivalents of 1,5-diazabicyclo(5.4.0)undec-7-ene
45
46 (DBU) were added. The reaction mixture was stirred at room temperature for 15 minutes, then 1.5
47
48 equivalents of the proper sulfonyl chloride were added. The mixture was stirred for further 2h. The
49
50 reaction was then washed with a saturated solution of NaHCO₃ and brine. The organic phase was
51
52 extracted, dried over anhydrous Na₂SO₄, filtered and concentrated *in vacuo*. Crude products were
53
54 purified using a linear gradient of n-hexane/ethyl acetate.
55
56
57
58
59
60

General procedure D: Synthesis of amides

1
2
3 Indolin-5-amino and 1H-indol-5-amino intermediates (1.0 eq) were dissolved in dry DCM under a
4 nitrogen positive pressure and added, under stirring, with 1.2 equivalents of N,N-
5 Diisopropylethylamine (DIPEA). The mixture was cooled to 0°C and added dropwise with a solution
6 of the proper acyl chloride or acyl bromide (1.2 eq) in DCM. The solution was allowed to cool to
7 room temperature and stirred for further 30 minutes. The reaction was then washed with a saturated
8 solution of NaHCO₃ and brine. The organic phase was extracted, dried over anhydrous NaSO₄,
9 filtered and concentrated in vacuo. Crude products were purified using a linear gradient of n-
10 exane/ethyl acetate.
11
12
13
14
15
16
17
18
19
20
21
22

23 **General procedure E: Synthesis of N-1 substituted 5-nitro indoline and 5-nitro-1H-indole** 24 **derivatives.**

25
26
27
28 The reactions were performed following the procedure described before.³⁸ Briefly, 5-nitroindoline
29 (**1**) or 5-nitro-1H-indole (**20**) (1.0 eq) were dissolved in dry DCM/DMF (2/1 v/v) under stirring, at 0
30 °C. To this solution, 1.2 equiv of NaH were added portionwise and the mixture stirred for 30 min at
31 0 °C. Then, a solution of of the proper alkyl halide (1.2 eq) in dry DCM was added dropwise. The
32 mixture was warmed to room temperature and stirred for 12 h. After quenching by 10% aqueous
33 solution of citric acid and washing with brine, the organic layer was separated, dried over anhydrous
34 Na₂SO₄ and evaporated in vacuo. Crude products were purified by flash chromatography coupled to
35 mass spectrometry, using a linear gradient of n-exane/ethyl acetate.
36
37
38
39
40
41
42
43
44
45
46
47
48

49 **1-(4-fluorobenzyl)-5-nitroindoline (2)**

50
51 Synthesized according to the general procedure A using 5-nitroindoline (**1**) and 4-fluorobenzaldehyde
52 as reagents. Intermediate **2** was isolated as a yellow powder in 65% yield. ¹H NMR (CDCl₃, 400
53 MHz): δ: 3.12 (t, 2H, CH₂, J = 8.6 Hz); 3.63 (t, 2H, CH₂, J = 8.6 Hz); 4.42 (s, 2H, CH₂); 6.37 (d, 1H,
54 aryl, J = 8.1 Hz); 7.04-7.09 (m, 2H, aryl); 7.24-7.28 (m, 2H, aryl); 7.94 (s, 1H, aryl); 8.08 (d, 1H,
55 aryl, J = 7.8 Hz). HR-MS *m/z*: calcd for C₁₉H₁₄FN₂O₂, [(M+H)⁺]: 273.1034; found 273.1039
56
57
58
59
60

1-(4-fluorobenzyl)indolin-5-amine (3)

Synthesized from intermediate **2** according to the general procedure B. The product was obtained as a grey powder in 98% yield. ¹H NMR (CDCl₃, 400 MHz): δ: 2.98 (t, 2H, CH₂, *J* = 8.7 Hz); 3.18 (t, 2H, CH₂, *J* = 8.7 Hz); 3.35 (bs, 2H, NH₂); 4.12 (s, 2H, CH₂); 6.38 (d, 1H, aryl, *J* = 8.1 Hz); 6.47 (d, 1H, aryl, *J* = 8.2 Hz); 6.60 (s, 1H, aryl); 6.99-7.07 (m, 2H, aryl); 7.34-7.39 (m, 2H, aryl). HR-MS *m/z*: calcd for C₁₅H₁₆FN₂, [(M+H)⁺]: 243.1292; found 243.1301

Ethyl (1-(4-fluorobenzyl)indolin-5-yl)carbamate (4a)

Intermediate **3** (1.0 eq) was dissolved in dry THF and stirred under nitrogen positive pressure. The solution was added with 1.1 equivalents of NaHCO₃ and the resulting suspension was cooled to 0°C in ice bath. To this suspension, 1.1 equivalents of ethyl chloroformate were added and the slurry was stirred at 0°C for further 30 minutes. After warming at room temperature, an equal volume of water was added and the solution was extracted three times with ethylacetate. Organic phases were dried over anhydrous NaSO₄, filtered and concentrated *in vacuo*. Final product was isolated as a white crystal in 72% yield and crystallized from n-hexane/diethyl ether. ¹H NMR (CDCl₃, 400 MHz): δ: 1.32 (t, 3H, CH₃, *J* = 7.1 Hz); 2.97 (t, 2H, CH₂, *J* = 8.2 Hz); 3.29 (t, 2H, CH₂, *J* = 8.2 Hz); 4.19-4.25 (m, 4H, CH₂); 6.37 (bs, 1H, NH); 6.45 (d, 1H, aryl, *J* = 8.3 Hz); 6.95 (d, 1H, aryl, *J* = 7.7 Hz); 7.04 (t, 2H, aryl, *J* = 8.4 Hz); 7.22 (bs, 1H, aryl); 7.32-7.36 (m, 2H, aryl). ¹³C NMR (CDCl₃, 100 MHz) δ: 14.6; 28.6; 53.5; 53.9; 61.0; 107.0; 115.2; 115.4; 118.8; 119.3; 129.4; 131.0; 134.0; 149.3; 160.8; 163.3. ¹⁹F NMR (CDCl₃, 376.3 MHz) δ: -(115.89-115.80) (m, 1F, CF) HR-MS *m/z*: calcd for C₁₈H₂₀FN₂O₂, [(M+H)⁺]: 315.1503; found 315.1514

(1S,2R,5S)-2-isopropyl-5-methylcyclohexyl (1-(4-fluorobenzyl)indolin-5-yl)carbamate (4b)

Final product **4b** was synthesized according to the same procedure described above for **4a**, using the commercially available (1S)-(+)-menthyl chloroformate as reagent. The product was obtained as a white wax in 63% yield. $[\alpha]_D^{25}$: 32.67 ± 0.04 ($c = 0.15$, MeOH). ^1H NMR (CDCl_3 , 400 MHz): δ : 0.83 (d, 3H, CH_3 , $J = 7.0$ Hz); 0.93 (d, 6H, CH_3 , $J = 7.1$ Hz); 0.99-1.16 (m, 2H, CH_2); 1.27-1.41 (m, 1H, CH_2); 1.49-1.56 (m, 1H, CH); 1.67-1.74 (m, 2H, CH_2); 1.94-2.02 (m, 1H, CH); 2.09-2.16 (m, 1H, CH_2); 2.96 (t, 2H, CH_2 , $J = 8.4$ Hz); 3.27 (t, 2H, CH_2 , $J = 8.4$ Hz); 4.18 (s, 2H, CH_2); 4.61-4.70 (m, 1H, CH); 6.35 (bs, 1H, NH); 6.42 (d, 1H, aryl, $J = 8.5$ Hz); 6.95 (d, 1H, aryl, $J = 8.2$ Hz); 7.03 (t, 2H, aryl, $J = 8.7$ Hz); 7.25 (bs, 1H, aryl); 7.31-7.36 (m, 2H, aryl). ^{13}C NMR (CDCl_3 , 100 MHz) δ : 16.5; 20.8; 22.1; 23.6; 26.3; 28.6; 31.4; 34.3; 41.5; 47.4; 53.5; 53.9; 74.8; 107.1; 115.2; 115.4; 117.4; 118.9; 129.1; 129.4; 129.5; 131.0; 134.0; 154.0; 160.8; 163.3. ^{19}F NMR (CDCl_3 , 376.3 MHz) δ : - (115.82-115.74) (m, 1F, CF) HR-MS m/z : calcd for $\text{C}_{26}\text{H}_{34}\text{FN}_2\text{O}_2$, [(M+H) $^+$]: 425.2599; found 425.2608

1-(1-(4-fluorobenzyl)indolin-5-yl)-3-neopentylurea (**5a**)

Triphosgene (1.0 eq) was dissolved in dry DCM, under nitrogen stream at 0°C. To the resulting mixture, a solution of 1.25 equivalents of 1-(4-fluorobenzyl)indolin-5-amine (**3**) and 2.6 equivalents of DIPEA dissolved in DCM were added dropwise in 5 minutes. The solution was maintained under stirring for further 5 minutes. Then, a solution of 2,2-dimethylpropan-1-amine (2.5 eq) and DIPEA (2.6 eq) in DCM was added dropwise. The reaction mixture was allowed to warm at room temperature, maintained under stirring overnight and quenched by adding an equal volume of water. The organic phase was washed with a saturated solution of NaHCO_3 and then with brine, before being dried over anhydrous Na_2SO_4 , filtered and evaporated to dryness. The crude product was isolated as white crystal in 69% yield and crystallized from ethyl acetate. ^1H NMR (CDCl_3 , 400 MHz): δ : 0.89 (s, 9H, 3 CH_3); 2.99 (t, 2H, CH_2 , $J = 8.3$ Hz); 3.05 (d, 2H, CH_2 , $J = 6.3$ Hz); 3.35 (t, 2H, CH_2 , $J = 8.3$ Hz); 4.23 (s, 2H, CH_2); 4.71 (t, 1H, NH, $J = 5.6$ Hz); 5.98 (s, 1H, NH); 6.45 (d, 1H, aryl, $J = 8.2$ Hz);

1
2
3 6.92 (d, 1H, aryl, $J = 8.2$ Hz); 7.02-7.07 (m, 3H, aryl); 7.32-7.35 (m, 2H, aryl). ^{13}C NMR (CDCl_3 ,
4
5 100 MHz) δ : 27.2; 28.4; 32.2; 51.4; 53.0; 53.7; 107.1; 115.3; 115.5; 122.8; 125.0; 127.7; 129.40;
6
7 129.45; 131.5; 133.7; 150.9; 157.5; 160.9; 163.3 ^{19}F NMR (CDCl_3 , 376.3 MHz) δ : -(115.55-115.34)
8
9 (m, 1F, CF). HR-MS m/z : calcd for $\text{C}_{21}\text{H}_{27}\text{FN}_3\text{O}$, $[(\text{M}+\text{H})^+]$: 356.2133; found 356.2148
10
11
12
13
14

1-cyclohexyl-3-(1-(4-fluorobenzyl)indolin-5-yl)urea (**5b**)

15
16
17 Final product **5b** was synthesized as described above for **5a**, using cyclohexylamine in place of 2,2-
18
19 dimethylpropan-1-amine. Final product was obtained as a white crystal in 57% yield and crystallized
20
21 from methanol. ^1H NMR (DMSO-d_6 , 400 MHz): δ : 1.08-1.34 (m, 5H, CH_2 and CH); 1.52-1.55 (m,
22
23 1H, CH); 1.63-1.67 (m, 2H, CH_2); 1.77-1.80 (m, 2H, CH_2); 2.82 (t, 2H, CH_2 , $J = 8.2$ Hz); 3.14 (t, 2H,
24
25 CH_2 , $J = 8.2$ Hz); 3.39-3.43 (m, 1H, CH); 4.16 (s, 2H, CH_2); 5.85 (d, 1H, NH , $J = 7.9$ Hz); 6.47 (d,
26
27 1H, aryl, $J = 8.4$ Hz); 6.90 (d, 1H, aryl, $J = 8.4$ Hz); 7.14-7.19 (m, 3H, aryl); 7.37-7.41 (m, 2H, aryl);
28
29 7.86 (s, 1H, NH). ^{13}C NMR (DMSO-d_6 , 100 MHz) δ : 24.9; 25.8; 28.7; 33.6; 48.0; 53.3; 53.8; 107.0;
30
31 115.4; 115.6; 116.6; 117.7; 130.4; 130.5; 132.1; 135.1; 147.6; 155.3; 160.5; 162.9. ^{19}F NMR (DMSO-
32
33 d_6 , 376.3 MHz) δ : -(116.04-115.96) (m, 1F, CF). HR-MS m/z : calcd for $\text{C}_{22}\text{H}_{27}\text{FN}_3\text{O}$, $[(\text{M}+\text{H})^+]$:
34
35 368.2133; found 368.2139
36
37
38
39
40
41
42

1-(1-(4-fluorobenzyl)indolin-5-yl)-3-neopentylthiourea (**6**)

43
44
45 Starting from 1-(4-fluorobenzyl)indolin-5-amine (**3**), final compound **6** was obtained via
46
47 isothiocyanate intermediate, followed by reaction with 2,2-dimethylpropan-1-amine slightly
48
49 modifying a previously described procedure.³⁹ In our procedure, the use of benzene as solvent was
50
51 avoided by replacing with dry toluene for the synthesis of the isothiocyanate intermediate, and dry
52
53 DCM for the conversion of the isothiocyanate to thiourea. The final product was obtained as a grey
54
55 powder in 54% yield and was crystallized from ethyl acetate. ^1H NMR (CDCl_3 , 400 MHz): δ : 0.89
56
57 (s, 9H, CH_3); 2.99 (t, 2H, CH_2 , $J = 8.4$ Hz); 3.39 (t, 2H, CH_2 , $J = 8.4$ Hz); 3.48 (d, 2H, CH_2 , $J = 5.8$
58
59
60

Hz); 4.25 (s, 2H, CH_2); 5.93 (t, 1H, NH , $J = 7.4$ Hz); 6.46 (d, 1H, aryl, $J = 8.1$ Hz); 6.90 (d, 2H, aryl, $J = 9.4$ Hz); 7.01-7.07 (m, 2H, aryl); 7.29-7.33 (m, 2H, aryl); 7.58 (s, 1H, NH). ^{13}C NMR ($CDCl_3$, 100 MHz) δ : 27.4; 28.2; 32.2; 52.5; 53.4; 56.4; 107.0; 115.3; 115.6; 123.3; 125.2; 126.1; 129.3; 132.0; 133.3; 152.1; 160.5; 163.7; 181.7. ^{19}F NMR ($CDCl_3$, 376.3 MHz) δ : -(115.25-115.18) (m, 1F, CF). HR-MS m/z : calcd for $C_{21}H_{27}FN_3S$, $[(M+H)^+]$: 372.1904; found 372.1911

1-(1-(4-fluorobenzyl)indolin-5-yl)-3-neopentylguanidine (7)

Final compound **7** was obtained from **6** via carbodiimide intermediate followed by reaction with 2,2-dimethylpropan-1-amine, using the procedure described by Plsikova et al.⁴⁰ The final product was obtained as white crystal in 40% yield and crystallized from methanol.

1H NMR ($CDCl_3$, 400 MHz): δ : 0.97 (s, 9H, 3 CH_3); 2.93 (t, 2H, CH_2 , $J = 8.1$ Hz); 2.99 (s, 2H, CH_2); 3.25 (t, 2H, CH_2 , $J = 8.1$ Hz); 4.18 (s, 2H, CH_2); 6.47 (d, 1H, aryl, $J = 8.1$ Hz); 6.67 (d, 1H, aryl, $J = 7.8$ Hz); 6.77 (s, 1H, aryl); 7.04 (t, 2H, aryl, $J = 8.5$ Hz); 7.34-7.37 (m, 2H, aryl). ^{13}C NMR ($CDCl_3$, 100 MHz) δ : 27.3; 28.7; 53.5; 53.9; 54.1; 107.9; 115.1; 115.4; 120.8; 122.1; 129.5; 129.6; 131.5; 134.3; 148.5; 160.8; 163.2. ^{19}F NMR ($CDCl_3$, 376.3 MHz) δ : -(115.86-115.78) (m, 1F, CF). HR-MS m/z : calcd for $C_{21}H_{28}FN_4$, $[(M+H)^+]$: 355.2293; found 355.2300

N-(1-(4-fluorobenzyl)indolin-5-yl)cyclohexanesulfonamide (8a)

Final product **8a** was obtained from 1-(4-fluorobenzyl)indolin-5-amine (**3**) and cyclohexanesulfonyl chloride following the general procedure C. The product was isolated in 67% yield as a grey powder that crystallizes from n-hexane/diethyl ether. 1H NMR ($CDCl_3$, 400 MHz): δ : 1.10-1.21 (m, 3H, CH_2 and CH); 1.47-1.60 (m, 3H, CH_2 and CH); 1.80-1.82 (m, 2H, CH_2); 2.08-2.11 (m, 2H, CH_2); 2.83-2.91 (m, 3H, CH_2 and CH); 3.25 (t, 2H, CH_2 , $J = 8.3$ Hz); 4.12 (s, 2H, CH_2); 5.96 (s, 1H, NH); 6.31 (d, 1H, aryl, $J = 8.2$ Hz); 6.81 (d, 1H, aryl, $J = 8.3$ Hz); 6.93-6.98 (m, 3H, aryl); 7.22-7.25 (m, 2H, aryl). ^{13}C NMR ($CDCl_3$, 100 MHz) δ : 25.1; 26.4; 28.4; 53.0; 53.7; 59.3; 106.9; 115.3; 115.5; 121.4;

1
2
3 123.3; 126.5; 129.3; 129.4; 131.4; 133.7; 151.0; 160.9; 163.33. ¹⁹F NMR (CDCl₃, 376.3 MHz) δ: -
4
5 (114.71-114.63) (m, 1F, CF) HR-MS *m/z*: calcd for C₂₁H₂₆FN₂O₂S, [(M+H)⁺]: 389.1694; found
6
7 389.1699; [(M+Na)⁺]: 411.1513; found 411.1520
8
9

10 11 12 **N-(1-(4-fluorobenzyl)indolin-5-yl)benzenesulfonamide (8b)** 13

14 Final product **8b** was obtained from 1-(4-fluorobenzyl)indolin-5-amine (**3**) and benzenesulfonyl
15 chloride following the general procedure C. The product was isolated in 70% yield as a grey powder
16 that crystallizes from n-hexane/ethyl acetate. ¹H NMR (CDCl₃, 400 MHz): δ: 2.92 (t, 2H, CH₂, *J* =
17 8.0 Hz); 3.31 (t, 2H, CH₂, *J* = 8.0 Hz); 4.18 (s, 2H, CH₂); 6.20 (s, s, 1H, NH); 6.29 (d, 1H, aryl, *J* =
18 8.2 Hz); 6.61 (d, 1H, aryl, *J* = 6.8 Hz); 6.87 (s, 1H, aryl); 7.03 (t, 2H, aryl, *J* = 8.4 Hz); 7.28-7.31 (m,
19 3H, aryl); 7.46 (t, 2H, aryl, *J* = 7.3 Hz); 7.56 (t, 1H, aryl, *J* = 7.1 Hz); 7.74 (d, 2H, aryl, *J* = 7.4 Hz).
20
21 ¹³C NMR (CDCl₃, 100 MHz) δ: 28.2; 52.8; 53.6; 106.6; 115.3; 115.5; 122.6; 124.7; 125.7; 127.4;
22
23 128.8; 129.3; 129.4; 131.1; 132.6; 133.6; 139.4; 151.4; 160.9; 163.3. ¹⁹F NMR (CDCl₃, 376.3 MHz)
24
25 δ: -(115.53-115.46) (m, 1F, CF) HR-MS *m/z*: calcd for C₂₁H₂₀FN₂O₂S, [(M+H)⁺]: 383.1224; found
26
27 383.1230
28
29
30
31
32
33
34
35
36
37
38
39

40 **N-(1-(4-fluorobenzyl)indolin-5-yl)butane-1-sulfonamide (8c)** 41

42 Final product **8c** was obtained from 1-(4-fluorobenzyl)indolin-5-amine (**3**) and butanesulfonyl
43 chloride following the general procedure C. The product was isolated in 72% yield as an off-white
44 powder that crystallizes from n-hexane/diethyl ether. ¹H NMR (CDCl₃, 400 MHz): δ: 0.94 (t, 3H,
45 CH₃, *J* = 7.3 Hz); 1.38-1.49 (m, 2H, CH₂); 1.78-1.88 (m, 2H, CH₂); 2.95-3.06 (m, 4H, 2 CH₂); 3.34
46
47 (t, 2H, CH₂, *J* = 7.9 Hz); 4.21 (s, 2H, CH₂); 6.28 (s, 1H, NH); 6.40 (d, 1H, aryl, *J* = 8.2 Hz); 6.91 (d,
48
49 1H, aryl, *J* = 8.1 Hz); 7.02-7.07 (m, 3H, aryl); 7.30-7.35 (m, 2H, aryl). ¹³C NMR (CDCl₃, 100 MHz)
50
51 δ: 13.6; 21.5; 25.5; 28.3; 50.6; 52.9; 53.7; 106.9; 115.3; 115.5; 121.7; 123.7; 126.2; 129.3; 129.4;
52
53
54
55
56
57
58
59
60

1
2
3 131.5; 133.6; 151.2; 160.5; 163.7. ^{19}F NMR (CDCl_3 , 376.3 MHz) δ : -(113.51-113.43) (m, 1F, CF)
4
5 HR-MS m/z : calcd for $\text{C}_{19}\text{H}_{24}\text{FN}_2\text{O}_2\text{S}$, $[(\text{M}+\text{H})^+]$: 363.1537; found 363.1545
6
7
8
9

10 **N-(1-(4-fluorobenzyl)indolin-5-yl)-2-methylpropane-1-sulfonamide (8d)**

11 Final product **8d** was obtained from 1-(4-fluorobenzyl)indolin-5-amine (**3**) and 2-methylpropane-1-
12 sulfonyl chloride following the general procedure C. The product was isolated in 71% yield as an off-
13 white powder that crystallizes from n-hexane/diethyl ether. ^1H NMR (CDCl_3 , 400 MHz): δ : 1.08 (d,
14 6H, CH_3 , $J = 6.6$ Hz); 2.26-2.31 (m, 1H, CH); 2.90 (d, 2H, CH_2 , $J = 6.3$ Hz); 2.96 (t, 2H, CH_2 , $J = 8.2$
15 Hz); 3.32 (t, 2H, CH_2 , $J = 8.2$ Hz); 4.19 (s, 2H, CH_2); 6.18 (s, 1H, NH); 6.38 (d, 1H, aryl, $J = 7.8$ Hz);
16 6.88 (d, 1H, aryl, $J = 7.4$ Hz); 7.00-7.04 (m, 3H, aryl); 7.29-7.32 (m, 2H, aryl). ^{13}C NMR (CDCl_3 ,
17 100 MHz) δ : 21.3; 24.6; 27.6; 48.5; 53.9; 58.6; 58.8; 115.6; 115.8; 116.5; 118.7; 119.2; 126.5; 132.7;
18 132.8; 136.4; 136.7; 139.6; 162.4; 164.9. ^{19}F NMR (CDCl_3 , 376.3 MHz) δ : -(114.75-114.68) (m, 1F,
19 CF) HR-MS m/z : calcd for $\text{C}_{19}\text{H}_{24}\text{FN}_2\text{O}_2\text{S}$, $[(\text{M}+\text{H})^+]$: 363.1537; found 363.1545
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34

35 **N-(1-(4-fluorobenzyl)indolin-5-yl)hexane-1-sulfonamide (8e)**

36 Final product **8e** was obtained from 1-(4-fluorobenzyl)indolin-5-amine (**3**) and hexanesulfonyl
37 chloride following the general procedure C. The product was isolated in 67% yield as a grey powder
38 that crystallizes from ethyl acetate. ^1H NMR (CD_3OD , 400 MHz): δ : 0.91 (t, 3H, CH_3 , $J = 7.9$ Hz);
39 1.28-1.34 (m, 4H, CH_2); 1.36-1.46 (m, 2H, CH_2); 1.75-1.82 (m, 2H, CH_2); 3.13-3.18 (m, 4H, 2 CH_2);
40 3.91 (t, 2H, CH_2 , $J = 8.2$ Hz); 4.70 (s, 2H, CH_2); 7.18-7.27 (m, 3H, aryl); 7.33-7.35 (m, 2H, aryl);
41 7.49-7.52 (m, 2H, aryl). ^{13}C NMR (CD_3OD , 100 MHz) δ : 12.9; 22.0; 23.2; 27.6; 31.0; 51.1; 53.4;
42 53.9; 58.9; 115.8; 116.3; 118.9; 119.3; 126.1; 133.0; 135.7; 137.0; 140.2; 162.5; 165.0. ^{19}F NMR
43 (CDCl₃, 376.3 MHz) δ : -(113.17-113.10) (m, 1F, CF) HR-MS m/z : calcd for $\text{C}_{21}\text{H}_{28}\text{FN}_2\text{O}_2\text{S}$,
44 $[(\text{M}+\text{H})^+]$: 391.1850; found 391.1862
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **1-((1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]heptan-1-yl)-N-(1-(4-fluorobenzyl)indolin-5-**
4
5
6 **yl)methanesulfonamide (8f)**

7 Final product **8f** was obtained from 1-(4-fluorobenzyl)indolin-5-amine (**3**) and (1S)-(+)-10-
8 camphorsulfonyl chloride following the general procedure C. The product was isolated in 57% yield
9
10 as a grey powder that crystallizes from n-hexane/ethyl acetate. $[\alpha]^{25}_{\text{D}}$: 37.50 ± 0.05 (c = 0.12, MeOH).

11
12
13
14 ^1H NMR (CDCl_3 , 400 MHz): δ : 0.92 (s, 3H, CH_3); 0.99 (s, 3H, CH_3); 1.47-1.52 (m, 1H, CH); 1.98-
15 2.20 (m, 4H, CH_2 and 2 CH); 2.44-2.51 (m, 1H, CH); 2.81 (d, 1H, CH , $J = 15.3$ Hz); 2.98 (t, 2H,
16 17 CH_2 , $J = 8.3$ Hz); 3.28-3.36 (m, 4H, 2 CH_2); 3.44 (d, 1H, CH , $J = 15.2$ Hz); 4.21 (s, 2H, CH_2); 6.41
18 19 (d, 1H, aryl, $J = 8.3$ Hz); 6.94 (d, 1H, aryl, $J = 8.3$ Hz); 7.04 (t, 2H, aryl $J = 8.7$ Hz); 7.10 (s, 1H,
20 21 aryl); 7.31-7.35 (m, 2H, aryl); 7.45 (s, 1H, NH). ^{13}C NMR (CDCl_3 , 100 MHz) δ : 19.4; 19.9; 27.1;
22 23 24 25 26 27 28 29 30 31 32 33 34 35
27.8; 28.4; 42.9; 43.1; 48.1; 49.1; 53.0; 53.7; 59.8; 106.8; 115.3; 115.5; 121.9; 123.5; 127.7; 129.3;
129.4; 131.3; 133.8; 151.1; 160.9; 163.3; 217.5. ^{19}F NMR (CDCl_3 , 376.3 MHz) δ : -(115.58-115.50)
(m, 1F, CF) HR-MS m/z : calcd for $\text{C}_{25}\text{H}_{30}\text{FN}_2\text{O}_3\text{S}$, $[(\text{M}+\text{H})^+]$: 457.1986; found 457.2001

36 **1-((1R,4S)-7,7-dimethyl-2-oxobicyclo[2.2.1]heptan-1-yl)-N-(1-(4-fluorobenzyl)indolin-5-**
37
38 **yl)methanesulfonamide (8g)**

39 Final product **8g** was obtained from 1-(4-fluorobenzyl)indolin-5-amine (**3**) and (1R)-(-)-10-
40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
42 camphorsulfonyl chloride following the general procedure C. The product was isolated in 50% yield
43 as a grey powder that crystallizes from n-hexane/ethyl acetate. $[\alpha]^{25}_{\text{D}}$: -38.10 ± 0.06 (c = 0.12,
44 MeOH).

45 ^1H NMR (CDCl_3 , 300 MHz): δ : 0.92 (s, 3H, CH_3); 0.98 (s, 3H, CH_3); 1.47-1.52 (m, 1H,
46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
49 CH); 1.97-2.22 (m, 5H, 2 CH_2 and CH); 2.44-2.52 (m, 1H, CH); 2.80 (d, 1H, CH , $J = 15.6$ Hz); 2.97
50 (t, 2H, CH_2 , $J = 8.6$ Hz); 3.32 (t, 2H, CH_2 , $J = 8.6$ Hz); 3.43 (d, 1H, CH , $J = 16.0$ Hz); 4.21 (s, 2H,
51 52 53 54 55 56 57 58 59 60
52 CH_2); 6.41 (d, 1H, aryl, $J = 8.4$ Hz); 6.93 (d, 1H, aryl, $J = 8.4$ Hz); 7.01-7.10 (m, 3H, aryl); 7.30-7.35
53 (m, 2H, aryl); 7.47 (s, 1H, NH). ^{13}C NMR (CDCl_3 , 75 MHz) δ : 19.4; 20.0; 27.1; 27.7; 28.4; 42.9;
43.1; 48.1; 49.1; 53.0; 53.7; 59.8; 106.8; 115.3; 115.56; 121.8; 123.5; 127.7; 129.40; 129.44; 131.3;

1
2
3 133.8; 151.1; 160.9; 163.3; 217.5. ^{19}F NMR (CDCl_3 , 376.3 MHz) δ : -(115.89-115.82) (m, 1F, CF).

4
5 HR-MS m/z : calcd for $\text{C}_{25}\text{H}_{30}\text{FN}_2\text{O}_3\text{S}$, $[(\text{M}+\text{H})^+]$: 457.1986; found 457.1995

6
7
8
9
10 **N-(1-(4-fluorobenzyl)indolin-5-yl)azepane-1-sulfonamide (8h)**

11
12 Final product **8h** was obtained from 1-(4-fluorobenzyl)indolin-5-amine (**3**) and azepane-1-sulfonyl
13 chloride following the general procedure C. The product was isolated in 69% yield as an off-white
14 powder that crystallizes from n-hexane/diethyl ether. ^1H NMR (CDCl_3 , 400 MHz): δ : 1.56-1.59 (m,
15 4H, 2 CH_2); 1.68-1.70 (m, 4H, 2 CH_2); 2.97 (t, 2H, CH_2 , $J = 8.3$ Hz); 3.29-3.34 (m, 6H, 3 CH_2); 4.21
16 (s, 2H, CH_2); 6.27 (s, 1H, NH); 6.41 (d, 1H, aryl, $J = 8.3$ Hz); 6.90 (d, 1H, aryl, $J = 8.2$ Hz); 7.02-
17 7.06 (m, 3H, aryl); 7.31-7.34 (m, 2H, aryl). ^{13}C NMR (CDCl_3 , 100 MHz) δ : 26.9; 28.4; 29.1; 48.9;
18 53.1; 53.7; 106.8; 115.2; 115.5; 121.4; 123.5; 127.4; 129.4; 129.5; 131.1; 133.8; 150.8; 160.9; 163.3.
19 ^{19}F NMR (CDCl_3 , 376.3 MHz) δ : -(115.58-115.51) (m, 1F, CF). HR-MS m/z : calcd for
20 $\text{C}_{21}\text{H}_{27}\text{FN}_3\text{O}_2\text{S}$, $[(\text{M}+\text{H})^+]$: 404.1803; found 404.1876

21
22
23
24
25
26
27
28
29
30
31
32
33
34
35 **N-(1-(4-fluorobenzyl)indolin-5-yl)-3,5-dimethylpiperidine-1-sulfonamide (8i)**

36
37 Final product **8i** was obtained as a conformers mixture (A:B, 4:1) from 1-(4-fluorobenzyl)indolin-5-
38 amine (**3**) and 3,5-dimethylpiperidine-1-sulfonyl chloride following the general procedure C. The
39 product was isolated in 65% yield as an off-white powder that crystallizes from ethyl acetate. ^1H
40 NMR (CD_3OD , 400 MHz): δ : (A) = 0.60-0.69 (m, 1H, CH); 0.88 (s, 3H, CH_3); 0.90 (s, 3H, CH_3);
41 1.56-1.60 (m, 2H, CH_2); 1.75 (d, 2H, CH_2 , $J = 12.9$ Hz); 2.24 (t, 2H, CH_2 , $J = 11.7$ Hz); 3.12 (bs,
42 2H, CH_2); 3.66-3.69 (m, 2H, CH_2); 3.86 (bs, 2H, CH_2); 4.66 (s, 2H, CH_2); 7.17-7.24 (m, 5H, aryl);
43 7.46-7.49 (m, 2H, aryl). (B) = 0.88 (s, 3H, CH_3); 0.90 (s, 3H, CH_3); 1.37 (t, 2H, CH_2 , $J = 5.7$ Hz);
44 1.75 (d, 2H, CH_2 , $J = 12.9$ Hz); 1.89-1.91 (m, 2H, CH_2); 2.83-2.88 (m, 2H, CH_2); 3.12 (bs, 2H, CH_2);
45 3.22-3.26 (m, 2H, CH_2); 3.86 (bs, 2H, CH_2); 4.66 (s, 2H, CH_2); 7.17-7.24 (m, 5H, aryl); 7.46-7.49
46 (m, 2H, aryl). ^{13}C NMR (CD_3OD , 100 MHz) δ : (A + B) = 17.2; 17.8; 26.7; 27.6; 30.8; 38.0; 41.3;

52.4; 52.6; 53.9; 58.7; 58.8; 115.6; 115.8; 118.4; 118.8; 132.8; 132.9; 136.5; 162.5; 164.9. ^{19}F NMR (CDCl_3 , 376.3 MHz) δ : -(116.04-116.12) (m, 1F, CF). HR-MS m/z : calcd for $\text{C}_{22}\text{H}_{29}\text{FN}_3\text{O}_2\text{S}$, [(M+H) $^+$]: 418.1959; found 418.1964

N-(1-(4-fluorobenzyl)indolin-5-yl)acetamide (9a)

Final product **9a** was obtained from 1-(4-fluorobenzyl)indolin-5-amine (**3**) and acetyl chloride following the general procedure D. The product was isolated in 84% yield as a white powder that crystallizes from n-hexane/diethyl ether. ^1H NMR (CD_3OD , 400 MHz) δ : 2.09 (s, 3H, CH_3); 2.91 (t, 2H, CH_2 , $J = 8.2$ Hz); 3.24 (t, 2H, CH_2 , $J = 8.2$ Hz); 4.20 (s, 2H, CH_2); 6.50 (d, 1H, aryl, $J = 8.4$ Hz); 7.04-7.12 (m, 3H, aryl); 7.27 (s, 1H, aryl); 7.37-7.40 (m, 2H, aryl). ^{13}C NMR (CD_3OD , 100 MHz) δ : 22.2; 28.0; 52.9; 53.5; 106.8; 114.6; 114.8; 118.0; 119.9; 129.3; 129.5; 130.5; 134.32; 134.35; 149.5; 160.9; 163.3; 169.9. ^{19}F NMR (CD_3OD , 376.3 MHz) δ : -(117.98-118.06) (m, 1F, CF). HR-MS m/z : calcd for $\text{C}_{17}\text{H}_{18}\text{FN}_2\text{O}$, [(M+H) $^+$]: 285.1398; found 285.1405

N-(1-(4-fluorobenzyl)indolin-5-yl)cyclohexanecarboxamide (9b)

Final product **9b** was obtained from 1-(4-fluorobenzyl)indolin-5-amine (**3**) and cyclohexanecarbonyl chloride following the general procedure D. The product was isolated in 79% yield as a white powder that crystallizes from ethyl acetate. ^1H NMR (CDCl_3 , 400 MHz) δ : 1.22-1.38 (m, 3H, CH_2); 1.50-1.71 (m, 3H, CH_2); 1.84-1.87 (m, 2H, CH_2); 1.95-1.98 (m, 2H, CH_2); 2.18-2.24 (m, 1H, CH); 2.96 (t, 2H, CH_2 , $J = 8.2$ Hz); 3.28 (t, 2H, CH_2 , $J = 8.2$ Hz); 4.19 (s, 2H, CH_2); 6.42 (d, 1H, aryl, $J = 8.3$ Hz); 7.01-7.06 (m, 4H, aryl); 7.31-7.35 (m, 2H, aryl); 7.39 (s, 1H, NH). ^{13}C NMR (CDCl_3 , 100 MHz) δ : 25.8; 28.6; 29.8; 46.4; 53.3; 53.8; 106.8; 115.2; 115.4; 118.4; 119.8; 129.0; 129.5; 133.97; 134.0; 149.5; 160.8; 163.3; 174.1. ^{19}F NMR (CDCl_3 , 376.3 MHz) δ : -(115.73-115.81) (m, 1F, CF); HR-MS m/z : calcd for $\text{C}_{22}\text{H}_{26}\text{FN}_2\text{O}$, [(M+H) $^+$]: 353.2024; found 353.2031

2-cyclohexyl-N-(1-(4-fluorobenzyl)indolin-5-yl)acetamide (9c)

Final product **9c** was synthesized starting from 1-(4-fluorobenzyl)indolin-5-amine (**3**) and 2-cyclohexylacetyl chloride following the general procedure D. The product was isolated in 81% yield as a white powder that crystallizes from methanol. ¹H NMR (DMSO-d₆, 400 MHz): δ: 0.92-1.00 (m, 2H, CH₂); 1.11-1.27 (m, 3H, CH₂); 1.60-1.74 (m, 5H, CH₂); 2.11 (d, 2H, CH₂, J = 7.0 Hz); 2.85 (t, 2H, CH₂, J = 8.3 Hz); 3.18 (t, 2H, CH₂, J = 8.3 Hz); 4.20 (s, 2H, CH₂); 6.51 (d, 1H, aryl, J = 8.4 Hz); 7.12-7.19 (m, 3H, aryl); 7.34-7.40 (m, 3H, aryl); 9.48 (s, 1H, NH). ¹³C NMR (DMSO-d₆, 100 MHz) δ: 26.1; 26.4; 28.6; 33.0; 35.4; 44.6; 52.8; 53.5; 107.3; 115.4; 115.6; 117.5; 119.0; 130.2; 130.4; 130.5; 130.7; 134.90; 134.92; 148.7; 160.5; 163.0; 170.0. ¹⁹F NMR (CDCl₃, 376.3 MHz) δ: -(115.99-115.91) (s, 1F, CF). HR-MS *m/z*: calcd for C₂₃H₂₈FN₂O, [(M+H)⁺]: 367.2186; found 367.2195

tert-butyl 5-nitroindoline-1-carboxylate (10b)

5-nitroindoline (**1**, 1.0 eq) was dissolved in DCM and added with 2.0 equivalents of TEA and 2.0 equivalents of di-tert-butyl dicarbonate. The mixture was refluxed overnight under stirring. Upon cooling to room temperature the mixture was extracted three times with aqueous 2N HCl. The organic phase was dried over anhydrous Na₂SO₄, filtered and evaporated under vacuum. Crude product was purified by silica gel chromatography using a linear gradient of n-hexane/ethyl acetate as mobile phase. After flash-chromatographic purification, tert-butyl 5-nitroindoline-1-carboxylate (**10b**) was obtained as an orange crystal in 64% yield. ¹H NMR (CDCl₃, 400 MHz) δ: 1.47 (s, 9H, Boc); 2.93 (t, 2H, CH₂, J = 8.0 Hz); 3.76-3.90 (m, 4H, CH₂ and NH₂); 6.42-6.47 (m, 2H, aryl); 7.57 (bs, 1H, aryl). HR-MS *m/z*: calcd for C₁₃H₁₉N₂O₂, [(M+H)⁺]: 235.1441; found 235.1452

1-(2,4-difluorobenzyl)-5-nitroindoline (11a)

Synthesized according to the general procedure A using 5-nitroindoline (**1**) and 2,4-difluorobenzaldehyde as reagents. Intermediate **11a** was obtained as a yellow powder in 72% yield.

¹H NMR (CDCl₃, 400 MHz): δ: 3.12 (t, 2H, CH₂, *J* = 8.4 Hz); 3.66 (t, 2H, CH₂, *J* = 8.4 Hz); 4.45 (s, 2H, CH₂); 6.40 (d, 1H, aryl, *J* = 8.5 Hz); 6.85-6.91 (m, 2H, aryl); 7.21-7.28 (m, 1H, aryl); 7.93 (s, 1H, aryl); 8.08 (d, 1H, aryl, *J* = 6.5 Hz). HR-MS *m/z*: calcd for C₁₅H₁₃F₂N₂O₂, [(M+H)⁺]: 291.0940; found 291.0951

1-(3,4-difluorobenzyl)-5-nitroindoline (11b)

Synthesized according to the general procedure A using 5-nitroindoline (**1**) and 3,4-difluorobenzaldehyde as reagents. Intermediate **11b** was obtained as a yellow powder in 60% yield.

¹H NMR (CDCl₃, 400 MHz): δ: 3.14 (t, 2H, CH₂, *J* = 8.4 Hz); 3.64 (t, 2H, CH₂, *J* = 8.4 Hz); 4.40 (s, 2H, CH₂); 6.35 (d, 1H, aryl, *J* = 8.6 Hz); 7.00-7.22 (m, 3H, aryl); 7.96 (s, 1H, aryl); 8.08 (d, 1H, aryl, *J* = 6.2 Hz). HR-MS *m/z*: calcd for C₁₅H₁₃F₂N₂O₂, [(M+H)⁺]: 291.0940; found 291.0952

5-nitro-1-(4-(trifluoromethyl)benzyl)indoline (11c)

Synthesized according to the general procedure A using 5-nitroindoline (**1**) and 4-(trifluoromethyl)benzaldehyde as reagents. Intermediate **11c** was obtained as a yellow powder in 76%

yield. ¹H NMR (CDCl₃, 400 MHz): δ: 3.14 (t, 2H, CH₂, *J* = 8.5 Hz); 3.67 (t, 2H, CH₂, *J* = 8.5 Hz); 4.51 (s, 2H, CH₂); 6.33 (d, 1H, aryl, *J* = 8.3 Hz); 7.41 (d, 2H, aryl, *J* = 12.0 Hz); 7.63 (d, 2H, aryl, *J* = 12.0 Hz); 7.92 (s, 1H, aryl); 8.03 (d, 1H, aryl, *J* = 6.5 Hz). HR-MS *m/z*: calcd for C₁₆H₁₄F₃N₂O₂, [(M+H)⁺]: 323.1002; found 323.1010

1-(4-methoxybenzyl)-5-nitroindoline (11d)

Synthesized according to the general procedure A using 5-nitroindoline (**1**) and p-anisaldehyde as reagents. Intermediate **11d** was isolated as a yellow powder in 72% yield. ¹H NMR (CDCl₃, 400

MHz): δ: 3.07 (t, 2H, CH₂, *J* = 8.4 Hz); 3.62 (t, 2H, CH₂, *J* = 8.4 Hz); 3.83 (s, 3H, CH₃); 4.39 (s, 2H, CH₂); 6.37 (d, 1H, aryl, *J* = 8.4 Hz); 6.90 (d, 2H, aryl, *J* = 9.8 Hz); 7.20 (d, 2H, aryl, *J* = 9.8 Hz); 7.93

(s, 1H, aryl); 8.08 (d, 1H, aryl, $J = 6.6$ Hz). HR-MS m/z : calcd for $C_{16}H_{17}N_2O_3$, $[(M+H)^+]$: 285.1234; found 185.1284

1-(2,4-bis(trifluoromethyl)benzyl)-5-nitroindoline (11e)

Synthesized according to the general procedure A using 5-nitroindoline (**1**) and 2,4-bis(trifluoromethyl)benzaldehyde as reagents. Intermediate **11e** was obtained as a yellow powder in 58% yield. 1H NMR ($CDCl_3$, 400 MHz): δ : 3.22 (t, 2H, CH_2 , $J = 8.4$ Hz); 3.75 (t, 2H, CH_2 , $J = 8.4$ Hz); 4.70 (s, 2H, CH_2); 6.25 (d, 1H, aryl, $J = 8.6$ Hz); 7.61 (d, 1H, aryl, $J = 8.6$ Hz); 7.81 (d, 1H, aryl, $J = 8.9$ Hz); 7.97-8.05 (m, 3H, aryl). HR-MS m/z : calcd for $C_{17}H_{13}F_6N_2O_2$, $[(M+H)^+]$: 391.0876; found 391.0884

1-(4-methoxybenzyl)-2-methyl-5-nitroindoline (11f)

Synthesized according to the general procedure A using 2-methyl-5-nitroindoline (**10a**) and *p*-anisaldehyde as reagents. Intermediate **11f** was isolated as a yellow powder in 72% yield. 1H NMR ($CDCl_3$, 400 MHz): δ : 1.33 (d, 3H, CH_3 , $J = 7.4$ Hz); 2.67-2.75 (m, 1H, CH); 3.20-3.28 (m, 1H, CH); 3.81-3.91 (m, 4H, CH and CH_3); 4.20 (d, 1H, CH , $J = 14.7$ Hz), 4.43 (d, 1H, CH , $J = 14.7$ Hz); 6.88 (d, 2H, aryl, $J = 10.1$ Hz); 7.10 (s, 1H, aryl); 7.51 (d, 2H, aryl, $J = 12.0$ Hz); 7.84 (d, 2H, aryl, $J = 8.5$ Hz). HR-MS m/z : calcd for $C_{17}H_{19}N_2O_3$, $[(M+H)^+]$: 299.1390; found 299.1401

tert-butyl 5-(cyclohexanesulfonamido)indoline-1-carboxylate (11g)

tert-butyl 5-nitroindoline-1-carboxylate (**10b**), synthesized according to the procedure described in supplementary materials, was reduced to the corresponding tert-butyl 5-aminoindoline-1-carboxylate by the general procedure B. The amine intermediate was reacted, without further purification, with cyclohexanesulfonyl chloride, following the general procedure C and giving **11g** in 54% yield as a grey solid. 1H NMR ($CDCl_3$, 400 MHz): δ : 1.12-1.26 (m, 3H, CH_2 and CH); 1.27-1.74 (m, 12H, Boc

and CH_2); 1.83-1.90 (m, 2H, CH_2); 2.07-2.17 (m, 2H, CH_2); 2.86-2.95 (m, 1H, CH); 3.07 (t, 2H, CH_2 , $J = 8.6$ Hz); 3.96 (t, 2H, CH_2 , $J = 8.6$ Hz); 6.99-3.07 (m, 1H, aryl); 7.14 (s, 1H, aryl); 7.37 (bs, 1H, aryl); 7.76 (bs, 1H, NH). HR-MS m/z : calcd for $C_{19}H_{29}N_2O_4S$, $[(M+H)^+]$: 381.1843; found 381.1849.

1-(2,4-difluorobenzyl)indolin-5-amine (12a)

Synthesized according to the general procedure B. Intermediate **12a** was isolated as a grey powder in 97% yield. 1H NMR ($CDCl_3$, 400 MHz): δ : 2.92 (t, 2H, CH_2 , $J = 8.7$ Hz); 3.23-3.32 (m, 4H, CH_2 and NH_2); 4.18 (s, 2H, CH_2); 6.41 (d, 1H, aryl, $J = 6.4$ Hz); 6.49 (d, 1H, aryl, $J = 6.4$ Hz); 6.61 (s, 1H, aryl); 6.81-6.90 (m, 2H, aryl); 7.40-7.48 (m, 1H, aryl). HR-MS m/z : calcd for $C_{15}H_{15}F_2N_2$, $[(M+H)^+]$: 261.1198; found 261.1205.

1-(3,4-difluorobenzyl)indolin-5-amine (12b)

Synthesized according to the general procedure B. Intermediate **12b** was isolated as an off-white powder in 98% yield. 1H NMR ($CDCl_3$, 400 MHz): δ : 2.93 (t, 2H, CH_2 , $J = 8.5$ Hz); 3.03 (bs, 2H, NH_2); 3.20 (t, 2H, CH_2 , $J = 8.5$ Hz); 4.11 (s, 2H, CH_2); 6.28 (d, 1H, aryl, $J = 6.4$ Hz); 6.35 (d, 1H, aryl, $J = 7.2$ Hz); 6.51 (s, 1H, aryl); 7.09-7.27 (m, 3H, aryl). HR-MS m/z : calcd for $C_{15}H_{15}F_2N_2$, $[(M+H)^+]$: 261.1198; found 261.1205.

1-(4-(trifluoromethyl)benzyl)indolin-5-amine (12c)

Synthesized according to the general procedure B. Intermediate **12c** was isolated as a white powder in 95% yield. 1H NMR ($CDCl_3$, 400 MHz): δ : 2.94 (t, 2H, CH_2 , $J = 8.6$ Hz); 3.21-3.27 (m, 4H, CH_2 and NH_2); 4.21 (s, 2H, CH_2); 6.35 (d, 1H, aryl, $J = 8.9$ Hz); 6.48 (d, 1H, aryl, $J = 8.9$ Hz); 6.63 (s, 1H, H-4); 7.54 (d, 2H, aryl, $J = 5.7$ Hz); 7.62 (d, 2H, aryl, $J = 6.1$ Hz). HR-MS m/z : calcd for $C_{16}H_{16}F_3N_2$, $[(M+H)^+]$: 293.1260; found 293.1269.

1-(4-methoxybenzyl)indolin-5-amine (12d)

Synthesized according to the general procedure B. Intermediate **12d** was isolated as a grey powder in 98% yield. ¹H NMR (CDCl₃, 400 MHz): δ: 2.88 (t, 2H, CH₂, *J* = 8.3 Hz); 3.17-3.23 (m, 4H, CH₂ and NH₂); 3.83 (s, 3H, CH₃); 4.10 (s, 2H, CH₂); 6.41 (d, 1H, aryl, *J* = 8.2 Hz); 6.47 (d, 1H, aryl, *J* = 9.2 Hz); 6.61 (s, 1H, aryl); 6.89 (d, 2H, aryl, *J* = 8.7 Hz); 7.31 (d, 2H, aryl, *J* = 8.7 Hz). HR-MS *m/z*: calcd for C₁₆H₁₉N₂O, [(M+H)⁺]: 255.1492; found 255.1501.

1-(2,4-bis(trifluoromethyl)benzyl)indolin-5-amine (12e)

Synthesized according to the general procedure B. Intermediate **12e** was isolated as a white powder in 94% yield. ¹H NMR (CDCl₃, 400 MHz): δ: 2.71 (t, 2H, CH₂, *J* = 8.5 Hz); 3.37 (t, 2H, CH₂, *J* = 8.5 Hz); 3.50 (bs, 2H, NH₂); 4.40 (s, 2H, CH₂); 6.20 (d, 1H, aryl, *J* = 7.5 Hz); 6.48 (d, 1H, aryl, *J* = 7.4 Hz); 6.56 (s, 1H, aryl); 7.58 (d, 1H, aryl, *J* = 6.2 Hz); 7.95-8.02 (m, 2H, aryl). HR-MS *m/z*: calcd for C₁₇H₁₅F₆N₂, [(M+H)⁺]: 361.1134; found 361.1140.

1-(4-methoxybenzyl)-2-methylindolin-5-amine (12f)

Synthesized according to the general procedure B. Intermediate **12f** was isolated as an off-white powder in 96% yield. ¹H NMR (CDCl₃, 400 MHz): δ: 1.33 (d, 3H, CH₃, *J* = 7.3 Hz); 2.52-2.62 (m, 1H, CH); 3.02-3.11 (m, 1H, CH); 3.35 (bs, 2H, NH₂); 3.84 (s, 3H, CH₃); 4.12 (d, 1H, CH₂, *J* = 15.4 Hz); 4.30 (d, 1H, CH₂, *J* = 15.4 Hz); 5.76 (d, 1H, aryl, *J* = 3.8 Hz); 6.00 (d, 1H, aryl, *J* = 8.2 Hz); 6.82-6.90 (m, 3H, aryl); 7.29 (d, 2H, aryl, *J* = 8.0 Hz); HR-MS *m/z*: calcd for C₁₇H₂₁N₂O, [(M+H)⁺]: 269.1348; found 269.1351.

N-(indolin-5-yl)cyclohexanesulfonamide (12g)

Intermediate **11g** was dissolved in a solution of TFA in DCM (20% v:v) and stirred at room temperature for 45 minutes. The reaction was then diluted with DCM and extracted with water and

saturated solution of NaHCO₃. The organic phase was dried over anhydrous Na₂SO₄, filtered and evaporated under vacuum. Purification by flash chromatography gave **12g** as a grey solid in 90% yield ¹H NMR (CD₃OD, 400 MHz): δ: 1.18-1.31 (m, 2H, CH₂); 1.48-1.70 (m, 4H, 2 CH₂); 1.85-1.89 (m, 2H, CH₂); 2.11-2.17 (m, 2H, CH₂); 2.99-3.08 (m, 1H, CH); 3.31 (t, 2H, CH₂, *J* = 8.9 Hz); 3.86 (t, 2H, CH₂, *J* = 8.9 Hz); 7.28 (d, 1H, aryl, *J* = 6.8 Hz); 7.41-7.43 (m, 2H, aryl). HR-MS *m/z*: calcd for C₁₄H₂₁N₂O₂S, [(M+H)⁺]: 281.1318; found 281.1326.

N-(1-(2,4-difluorobenzyl)indolin-5-yl)cyclohexanesulfonamide (13a)

Final product **13a** was synthesized according to the general procedure C. It was isolated in 71% yield as an off-white powder that crystallizes from n-hexane/ethyl acetate. ¹H NMR (CDCl₃, 400 MHz): δ: 1.21-1.26 (m, 3H, CH₂); 1.55-1.71 (m, 3H, CH₂); 1.88-1.91 (m, 2H, CH₂); 2.17-2.20 (m, 2H, CH₂); 2.95-3.02 (m, 3H, CH₂ and CH); 3.40 (t, 2H, CH₂, *J* = 8.3 Hz); 4.26 (s, 2H, CH₂); 6.21 (s, 1H, NH); 6.43 (d, 2H, aryl, *J* = 8.3 Hz); 6.82-6.93 (m, 3H, aryl); 7.07 (s, 1H, aryl); 7.34-7.40 (m, 1H, aryl). ¹³C NMR (CDCl₃, 100 MHz) δ: 25.1; 26.4; 28.4; 46.5; 53.7; 59.3; 103.6; 103.9; 104.1; 106.8; 111.13; 111.17; 111.34; 111.38; 115.0; 116.5; 120.75; 120.79; 120.90; 120.94; 121.29; 123.19; 123.23; 126.61; 126.71; 126.75; 130.72; 130.78; 130.81; 130.87; 131.3; 150.6; 159.63; 159.75; 160.98; 161.10; 162.1; 162.2; 163.45; 163.57. ¹⁹F NMR (CDCl₃, 376.3 MHz) δ: -(113.98-113.91) (m, 1F, CF); -(115.54-115.46) (m, 1F, CF); HR-MS *m/z*: calcd for C₂₁H₂₅F₂N₂O₂S, [(M+H)⁺]: 407.1599; found 407.1611; [(M+Na)⁺]: 429.1419; found 429.1427

N-(1-(3,4-difluorobenzyl)indolin-5-yl)cyclohexanesulfonamide (13b)

Final product **13b** was synthesized according to the general procedure C. It was isolated in 68% yield as an off-white powder that crystallizes from n-hexane/ethyl acetate. ¹H NMR (CDCl₃, 400 MHz): δ: 1.20-1.31 (m, 3H, CH₂); 1.56-1.72 (m, 3H, CH₂); 1.89-1.92 (m, 2H, CH₂); 2.17-2.21 (m, 2H, CH₂); 2.92-2.96 (m, 1H, CH); 3.01 (t, 2H, CH₂, *J* = 8.3 Hz); 3.37 (t, 2H, CH₂, *J* = 8.3 Hz); 4.19 (s, 2H,

1
2
3 CH_2); 6.02 (s, 1H, NH); 6.36 (d, 1H, aryl, $J = 8.3$ Hz); 6.89 (d, 1H, aryl, $J = 10.3$ Hz); 7.08-7.23 (m,
4 4H, aryl). ^{13}C NMR ($CDCl_3$, 100 MHz) δ : 25.11; 25.14; 26.4; 28.4; 52.9; 53.9; 59.4; 106.9; 116.4;
5 116.6; 117.2; 117.4; 121.4; 123.29; 123.39; 123.43; 123.46; 123.49; 126.8; 131.4; 150.7; ^{19}F NMR
6 (CDCl₃, 376.3 MHz) δ : -(1137.54-137.43) (m, 1F, CF); -(139.98-139.87) (m, 1F, CF); HR-MS m/z :
7 calcd for $C_{21}H_{25}F_2N_2O_2S$, [(M+H)⁺]: 407.1599; found 407.1612; [(M+Na)⁺]: 429.1419; found
8 429.1426
9
10
11
12
13
14
15
16
17
18

19 **N-(1-(4-(trifluoromethyl)benzyl)indolin-5-yl)cyclohexanesulfonamide (13c)**

20
21 Final product **13c** was synthesized according to the general procedure C. It was isolated in 68% yield
22 as a white powder that crystallizes from n-hexane/ethyl acetate. 1H NMR ($CDCl_3$, 400 MHz): δ : 1.20-
23 1.31 (m, 3H, CH_2); 1.56-1.62 (m, 3H, CH_2); 1.70-1.72 (m, 2H, CH_2); 2.18-2.21 (m, 2H, CH_2); 2.92-
24 2.98 (m, 1H, CH); 3.02 (t, 2H, CH_2 , $J = 8.3$ Hz); 3.39 (t, 2H, CH_2 , $J = 8.3$ Hz); 4.30 (s, 2H, CH_2);
25 6.14 (s, 1H, NH); 6.37 (d, 1H, aryl, $J = 8.2$ Hz); 6.91 (d, 1H, aryl, $J = 8.2$ Hz); 7.09 (s, 1H, aryl); 7.50
26 (d, 2H, aryl, $J = 8.0$ Hz); 7.63 (d, 2H, aryl, $J = 8.0$ Hz). ^{13}C NMR ($CDCl_3$, 100 MHz) δ : 20.36; 20.40;
27 21.6; 23.7; 48.7; 49.3; 54.6; 102.12; 116.6; 118.5; 120.74; 120.77; 120.81; 120.85; 122.1; 123.2;
28 124.7; 125.0; 126.6; 137.6; 146.1; ^{19}F NMR ($CDCl_3$, 376.3 MHz) δ : -63.21 (s, 3F, CF_3); HR-MS
29 m/z : calcd for $C_{22}H_{26}F_3N_2O_2S$, [(M+H)⁺]: 439.1662; found 439.1677; [(M+Na)⁺]: 461.1481; found
30 461.1490
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

47 **N-(1-(4-methoxybenzyl)indolin-5-yl)cyclohexanesulfonamide (13d)**

48
49 Final product **13d** was synthesized according to the general procedure C. It was isolated in 68% yield
50 as a grey powder that crystallizes from n-hexane/ethyl acetate. 1H NMR ($CDCl_3$, 400 MHz): δ : 1.22-
51 1.28 (m, 3H, CH_2); 1.57-1.72 (m, 3H, CH_2); 1.89-1.93 (m, 2H, CH_2); 2.17-2.21 (m, 2H, CH_2); 2.94-
52 2.99 (m, 3H, H-3 and CH); 3.34 (t, 2H, H-2, $J = 8.3$ Hz); 3.83 (s, 3H, CH_3); 4.19 (s, 2H, CH_2); 5.93
53 (s, 1H, NH); 6.43 (d, 1H, H-7, $J = 8.3$ Hz); 6.88-6.92 (m, 3H, H-6 and aryl); 7.05 (s, 1H, H-4); 7.28
54
55
56
57
58
59
60

(d, 2H, aryl, $J = 8.6$ Hz). ^{13}C NMR (CDCl_3 , 100 MHz) δ : 25.13; 25.15; 26.4; 28.4; 53.0; 53.5; 55.3; 59.2; 106.8; 113.9; 121.5; 123.5; 126.2; 129.1; 130.0; 131.5; 151.2; 158.9; HR-MS m/z : calcd for $\text{C}_{22}\text{H}_{29}\text{F}_3\text{N}_2\text{O}_3\text{S}$, $[(\text{M}+\text{H})^+]$: 401.1893; found 401.1902; $[(\text{M}+\text{Na})^+]$: 423.1718; found 423.1724

N-(1-(2,4-bis(trifluoromethyl)benzyl)indolin-5-yl)cyclohexanesulfonamide (13e)

Final product **13e** was synthesized according to the general procedure C. It was isolated in 65% yield as a white powder that crystallizes from n-hexane/ethyl acetate. ^1H NMR (CDCl_3 , 400 MHz): δ : 1.20-1.31 (m, 3H, CH_2); 1.56-1.72 (m, 3H, CH_2); 1.90-1.92 (m, 2H, CH_2); 2.19-2.21 (m, 2H, CH_2); 2.93-2.99 (m, 1H, CH); 3.09 (t, 2H, H-3, $J = 8.3$ Hz); 3.50 (t, 2H, H-2, $J = 8.3$ Hz); 4.49 (s, 2H, CH_2); 6.17 (s, 1H, NH); 6.24 (d, 1H, H-7, $J = 8.3$ Hz); 6.89 (d, 1H, H-6, $J = 9.2$ Hz); 7.13 (s, 1H, H-4); 7.80 (d, 1H, aryl, $J = 8.1$ Hz); 7.87 (d, 1H, aryl, $J = 8.1$ Hz); 7.96 (s, 1H, aryl). ^{13}C NMR (CDCl_3 , 100 MHz) δ : 25.10; 25.14; 26.4; 28.6; 50.3; 54.5; 59.5; 106.7; 121.2; 121.4; 122.3; 123.1; 123.2; 123.31; 123.35; 125.0; 127.2; 128.5; 128.8; 128.9; 129.0; 129.5; 129.7; 130.0; 131.2; 141.7; 150.4; ^{19}F NMR (CDCl_3 , 376.3 MHz) δ : -60.57 (s, 3F, CF_3), -62.80 (s, 3F, CF_3) HR-MS m/z : calcd for $\text{C}_{23}\text{H}_{25}\text{F}_6\text{N}_2\text{O}_2\text{S}$, $[(\text{M}+\text{H})^+]$: 507.1535; found 507.1541; $[(\text{M}+\text{Na})^+]$: 529.1355; found 529.1362

(S, R)-N-(1-(4-methoxybenzyl)-2-methylindolin-5-yl)cyclohexanesulfonamide (13f)

Final product **13f** was synthesized according to the general procedure C. It was isolated in 65% yield as a yellowish wax and was not crystallized. ^1H NMR (CDCl_3 , 400 MHz): δ : 1.17-1.28 (m, 3H, CH_2); 1.33 (d, 3H, CH_3 , $J = 8.0$ Hz); 1.53-1.68 (m, 3H, CH_2); 1.84-1.86 (m, 2H, CH_2); 2.07-2.10 (m, 2H, CH_2); 2.60-2.66 (m, 1H, CH); 2.89-2.97 (m, 1H, CH); 3.10-3.16 (m, 1H, CH); 3.74-3.81 (m, 4H, CH and CH_3); 4.12 (d, 1H, CH , $J = 15.7$ Hz), 4.36 (d, 1H, CH , $J = 15.7$ Hz); 6.06 (s, 1H, NH); 6.23 (s, 1H, aryl); 6.39 (d, 1H, aryl, $J = 7.7$ Hz); 6.87 (d, 2H, aryl, $J = 8.7$ Hz); 6.94 (d, 1H, aryl, $J = 7.7$ Hz); 7.27 (d, 2H, aryl, $J = 8.7$ Hz); ^{13}C NMR (CDCl_3 , 100 MHz) δ : 19.55; 25.04; 26.29; 36.69; 49.64; 55.23; 59.62; 60.28; 99.67; 109.12; 113.89; 124.45; 125.65; 128.70; 130.24; 136.48; 153.47; 158.71 HR-

MS m/z : calcd for $C_{23}H_{31}N_2O_3S$, $[(M+H)^+]$: 415.2050; found 415.2059; $[(M+Na)^+]$: 437.1869; found 437.1874

N-(1-(4-bromo-2-nitrobenzyl)indolin-5-yl)cyclohexanesulfonamide (13g)

The final product **13g** was synthesized from **12g** and 4-bromo-2-nitrobenzaldehyde following the general procedure A. It was isolated in 71% yield as a yellowish solid that crystallizes from n-hexane/ethyl acetate 1H NMR ($CDCl_3$, 400 MHz): δ : 1.20-1.31 (m, 3H, CH_2 and CH); 1.58-1.72 (m, 3H, CH_2 and CH); 1.89-1.93 (m, 2H, CH_2); 2.17-2.20 (m, 2H, CH_2); 2.91-2.99 (m, 1H, CH); 3.06 (t, 2H, CH_2 , $J = 8,3$ Hz); 3.46 (t, 2H, H-2, $J = 8.3$ Hz); 4.54 (s, 2H, CH_2); 5.99 (s, 1H, NH); 6.26 (d, 1H, aryl, $J = 8.3$ Hz); 6.87 (d, 1H, aryl, $J = 8.2$ Hz); 7.10 (s, 1H, aryl); 7.59 (d, 1H, aryl, $J = 8.3$ Hz); 7.74 (d, 1H, aryl, $J = 10.3$ Hz); 8.21 (s, 1H, aryl). ^{13}C NMR ($CDCl_3$, 100 MHz) δ : 25.10, 25.13; 26.4; 28.5; 51.6; 54.7; 59.4; 106.8; 121.2; 121.4; 123.3; 127.2; 128.0; 131.2; 133.5; 136.5; 148.8; 150.4. HR-MS m/z : calcd for $C_{21}H_{25}BrN_3O_4S$, $[(M+H)^+]$: 494.0744; found 494.0755; $[(M+Na)^+]$: 516.0563; found 516.0570

(4-fluorophenyl)(5-nitroindolin-1-yl)methanone (14a)

To a solution of 5-nitro indoline (**1**, 1.0 eq) and DIPEA (1.2 eq) stirred at 0°C under nitrogen stream, was added dropwise a solution of 4-fluorobenzoyl chloride (1.2 eq) in DCM. The resulting mixture was allowed to warm to room temperature and stirred for further 2h. Then, the reaction was quenched by adding a saturated solution of $NaHCO_3$. The organic phase was extracted two more times with aqueous HCl 2N, dried over anhydrous Na_2SO_4 , filtered and evaporated under vacuum. Crude product was purified by flash chromatography giving **14a** as a yellowish solid in 81% yield. 1H NMR ($CDCl_3$, 400 MHz): δ : 3.24 (t, 2H, CH_2 , $J = 8.5$ Hz); 4.21 (t, 2H, CH_2 , $J = 8.5$ Hz); 7.16-7.19 (m, 2H, aryl); 7.60-7.64 (m, 2H, aryl); 7.79 (bs, 1H, aryl); 8.10-8.14 (m, 2H, aryl). HR-MS m/z : calcd for $C_{15}H_{12}FN_2O_3$, $[(M+H)^+]$: 287.0826; found 287.0833

2-(4-chlorophenyl)-1-(5-nitroindolin-1-yl)ethan-1-one (14b)

Intermediate **14b** was synthesized using the same procedure described above for **14a**, starting from 5-nitro indoline (**1**) and 2-(4-chlorophenyl)acetyl chloride. Flash chromatographic purification gave **14b** as a dark yellow solid in 79% yield. ¹H NMR (CDCl₃, 400 MHz): δ: 3.29 (t, 2H, CH₂, *J* = 8.3 Hz); 3.82 (s, 2H, CH₂); 4.23 (t, 2H, CH₂, *J* = 8.3 Hz); 7.24 (d, 2H, aryl, *J* = 8.5 Hz); 7.36 (d, 2H, aryl, *J* = 8.5 Hz); 8.04 (s, 1H, aryl); 8.12 (d, 1H, aryl, *J* = 6.8 Hz); 8.33 (d, 1H, aryl, *J* = 7.2 Hz). HR-MS *m/z*: calcd for C₁₆H₁₄ClN₂O₃, [(M+H)⁺]: 317.0687 and [(M+H)⁺+2]: 319.0658; found 319.0690 and 319.0663

(5-aminoindolin-1-yl)(4-fluorophenyl)methanone (15a)

Prepared from **14a** using the general procedure B. After purification the product was isolated in 94% yield as a white solid. ¹H NMR (CDCl₃, 400 MHz): δ: 3.05 (t, 2H, CH₂, *J* = 8.6 Hz); 3.59 (bs, 2H, NH₂); 4.01 (t, 2H, CH₂, *J* = 8.6 Hz); 6.57-6.62 (m, 2H, aryl); 7.10-7.16 (m, 2H, aryl); 7.55-7.59 (m, 2H, aryl); 8.02 (bs, 1H, aryl). HR-MS *m/z*: calcd for C₁₅H₁₄FN₂O, [(M+H)⁺]: 257.1085; found 257.1094

1-(5-aminoindolin-1-yl)-2-(4-chlorophenyl)ethanone (15b)

Prepared from **14b** using the general procedure B. After purification the product was isolated in 89% yield as a white solid. ¹H NMR (CDCl₃, 400 MHz): δ: 3.09 (t, 2H, CH₂, *J* = 8.4 Hz); 3.43 (bs, 2H, NH₂); 3.63 (s, 2H, CH₂); 4.09 (t, 2H, CH₂, *J* = 8.3 Hz); 7.20 (d, 2H, aryl, *J* = 8.3 Hz); 7.31 (d, 2H, aryl, *J* = 8.3 Hz); 7.49-7.54 (m, 2H, aryl); 7.73 (d, 1H, aryl, *J* = 6.9 Hz). HR-MS *m/z*: calcd for C₁₆H₁₆ClN₂O, [(M+H)⁺]: 287.0946; found 287.0954

N-(1-(4-fluorobenzoyl)indolin-5-yl)cyclohexanesulfonamide (16a)

1
2
3 Synthesized by coupling intermediate **15a** with cyclohexylsulfonyl chloride as for the general
4 procedure C. After purification, **16a** was obtained in 61% yield as a white solid that crystallizes from
5 ethyl acetate. ¹H NMR (DMSO-d₆, 400 MHz): δ: 1.06-1.24 (m, 3H, CH₂); 1.36-1.45 (m, 2H, CH₂);
6 1.58-1.60 (m, 1H, CH₂); 1.75-1.78 (m, 2H, CH₂); 2.00-2.03 (m, 2H, CH₂); 2.89-2.97 (m, 1H, CH);
7 3.07 (t, 2H, CH₂, *J* = 8.2 Hz); 4.00 (t, 2H, CH₂, *J* = 8.2 Hz); 7.04 (bs, 1H, aryl); 7.15 (s, 1H, aryl);
8 7.32 (t, 1H, aryl, *J* = 8.8 Hz); 7.65-7.68 (m, 2H, aryl); 7.95 (bs, 1H, aryl); 9.65 (s, 1H, NH). ¹³C NMR
9 (DMSO-d₆, 100 MHz) δ: 24.8; 25.2; 26.4; 28.3; 50.9; 59.1; 115.8; 116.0; 117.3; 118.9; 130.0; 130.1;
10 133.9; 134.5; 134.9; 139.4; 162.1; 164.6; 167.2; ¹⁹F NMR (DMSO-d₆, 376.3 MHz) δ: -(117.14-
11 117.21) (m, 1F, CF). HR-MS *m/z*: calcd for C₂₁H₂₄FN₂O₃S, [(M+H)⁺]: 403.1486; found 403.1495;
12 [(M+Na)⁺]: 425.1306; found 425.1316
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27

28 **N-(1-(2-(4-chlorophenyl)acetyl)indolin-5-yl)cyclohexanesulfonamide (16b)**

29 Synthesized by coupling intermediate **15b** with cyclohexanesulfonyl chloride as for the general
30 procedure C. After purification, **16b** was obtained in 57% yield as an off-white solid that crystallizes
31 from ethyl acetate. ¹H NMR (DMSO-d₆, 400 MHz): δ: 1.05-1.24 (m, 3H, CH₂); 1.34-1.43 (m, 2H,
32 CH₂); 1.56-1.58 (m, 1H, CH); 1.73-1.76 (m, 2H, CH₂); 1.98-2.01 (m, 12H, CH₂); 2.86-2.93 (m, 1H,
33 CH); 3.14 (t, 2H, CH₂, *J* = 8.2 Hz); 3.83 (d, 2H, CH₂, *J* = 6.0 Hz); 4.16 (t, 2H, CH₂, *J* = 8.2 Hz);
34 6.99 (d, 1H, aryl, *J* = 8.6 Hz); 7.12 (s, 1H, aryl); 7.25-7.33 (m, 3H, aryl); 7.38 (d, 1H, aryl, *J* = 8.4 Hz);
35 7.94-7.98 (m, 1H, aryl); 9.59 (s, 1H, NH). ¹³C NMR (DMSO-d₆, 100 MHz) δ: 24.8; 25.2; 26.4; 27.9;
36 41.5; 48.2; 59.1; 116.7; 117.41; 117.4; 119.1; 126.9; 128.6; 128.7; 129.9; 131.7; 132.0; 133.5; 134.4;
37 134.7; 135.6; 139.8; 162.8; 169.2; HR-MS *m/z*: calcd for C₂₂H₂₆ClNO₃S, [(M+H)⁺]: 433.1347 and
38 [(M+H)⁺+2]: 435.1318; found 433.1342 and 435.1323
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55

56 **1-(4-fluorophenethyl)-5-nitroindoline (17)**

1
2
3 Synthesized from 5-nitroindoline (**1**) following the general procedure E. The product was isolated in
4
5 68% yield as a yellowish solid. ¹H NMR (CDCl₃, 400 MHz): δ: 2.89 (t, 2H, CH₂, *J* = 6.7 Hz); 3.06
6
7 (t, 2H, CH₂, *J* = 8.4 Hz); 3.48 (t, 2H, CH₂, *J* = 6.7 Hz); 3.62 (t, 2H, CH₂, *J* = 8.4 Hz); 6.20 (d, 1H,
8
9 CH₂, *J* = 8.6 Hz); 6.98-7.04 (m, 2H, aryl); 7.16-7.20 (m, 2H, aryl); 7.89 (s, 1H, aryl); 8.05 (d, 1H,
10
11 aryl, *J* = 8.3 Hz). HR-MS *m/z*: calcd for C₁₆H₁₆FN₂O₂, [(M+H)⁺]: 287.1190; found 287.1200
12
13
14
15
16

17 18 **1-(4-fluorophenethyl)indolin-5-amine (18)**

19 Prepared from **17** using the general procedure B for continuous flow hydrogenation. The intermediate
20
21 was isolated in 92% yield as a white solid. ¹H NMR (CDCl₃, 400 MHz): δ: 2.79-2.96 (m, 4H, 2 CH₂);
22
23 3.26-3.49 (m, 6H, 2 CH₂ and NH₂); 6.23 (d, 1H, aryl, *J* = 8.5 Hz); 6.95-7.05 (m, 2H, aryl); 7.13-7.28
24
25 (m, 4H, aryl). HR-MS *m/z*: calcd for C₁₆H₁₈FN₂, [(M+H)⁺]: 257.1449; found 257.1453
26
27
28
29
30

31 32 **N-(1-(4-fluorophenethyl)indolin-5-yl)cyclohexanesulfonamide (19)**

33 Obtained by coupling of **18** with cyclohexane sulfonyl chloride as for the general procedure C. The
34
35 final product was isolated in 57% yield as an off-white solid that crystallizes in n-hexane/diethyl ether.
36
37 ¹H NMR (CDCl₃, 400 MHz): δ: 1.19-1.30 (m, 3H, CH₂ and CH); 1.56-1.71 (m, 3H, CH₂ and CH);
38
39 1.89-1.92 (m, 2H, CH₂); 2.17-2.20 (m, 2H, CH₂); 2.85-3.00 (m, 5H, CH and 2 CH₂); 3.30 (t, 2H, CH₂,
40
41 *J* = 7.9 Hz); 3.42 (t, 2H, CH₂, *J* = 8.3 Hz); 5.99 (s, 1H, NH); 6.35 (d, 1H, aryl, *J* = 8.3 Hz); 6.90 (d,
42
43 1H, aryl, *J* = 8.3 Hz); 6.99-7.04 (m, 3H, aryl); 7.20-7.23 (m, 2H, aryl). ¹³C NMR (CDCl₃, 100 MHz)
44
45 δ: 25.1; 26.4; 28.4; 32.8; 50.89; 50.90; 53.2; 59.2; 106.4; 115.19; 115.2; 115.4; 121.5; 123.5; 126.0;
46
47 130.0; 131.2; 135.3; 150.8; 160.3; 162.8; ¹⁹F NMR (CDCl₃-d₆, 376.3 MHz) δ: -(115.51-115.59) (m,
48
49 1F, CF); HR-MS *m/z*: calcd for C₂₂H₂₈FN₂O₂S, [(M+H)⁺]: 403.1850; found 403.1862; [(M+Na)⁺]:
50
51 425.1669; found 425.1675
52
53
54
55
56
57
58
59
60

4-(methoxymethoxy)benzaldehyde (19a)

1
2
3 4-hydroxybenzaldehyde (1.0 eq) was dissolved in dry dimethylformamide (DMF) and added with 1.2
4
5 equivalents of potassium tert-butoxide. After 5 minutes stirring at room temperature a solution of
6
7 methoxymethyl chloride (MOMCl, 1.2 eq) in DMF was added dropwise. The mixture was stirred for
8
9 4h before being quenched by aqueous 2N HCl. The aqueous phase was extracted three times with
10
11 DMC. The organic phases were collected, dried over anhydrous Na₂SO₄, filtered and evaporated.
12
13 Purification of the crude product by flash chromatography gave **33** in 76% yield. ¹H NMR (CDCl₃,
14
15 400 MHz) δ: 3.44 (s, 3H, CH₃), 5.22 (s, 2H, CH₂), 7.12 (d, 2H, aryl, J= 8.0 Hz), 7.80 (d, 2H, aryl,
16
17 J= 8.0 Hz); 9.87 (s, 1H, OCH).

21 22 23 24 **(4-(methoxymethoxy)phenyl)methanol (20a)**

25
26 The reaction was A solution of **19a** (1.0 eq) in methanol was cooled in an ice bath and added
27
28 portionwise with 3 equivalents of NaBH₄. The reaction warmed to room temperature and was
29
30 maintained under stirring for 15 minutes. Aqueous 2N HCl was then slowly added to quench the
31
32 excess of hydride. The aqueous phase was extracted with ethyl acetate and the resulting organic phase
33
34 washed two times with brine, dried over anhydrous Na₂SO₄, filtered and evaporated *in vacuo*. After
35
36 flash chromatographic purification, **20a** was obtained in 86% yield. ¹H NMR (CDCl₃, 400 MHz) δ:
37
38 2.83 (bs, 1H, OH), 3.48 (s, 3H, CH₃); 4.57 (s, 2H, CH₂), 5.16 (s, 2H, CH₂); 7.02 (d, 2H, aryl, J= 8.0
39
40 Hz); 7.27 (d, 2H, aryl, J= 8.0 Hz).

41 42 43 44 45 46 47 **1-(iodomethyl)-4-(methoxymethoxy)benzene (20b)**

48
49 Synthesized according to the procedure previously described.⁴¹ Iodine (1.5 eq) was dissolved in dry
50
51 DCM and added with 1.5 equivalents of triphenylphosphine. The solution was stirred for 1.5 hours
52
53 and then added with 1.5 equivalents of imidazole, sitting for further 1 hour. Then alcohol **20a** was
54
55 added to the resulting slurry, mantaining under stirring overnight. Then a saturated aqueous solution
56
57 of Na₂S₂O₃ was added and the organic layer was further washed with brine. The organic layer was
58
59 dried over Na₂SO₄, filtered and concentrated in vacuo. Compound **20b** was obtained in 67% yield
60

1
2
3 after purification of the crude product by flash-chromatography using a linear gradient of n-
4 hexane/ethyl acetate as mobile phase. ¹H NMR (CDCl₃, 400 MHz) δ: 3.50 (s, 3H, CH₃); 4.49 (s, 2H,
5 CH₂), 5.19 (s, 2H, CH₂); 6.99 (d, 2H, aryl, J= 8.0 Hz); 7.34 (d, 2H, aryl, J= 8.0 Hz). HR-MS *m/z*:
6
7
8 calcd for C₉H₁₁IO₂, [(M+H)⁺]: 277.9804; found 277.9812;
9
10
11
12
13
14

15 **2-cyclohexylethane-1-thiol (20c)**

16
17 2-cyclohexylethane-1-thiol (**20c**) was synthesized according to Thuo et al.⁴² from (2-
18 bromoethyl)cyclohexane (2.0 mmol) that was dissolved in 20 mL of ethanol, added with thiourea (2.4
19 mmol) and heated to reflux overnight. Removal of the solvent led to an oil that was mixed with
20 aqueous NaOH (6.0 mmol in 20 mL) and refluxed under magnetic stirring for 2 hours. After colling
21 to room temperature the resulting solution was extracted three times with diethyl ether. The organic
22 phases were collected, dried over Na₂SO₄, and concentrated in vacuo. After purification by flash
23 chromatography eluting with n-hexane, intermediate 20c was isolated in 65% yield. ¹H NMR (CDCl₃,
24 400 MHz) δ: 0.79-0.88 (m, 2H, CH₂), 1.06-1.22 (m, 4H, 2 CH₂), 1.46 (q, 2H CH₂, J₁=7.2 Hz, J₂=15.2
25 Hz); 1.56-1.65 (m, 5H, CH and CH₂), 2.60 (t, 2H, CH₂, J=7.7 Hz).
26
27
28
29
30
31
32
33
34
35
36
37
38
39

40 **2-cyclohexylethane-1-sulfonyl bromide (20d)**

41
42 Compound **20c** was prepared in 75% yield as previously described.⁴³ Briefly, **20b** (1 mmol) was
43 suspended in 5 mL of water and added with 1.0 mmol of KBr and 2.5 mmol of oxone. The reaction
44 was stirred for 20 minutes and then extracted two times with ethyl acetate. The organic layers were
45 collected, dyied over Na₂SO₄ and concentrated in vacuo. Crude product was purified by flash
46 chromatography using n-hexane as eluent. ¹H NMR (CDCl₃, 400 MHz) δ: 0.79-0.95 (m, 2H, CH₂),
47 1.10-1.24 (m, 4H, 2 CH₂), 1.54-1.70 (m, 5H, CH and 2 CH₂), 1.76 (q, 2H, CH₂, J₁=6.7 Hz, J₂=16.1
48 Hz), 3.88 (q, 2H, CH₂, J₁=7.8 Hz, J₂=10.2 Hz). HR-MS *m/z*: calcd for C₈H₁₅BrO₂S, [(M+H)⁺]:
49 253.9976; found 253.9984.
50
51
52
53
54
55
56
57
58
59
60

5-nitro-1-(4-(trifluoromethyl)benzyl)-1H-indole (21a)

Synthesized according to the general procedure E, starting from 5-nitro-1H-indole (**20**) and commercially available 1-(bromomethyl)-4-(trifluoromethyl)benzene. The intermediate was obtained in 71% yield as an orange solid ¹H NMR (CDCl₃, 400 MHz): δ: 5.44 (s, 2H, CH₂); 6.75 (d, 1H, aryl, *J* = 3.2 Hz); 7.18 (d, 2H, aryl, *J* = 8.4 Hz); 7.24 (d, 1H, aryl, *J* = 8.3 Hz); 7.31 (d, 1H, aryl, *J* = 4.0 Hz); 7.56 (d, 2H, aryl, *J* = 8.5 Hz); 8.04 (d, 1H, aryl, *J* = 8.2 Hz); 8.58 (s, 1H, aryl). HR-MS *m/z*: calcd for C₁₆H₁₂F₃N₂O₂, [(M+H)⁺]: 321.0845; found 321.0254

1-(4-(methoxymethoxy)benzyl)-5-nitro-1H-indole (21b)

Synthesized according to the general procedure E, starting from 5-nitro-1H-indole (**20**) and 1-(iodomethyl)-4-(methoxymethoxy)benzene. The intermediate was obtained in 65% yield as a yellowish solid ¹H NMR (CDCl₃, 400 MHz) δ: 3.48 (s, 3H, CH₃); 5.17 (s, 2H, CH₂), 5.32 (s, 2H, CH₂); 6.73 (d, 1H, aryl, *J* = 3.5 Hz); 7.02 (d, 2H, aryl, *J* = 8.3 Hz); 7.09 (d, 2H, aryl, *J* = 8.4 Hz); 7.28 (d, 1H, aryl, *J* = 4.7 Hz); 7.34 (d, 1H, aryl, *J* = 8.2 Hz); 8.09 (d, 1H, aryl, *J* = 8.5 Hz); 8.61 (s, 1H, aryl). HR-MS *m/z*: calcd for C₁₇H₁₇N₂O₄, [(M+H)⁺]: 313.1183; found 313.1201

1-(4-fluorobenzyl)-5-nitro-1H-indole (21c)

Synthesized according to the general procedure E, starting from 5-nitro-1H-indole (**20**) and commercially available 1-(bromomethyl)-4-fluorobenzene. The intermediate was obtained in 74% yield as an orange solid. ¹H NMR (CDCl₃, 400 MHz): δ: 5.36 (s, 2H, CH₂); 6.75 (d, 1H, aryl, *J* = 3.7 Hz); 7.01-7.13 (m, 4H, aryl); 7.28 (d, 2H, aryl, *J* = 4.2 Hz); 8.10 (d, 2H, aryl, *J* = 8.6 Hz); 8.63 (s, 1H, aryl). HR-MS *m/z*: calcd for C₁₅H₁₂FN₂O₂, [(M+H)⁺]: 271.0805; found 271.0811

1-(4-methoxybenzyl)-5-nitro-1H-indole (21d)

1
2
3 Synthesized according to the general procedure E, starting from 5-nitro-1H-indole (**20**) and
4 commercially available 1-(bromomethyl)-4-methoxybenzene. The intermediate was obtained in 64%
5 yield as a dark yellow solid. ¹H NMR (CDCl₃, 400 MHz): δ: 3.80 (s, 3H, CH₃); 5.32 (s, 2H, CH₂);
6 6.73 (d, 1H, aryl, *J* = 4.0 Hz); 6.88 (d, 2H, aryl, *J* = 8.2 Hz); 7.09 (d, 2H, aryl, *J* = 8.3 Hz); 7.31-7.35
7 (m, 2H, aryl); 8.10 (d, 1H, aryl, *J* = 8.6 Hz); 8.62 (s, 1H, aryl). HR-MS *m/z*: calcd for C₁₆H₁₅N₂O₃,
8 [(M+H)⁺]: 283.1077; found 283.1085
9
10
11
12
13
14
15
16
17
18

19 **1-(4-(trifluoromethyl)benzyl)-1H-indol-5-amine (22a)**

20
21 Synthesized from **21a** using general procedure B. The intermediate was obtained in 93% yield as an
22 off-white solid. ¹H NMR (CDCl₃, 400 MHz): δ: 3.71 (bs, 2H, NH₂); 5.32 (s, 2H, CH₂); 6.43 (d, 1H,
23 aryl, *J* = 3.7 Hz); 6.67 (d, 1H, aryl, *J* = 8.4 Hz); 7.00-7.09 (m, 3H, aryl); 7.18 (d, 2H, aryl, *J* = 8.6
24 Hz); 7.55 (d, 2H, aryl, *J* = 8.6 Hz). HR-MS *m/z*: calcd for C₁₆H₁₄F₃N₂, [(M+H)⁺]: 291.1104; found
25 291.1111
26
27
28
29
30
31
32
33
34

35 **1-(4-(methoxymethoxy)benzyl)-1H-indol-5-amine (22b)**

36
37 Synthesized from **21b** using general procedure B. The intermediate was obtained in 91% yield as a
38 grey solid. ¹H NMR (CDCl₃, 400 MHz): 3.48 (s, 3H, CH₃); 5.16 (s, 2H, CH₂), 5.21 (s, 2H, CH₂); 6.36
39 (d, 1H, aryl, *J* = 3.9 Hz); 6.66 (d, 1H, aryl, *J* = 7.9 Hz); 6.96-7.00 (m, 3H, aryl); 7.06-7.12 (m, 4H,
40 aryl); HR-MS *m/z*: calcd for C₁₇H₁₉N₂O₂, [(M+H)⁺]: 283.1441; found 283.1498
41
42
43
44
45
46
47
48

49 **1-(4-fluorobenzyl)-1H-indol-5-amine (22c)**

50
51 Synthesized from **21c** using general procedure B. The intermediate was obtained in 94% yield as a
52 dark grey solid. ¹H NMR (CDCl₃, 400 MHz) δ: 3.50 (bs, 2H, NH₂); 5.24 (s, 2H, CH₂); 6.38 (d, 1H,
53 aryl, *J* = 4.1 Hz); 6.65 (d, 1H, aryl, *J* = 8.4 Hz); 6.97-7.10 (m, 7H, aryl). HR-MS *m/z*: calcd for
54 C₁₅H₁₄FN₂, [(M+H)⁺]: 241.1136; found 241.1144
55
56
57
58
59
60

1-(4-methoxybenzyl)-1H-indol-5-amine (22d)

Synthesized from **21d** using general procedure B. The intermediate was obtained in 92% yield as a brown solid. ^1H NMR (CDCl_3 , 400 MHz) δ : 3.03 (bs, 2H, NH_2); 3.79 (s, 3H, CH_3); 5.20 (s, 2H, CH_2); 6.36 (d, 1H, aryl, $J = 3.8$ Hz); 6.65 (d, 1H, aryl, $J = 8.6$ Hz); 6.85 (d, 2H, aryl, $J = 8.4$ Hz); 6.96 (s, 1H, aryl); 7.05-7.12 (m, 4H, aryl). HR-MS m/z : calcd for $\text{C}_{16}\text{H}_{17}\text{N}_2\text{O}$, $[(\text{M}+\text{H})^+]$: 253.1335; found 253.1344

N-(1-(4-(trifluoromethyl)benzyl)-1H-indol-5-yl)heptanamide (23a)

Synthesized from **22a** and heptanoyl chloride following general procedure D. The final product was obtained in 80% yield as a white solid that crystallizes in n-hexane/diethyl ether. ^1H NMR (CDCl_3 , 400 MHz) δ : 0.92 (t, 3H, CH_3 , $J = 6.5$ Hz); 1.34-1.44 (m, 6H, 3 CH_2); 1.73-1.79 (m, 2H, CH_2); 2.39 (t, 2H, CH_2 , $J = 7.6$ Hz); 5.38 (s, 2H, CH_2); 6.56 (d, 1H, aryl, $J = 2.7$ Hz); 7.15-7.23 (m, 6H, aryl); 7.56 (d, 2H, aryl, $J = 8.0$ Hz); 7.90 (s, 1H, NH). ^{13}C NMR (CDCl_3 , 100 MHz) δ : 14.0; 22.5; 25.8; 29.0; 31.6; 37.8; 49.8; 102.4; 109.6; 113.2; 116.4; 125.8; 126.8; 129.0; 130.5; 133.6; 141.5; 171.5. ^{19}F NMR (CDCl_3 , 376.3 MHz) δ : -62.61 (s, 3F, CF_3). HR-MS m/z : calcd for $\text{C}_{23}\text{H}_{26}\text{F}_3\text{N}_2\text{O}$, $[(\text{M}+\text{H})^+]$: 403.1992; found 403.2003; $[(\text{M}+\text{Na})^+]$: 425.1811; found 425.1820

N-(1-(4-(methoxymethoxy)benzyl)-1H-indol-5-yl)heptanamide (23b)

Synthesized from **22b** and heptanoyl chloride following general procedure D. The final product was obtained in 76% yield as a grey wax that was not crystallized. ^1H NMR (CDCl_3 , 400 MHz): 0.92 (t, 3H, CH_3 , $J = 6.6$ Hz); 1.28-1.43 (m, 6H, 3 CH_2); 1.72-1.80 (m, 2H, CH_2); 2.38 (t, 2H, CH_2 , $J = 7.6$ Hz); 3.48 (s, 3H, CH_3); 5.16 (s, 2H, CH_2), 5.24 (s, 2H, CH_2); 6.50 (d, 1H, aryl, $J = 3.0$ Hz); 6.96 (d, 2H, aryl, $J = 8.6$ Hz); 7.05 (d, 2H, aryl, $J = 8.6$ Hz); 7.11 (d, 1H, aryl, $J = 3.0$ Hz); 7.19-7.22 (m, 2H, aryl); 7.30 (s, 1H, aryl); 7.85 (s, 1H, NH). ^{13}C NMR (CDCl_3 , 100 MHz) δ : 14.1; 22.5; 25.8; 29.0;

1
2
3 31.6; 37.8; 49.7; 56.0; 94.4; 101.7; 109.8; 112.9; 116.1; 116.5; 128.1; 128.9; 129.0; 130.4; 130.7;
4
5 133.7; 156.7; 171.2. HR-MS m/z : calcd for $C_{24}H_{31}N_2O_3$ [(M+H)⁺]: 395.2329; found 395.2391
6
7
8
9

10 **N-(1-(4-fluorobenzyl)-1H-indol-5-yl)cyclohexanesulfonamide (23c)**

11 Synthesized from **22c** and cyclohexanesulfonyl chloride following general procedure C. The final
12 product was obtained in 71% yield as an off-white solid that crystallizes in n-hexane/ethyl acetate ¹H
13 NMR (CDCl₃, 400 MHz) δ: 1.19-1.29 (m, 3H, CH₂); 1.61-1.68 (m, 3H, CH₂); 1.86-1.88 (m, 2H,
14 CH₂); 2.19-2.22 (m, 2H, CH₂); 2.95-3.03 (m, 1H, CH); 5.29 (s, 2H, CH₂); 6.41 (s, 1H, NH); 6.55 (d,
15 1H, aryl, $J = 2.8$ Hz); 7.00-7.04 (m, 2H, aryl); 7.08-7.13 (m, 3H, aryl). 7.16 (d, 1H, aryl, $J = 3.2$ Hz);
16 7.22 (d, 1H, aryl, $J = 8.7$ Hz); 7.56 (d, 1H, aryl, $J = 1.7$ Hz). ¹³C NMR (CDCl₃, 100 MHz) δ: 25.09;
17 25.11; 26.4; 49.7; 59.3; 102.0; 110.3; 115.3; 115.7; 115.9; 118.1; 128.5; 128.6; 129.0; 129.2; 129.4;
18 132.84; 132.88; 134.4; 161.1; 163.5. ¹⁹F NMR (CDCl₃, 376.3 MHz) δ: -115.82 (s, 1F, CF). HR-MS
19 m/z : calcd for $C_{21}H_{24}FN_2O_2S$, [(M+H)⁺]: 387.1537; found 387.1548; [(M+Na)⁺]: 409.1356; found
20 409.1362
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37

38 **N-(1-(4-methoxybenzyl)-1H-indol-5-yl)cyclohexanesulfonamide (23d)**

39 Synthesized from **22d** and cyclohexanesulfonyl chloride following general procedure C. The final
40 product was obtained in 65% yield as dark grey solid that crystallizes in n-hexane/ethyl acetate ¹H
41 NMR (CDCl₃, 400 MHz): δ: 1.20-1.28 (m, 3H, CH₂); 1.58-1.68 (m, 3H, CH₂); 1.87-1.90 (m, 2H,
42 CH₂); 2.19-2.22 (m, 2H, CH₂); 2.95-3.02 (m, 1H, CH); 3.80 (s, 3H, CH₃); 5.26 (s, 2H, CH₂); 6.21 (s,
43 1H, NH); 6.53 (d, 1H, aryl, $J = 3.0$ Hz); 6.86 (d, 2H, aryl, $J = 8.6$ Hz); 7.06-7.11 (m, 3H, aryl); 7.16
44 (d, 1H, aryl, $J = 3.0$ Hz); 7.26 (d, 1H, aryl, $J = 8.8$ Hz); 7.55 (d, 1H, aryl, $J = 2.0$ Hz). ¹³C NMR
45 (CDCl₃, 100 MHz) δ: 25.1; 26.4; 49.9; 55.3; 59.2; 101.7; 110.5; 114. 2; 115.3; 118.0; 128.3; 128.7;
46 129.06; 129.16; 129.4; 134.5; 159.2. HR-MS m/z : calcd for $C_{22}H_{27}N_2O_3$, [(M+H)⁺]: 399.1737; found
47 399.1745; [(M+Na)⁺]: 421.1556; found 421.1566
48
49
50
51
52
53
54
55
56
57
58
59
60

3,3-dimethyl-N-(1-(4-(trifluoromethyl)benzyl)-1H-indol-5-yl)butanamide (24a)

Synthesized from **22a** and 3,3-dimethylbutanoyl chloride following general procedure D. The final product was obtained in 74% yield as a white solid that crystallizes in n-hexane/diethyl ether. ¹H NMR (CDCl₃, 400 MHz): δ: 1.13 (s, 9H, CH₃); 2.24 (s, 2H, CH₂); 5.35 (s, 2H, CH₂); 6.54 (d, 1H, aryl, *J* = 3.0 Hz); 7.10-7.20 (m, 6H, aryl); 7.54 (d, 2H, aryl, *J* = 8.1 Hz); 7.88 (s, 1H, NH). ¹³C NMR (CDCl₃, 100 MHz) δ: 29.9; 31.3; 49.7; 51.6; 102.4; 109.6; 113.1; 113.3; 116.5; 125.7; 126.8; 128.9; 129.0; 130.1; 130.5; 130.6; 133.6; 141.6; 170.1. ¹⁹F NMR (CDCl₃, 376.3 MHz) δ: -61.85 (s, 3F, CF₃). HR-MS *m/z*: calcd for C₂₂H₂₄F₃N₂O, [(M+H)⁺]: 389.1835; found 389.1901

N-(1-(4-hydroxybenzyl)-1H-indol-5-yl)heptanamide (24b)

Compound **23b** was dissolved in a mixture of solution of TFA in DCM (15% v:v) and stirred at room temperature for 1.5h. The reaction was then diluted with DCM and extracted with a saturated solution of NaHCO₃ and brine. The organic phase was dried over anhydrous Na₂SO₄, filtered and evaporated under vacuum. After purification of the crude product, **24b** was obtained in 87% yield as a white solid that crystallizes from n-hexane/ethyl acetate. ¹H NMR (CD₃OD, 400 MHz): 0.93 (t, 3H, CH₃, *J* = 6.6 Hz); 1.30-1.43 (m, 4H, CH₂); 1.68-1.75 (m, 2H, CH₂); 2.37 (t, 2H, CH₂, *J* = 7.6 Hz); 4.87 (s, 2H, CH₂); 6.42 (d, 1H, aryl, *J* = 3.0 Hz); 6.71 (d, 2H, aryl, *J* = 8.4 Hz); 6.99 (d, 2H, aryl, *J* = 8.4 Hz); 7.16-7.20 (m, 2H, aryl); 7.26 (d, 1H, aryl, *J* = 8.8 Hz); 7.77 (s, 1H, aryl). ¹³C NMR (CH₃OD, 100 MHz) δ: 13.0; 22.2; 25.7; 28.7; 31.4; 36.6; 49.1; 100.8; 109.5; 112.9; 115.0; 115.9; 128.0; 128.7; 128.9; 130.2; 133.8; 156.5; 173.3. HR-MS *m/z*: calcd for C₂₂H₂₆N₂O₂ [(M+H)⁺]: 351.2067; found 351.2073

N-(1-(4-(trifluoromethyl)benzyl)-1H-indol-5-yl)palmitamide (25a)

1
2
3 Synthesized from **22a** and palmitoyl chloride following general procedure D. The final product was
4
5 obtained in 66% yield as a white wax that did not crystallize. ¹H NMR (CDCl₃, 400 MHz): δ: 0.90 (t,
6
7 3H, CH₃, *J* = 7.0 Hz); 1.28-1.42 (m, 24H, CH₂); 1.73-1.80 (m, 2H, CH₂); 2.38 (t, 2H, CH₂, *J* = 7.6
8
9 Hz); 5.38 (s, 2H, CH₂), 6.56 (d, 1H, aryl, *J* = 3.0 Hz); 7.14-7.23 (m, 6H, aryl); 7.56 (d, 2H, aryl, *J* =
10
11 8.1 Hz); 7.89 (s, 1H, NH); ¹³C NMR (CDCl₃, 100 MHz) δ: 14.1; 22.7; 25.8; 29.33; 29.36; 29.4; 29.5;
12
13 29.66; 29.68; 29.70; 31.9; 37.8; 49.8; 102.4; 109.6; 113.1; 116.3; 125.8; 125.8; 126.8; 128.96; 129.03;
14
15 130.6; 133.6; 141.5; 171.3. ¹⁹F NMR (CDCl₃, 376.3 MHz) δ: -62.54 (s, 3F, CF₃). HR-MS *m/z*: calcd
16
17 for C₃₃H₄₄F₃N₂O, [(M+H)⁺]: 529.3400; found 529.3392
18
19
20
21
22
23

24 **N-(1-(4-(trifluoromethyl)benzyl)-1H-indol-5-yl)cyclohexanesulfonamide (26a)**

25
26 Synthesized from **22a** and cyclohexanesulfonyl chloride following general procedure C. The final
27
28 product was obtained in 69% yield as a grey solid that crystallizes in n-hexane/ethyl acetate. ¹H NMR
29
30 (CDCl₃, 400 MHz): δ: 1.20-1.28 (m, 3H, CH₂); 1.58-1.68 (m, 3H, CH₂); 1.87-1.91 (m, 2H, CH₂);
31
32 2.20-2.23 (m, 2H, CH₂); 2.95-3.02 (m, 1H, CH); 5.39 (s, 2H, CH₂); 6.24 (s, 1H, NH); 6.58 (d, 1H,
33
34 aryl, *J* = 2.7 Hz); 7.08 (d, 1H, aryl, *J* = 8.7 Hz); 7.17-7.22 (m, 5H, aryl); 7.58 (d, 2H, aryl, *J* = 8.7
35
36 Hz). ¹³C NMR (CDCl₃, 100 MHz) δ: 25.1; 26.4; 49.9; 59.4; 102.4; 110.2; 115.4; 118.3; 125.85;
37
38 125.88; 125.92; 126.9; 129.19; 129.22; 129.50; 130.0; 130.3; 134.4; 141.2. ¹⁹F NMR (CDCl₃, 376.3
39
40 MHz) δ: -61.89 (s, 3F, CF₃). HR-MS *m/z*: calcd for C₂₂H₂₄F₃N₂O₂S, [(M+H)⁺]: 437.1505; found
41
42 437.1513; [(M+Na)⁺]: 459.1325; found 459.1333
43
44
45
46
47
48
49

50 **2-cyclohexyl-N-(1-(4-(trifluoromethyl)benzyl)-1H-indol-5-yl)ethane-1-sulfonamide (27a)**

51
52 Synthesized, following general procedure C, from **22a** and 2-cyclohexylethane-1-sulfonyl bromide.
53
54 The final product was obtained in 64% yield as an off-white solid that crystallizes in n-hexane/ethyl
55
56 acetate. ¹H NMR (CDCl₃, 400 MHz): δ: 0.85-0.93 (m, 2H, CH₂); 1.11-1.33 (m, 4H, CH₂); 1.63-1.78
57
58 (m, 7H, CH and 3 CH₂); 3.05-3.09 (m, 2H, CH₂), 5.30 (s, 2H, CH₂); 6.48 (s, 1H, NH); 6.55 (d, 1H,
59
60

1
2
3 aryl, $J = 3.1$ Hz), 7.01 (t, 2H, aryl, $J = 8.6$ Hz); 7.07-7.12 (m, 3H, aryl); 7.17 (d, 1H, aryl, $J = 3.1$ Hz);
4
5 7.22 (d, 1H, aryl, $J = 8.7$ Hz); 7.56 (d, 1H, aryl, $J = 1.6$ Hz). ^{13}C NMR (CDCl_3 , 100 MHz) δ : 26.0;
6
7 26.3; 30.7; 32.8; 36.6; 48.9; 49.7; 102.1; 110.4; 115.7; 115.83; 115.89, 118.4; 128.4; 128.5; 128.7;
8
9 129.2; 129.5; 132.9; 134.6; 161.1; 163.5. ^{19}F NMR (CDCl_3 , 376.3 MHz) δ : -62.01 (s, 3F, CF_3). HR-
10
11 MS m/z : calcd for $\text{C}_{24}\text{H}_{28}\text{F}_3\text{N}_2\text{O}_2\text{S}$, $[(\text{M}+\text{H})^+]$: 465,1818; found 465.1820
12
13
14
15
16

17 **2-(butylamino)-N-(1-(4-(trifluoromethyl)benzyl)-1H-indol-5-yl)acetamide (28a)**

18
19 Intermediate **22a** was reacted with chloroacetyl chloride following the general procedure D. After
20
21 work up the obtained 2-chloro-N-(1-(4-(trifluoromethyl)benzyl)-1H-indol-5-yl)acetamide
22
23 crystallized from DCM at 0°C and, upon filtration, was used without further purification. 2-chloro-
24
25 N-(1-(4-(trifluoromethyl)benzyl)-1H-indol-5-yl)acetamide (1.0 eq) was then dissolved in DMF and
26
27 added with 2.6 equivalents of potassium tert-butoxyde and 2.6 equivalents of n-butylamine. The
28
29 reaction was stirred under reflux overnight. Then water was added and the mixture was extracted four
30
31 times with DCM. The organic phases were collected, dried over anhydrous Na_2SO_4 , filtered and
32
33 concentrated *in vacuo*. After purification by flash chromatography, final product **28a** was obtained in
34
35 57% yield as a white solid that crystallized from n-hexane/ethyl acetate.
36
37
38
39

40 **2-chloro-N-(1-(4-(trifluoromethyl)benzyl)-1H-indol-5-yl)acetamide:**

41
42 ^1H NMR (CDCl_3 , 400 MHz): 4.15 (s, 2H, CH_2), 5.30 (s, 2H, CH_2), 6.50 (d, 1H, aryl, $J = 3.7$ Hz), 7.08-
43
44 7.19 (m, 5H, aryl); 7.48 (d, 2H, aryl, $J = 8.0$ Hz); 7.82 (s, 1H, aryl); 8.19 (bs, 1H, NH). HR-MS m/z :
45
46 calcd for $\text{C}_{18}\text{H}_{14}\text{ClF}_3\text{N}_2\text{O}$, $[(\text{M}+\text{H})^+]$: 367.0820; found 367.0824
47
48

49 **2-(butylamino)-N-(1-(4-(trifluoromethyl)benzyl)-1H-indol-5-yl)acetamide**

50
51 ^1H NMR (CH_3OD , 400 MHz): 1.03 (t, 3H, CH_3 , $J = 7.3$ Hz); 1.42-1.51 (m, 2H, CH_2); 1.71-1.79 (m,
52
53 2H, CH_2), 3.12 (t, 2H, CH_2 , $J = 8.0$ Hz); 3.99 (s, 2H, CH_2) 5.50 (s, 2H, CH_2), 6.54 (d, 1H, aryl, $J =$
54
55 2.9 Hz), 7.22-7.29 (m, 5H, aryl); 7.36 (d, 1H, aryl, $J = 2.9$ Hz); 7.59 (d, 2H, aryl, $J = 8.0$ Hz); 7.90
56
57 (s, 1H, NH). ^{13}C NMR (CD_3OD , 100 MHz) δ : 12.5; 19.4; 27.7; 48.2; 49.0; 101.5; 109.6; 112.6; 115.5;
58
59
60

1
2
3 125.1; 126.9; 129.0; 129.5; 129.8; 133.9; 142.7; 162.9. ¹⁹F NMR (CDCl₃, 376.3 MHz) δ: -61.33 (s,
4 3F, CF₃). HR-MS *m/z*: calcd for C₂₂H₂₄F₃N₃O [(M+H)⁺]: 404,1944; found 404,2000
5
6
7
8
9

10 **2-(butyl(methyl)amino)-N-(1-(4-(trifluoromethyl)benzyl)-1H-indol-5-yl)acetamide (29a)**

11
12 Compound **28a** (1.0 eq) was dissolved in dry methanol and the solution was added with 1.5
13 equivalents of formaldehyde. The reaction was stirred at room temperature under positive nitrogen
14 pressure overnight. Then, 3 equivalents of NaBH₄ were added and the reaction mixture was stirred
15 for further 3h. Water was added to quench the excess of hydride, and the aqueous solution was
16 extracted four times with DCM. The organic phases were washed with brine, dried over anhydrous
17 Na₂SO₄, filtered and concentrated. Purification by flash chromatography gave **29a** in 81% yield as a
18 white solid that crystallized from n-hexane/ethyl acetate. ¹H NMR (CDCl₃, 400 MHz): 0.88 (t, 3H,
19 CH₃, *J* = 7.2 Hz); 1.30-1.38 (m, 2H, CH₂); 1.42-1.49 (m, 2H, CH₂); 2.59 (t, 2H, CH₂, *J* = 7.5 Hz);
20 3.40 (s, 3H, CH₃); 4.52 (s, 2H, CH₂); 5.30 (s, 2H, CH₂), 6.49 (d, 1H, aryl, *J* = 3.1 Hz), 7.06-7.13 (m,
21 4H, aryl); 7.30-7.32 (m, 1H, aryl); 7.47 (d, 2H, aryl, *J* = 8.2 Hz); 7.60 (d, 1H, aryl, *J* = 2.0 Hz). ¹³C
22 NMR (CDCl₃, 100 MHz) δ: 13.9; 20.4; 30.2; 49.8; 54.9; 57.4; 72.2; 102.5; 109.9; 113.3; 116.2; 125.8;
23 126.8; 128.8; 129.3; 130.2; 134.0; 141.4; 170.2. ¹⁹F NMR (CDCl₃, 376.3 MHz) δ: -62.14 (s, 3F, CF₃).
24 HR-MS *m/z*: calcd for C₂₃H₂₆F₃N₃O [(M+H)⁺]: 418,2101; found 418,2114.
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44

45 **N-(5-oxo-5,6,7,8-tetrahydronaphthalen-2-yl)heptanamide (31)**

46
47 Intermediate **31** was synthesized in 84% yield, using 6-amino-3,4-dihydronaphthalen-1(2H)-one (**30**)
48 and heptanoyl chloride as starting materials and following the general procedure D. ¹H NMR (CDCl₃,
49 400 MHz) δ: 0.90 (t, 3H, CH₃, *J*= 9.8 Hz); 1.27-1.27 (m, 6H, 3 CH₂); 1.69-1.78 (m, 2H, CH₂); 2.08-
50 2.17 (m, 2H, CH₂); 2.40 (t, 2H, CH₂, *J*= 12.1 Hz); 2.64 (t, 2H, CH₂, *J*= 12.1 Hz); 2.94 (t, 2H, CH₂,
51 *J*= 8.5 Hz), 7.23 (d, 1H, aryl, *J*= 11.6 Hz); 7.62 (bs, 1H, NH); 7.76 (s, 1H, aryl), 8.00 d (1H, H-4,
52 *J*=11.5 Hz) HR-MS *m/z*: calcd for C₁₇H₂₄NO₂, [(M+H)⁺]:274.1802; found 274.1810
53
54
55
56
57
58
59
60

N-(5-hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)heptanamide (32)

Alcohol **32** was synthesized in 90% yield by reduction of the ketone precursor **31** as already described.¹³ ¹H NMR (CDCl₃, 400 MHz) δ: 0.90 (t, 3H, CH₃, J= 9.5 Hz); 1.28-1.36 (m, 6H, 3 CH₂); 1.68-1.76 (m, 4H, 2 CH₂); 1.95-2.00 (m, 2H, CH₂); 2.36 (t, 2H, CH₂, J= 11.7 Hz); 2.65-2.86 (m, 2H, CH₂); 4.76 (t, 1H, H-5, J=3.6 Hz); 7.18 (bs, 1H, NH); 7.24 (d, 1H, aryl, J= 11.4 Hz); 7.36-7.39 (m, 2H, aryl), HR-MS *m/z*: calcd for C₁₇H₂₆NO₂, [(M+H)⁺]:276.1958; found 276.1949.

(Z)-N-(5-(4-(trifluoromethyl)benzylidene)-5,6,7,8-tetrahydronaphthalen-2-yl)heptanamide (33a)

Final compound **32a** was synthesized from **31** as described by Ulmschneider et al.¹³ After purification, **32a** was isolated in 32% yield as a white solid that crystallized from petroleum ether. The geometry of the double bond was assigned by bidimensional NMR experiments (please see supplementary material file). ¹H NMR (CDCl₃, 400 MHz): δ: 0.91 (t, 3H, CH₃, J=6.8 Hz); 1.28-1.40 (m, 8H, 3 CH₂); 1.68-1.76 (m, 2H, CH₂); 1.99-2.05 (m, 2H, CH₂); 2.34 (t, 2H, CH₂, J=7.6 Hz); 2.52-2.55 (m, 2H, CH₂); 2.90 (t, 2H, CH₂, J=6.6 Hz); 6.39 (s, 1H, C_{sp2}H); 6.81-6.84 (m, 1H aryl); 7.03 (d, 1H aryl, J=8.5 Hz); 7.08 (s, 1H, NH); 7.33 (d, 2H, aryl, J= 8.2 Hz); 7.46 (d, 2H, aryl, J=8.2 Hz); 7.55 (s, 1H, aryl). ¹³C NMR (CDCl₃, 100 MHz) δ: 14.0; 22.5; 23.9; 25.6; 28.9; 29.7; 31.6; 34.9; 37.9; 116.1; 119.6; 122.4; 125.1; 125.7; 127.9; 128.3; 129.2; 129.5; 130.3; 137.4; 139.8; 140.2; 142.5; 171.3; ¹⁹F NMR (CDCl₃, 376.3 MHz) δ: -62.51 (s, 3F, CF₃). HR-MS *m/z*: calcd for C₂₅H₂₉F₃NO, [(M+H)⁺]: 416.2193; found 416.2198;

(E)-N-(5-(4-(trifluoromethyl)benzylidene)-5,6,7,8-tetrahydronaphthalen-2-yl)heptanamide (33b)

Final compound **32b** was synthesized from **31** as described by Ulmschneider et al.¹³ After purification, **32a** was isolated in 51% yield as a white solid that crystallized from petroleum ether.

The geometry of the double bond was assigned by bidimensional NMR experiments (please see supplementary material file). ^1H NMR (CDCl_3 , 400 MHz): δ : 0.92 (t, 3H, CH_3 , $J=6.7$ Hz); 1.28-1.43 (m, 8H, 3 CH_2); 1.72-1.79 (m, 2H, CH_2); 1.82-1.89 (m, 2H, CH_2); 2.38 (t, 2H, CH_2 , $J=7.6$ Hz); 2.76-2.80 (m, 2H, CH_2); 2.85 (t, 2H, CH_2 , $J=6.2$ Hz); 7.00 (s, 1H, $\text{C}_{\text{sp}^2}\text{H}$); 7.19 (s, 1H, NH); 7.31 (d, 1H, aryl, $J=8.5$ Hz); 7.46 (d, 3H, aryl, $J=7.8$ Hz); 7.62 (d, 2H, aryl, $J=8.2$ Hz); 7.68 (d, 1H, aryl, $J=8.6$ Hz) ^{13}C NMR (CDCl_3 , 100 MHz) δ : 14.0; 22.5; 23.5; 25.6; 28.0; 28.9; 30.4; 31.6; 37.9; 117.7; 119.7; 121.3; 123.0; 125.2; 125.7; 128.0; 128.3; 129.5; 131.7; 137.5; 138.9; 139.2; 141.8; 171.4; ^{19}F NMR (CDCl_3 , 376.3 MHz) δ : -62.37 (s, 3F, CF_3). HR-MS m/z : calcd for $\text{C}_{25}\text{H}_{29}\text{F}_3\text{NO}$, $[(\text{M}+\text{H})^+]$: 416.2193; found 416.2201

N-(5-(4-(trifluoromethyl)benzyl)-5,6,7,8-tetrahydronaphthalen-2-yl)heptanamide (34)

Compounds **33b** (1.0 eq) was dissolved in methanol and added with a catalytic amount of Pd/C 10% and ammonium formate (10.0 eq). The reaction was refluxed under stirring. After 40 minutes, the mixture was cooled to room temperature and filtered through celite. The resulting solution was evaporated and reconstituted in DCM. The organic phase was washed with water (three times) and brine (two times) before being dried over anhydrous Na_2SO_4 , filtered and concentrated at the rotary evaporator. After purification, product **34** was obtained in 86% yield as a white solid that was unable to crystallize. $[\alpha]_D^{25}$: $+11.0 \pm 0.03$ ($c = 0.05$, MeOH). ^1H NMR (CDCl_3 , 400 MHz): δ : 0.92 (t, 3H, CH_3 , $J=6.8$ Hz); 1.28-1.42 (m, 6H, 3 CH_2); 1.56-1.78 (m, 5H, CH_2); 1.81-1.92 (m, 1H, CH); 2.36 (t, 2H, CH_2 , $J=7.86$ Hz); 2.72-2.83 (m, 3H, CH_2 and CH); 3.04-3.15 (m, 2H, CH_2); 7.10-7.14 (m, 2H, aryl and NH); 7.23-7.25 (m, 1H, aryl); 7.31 (d, 2H, aryl, $J=8.0$ Hz); 7.35 (s, 1H, aryl); 7.57 (d, 2H, aryl, $J=8.0$ Hz); ^{13}C NMR (CDCl_3 , 100 MHz) δ : 14.0; 19.2; 22.5; 25.6; 26.8; 28.9; 29.8; 31.6; 37.8; 39.0; 43.1; 117.5; 120.3; 123.0; 125.16; 125.19; 125.5; 125.4; 128.2; 128.5; 129.1; 129.5; 135.7; 135.9; 137.9; 145.0; 171.3; ^{19}F NMR (CDCl_3 , 376.3 MHz) δ : -62.21 (s, 3F, CF_3). HR-MS m/z : calcd for $\text{C}_{25}\text{H}_{31}\text{F}_3\text{NO}$, $[(\text{M}+\text{H})^+]$: 418.2352; found 418.2361;

Structures preparation.

Molecules were sketched using the Maestro GUI⁴⁴ and then submitted to the ligprep utility⁴⁵ to generate low-energy 3D structures from each input molecule, with various ionization states and tautomers at a pH range of 6–8. For each molecule, the state with the lowest state penalty was retained for the following studies. Compounds were studied for their conformational landscape using MacroModel.⁴⁶ The “Mixed torsional/Low mode sampling method” was employed, using the automatic setup of the search variables, with the torsion sampling set to extended; the maximum number of steps was set to 5000 and 200 per molecule and rotatable bond, respectively. Conformers in an energy window of 82 kJ/mol were saved, discarding the redundant ones (cutoff of maximum atom deviation=0.5Å). Minimization of conformers was performed using the Polak–Ribiere conjugate gradient method, using a maximum of 2500 minimization step and a 0.05 J/(Å mol) gradient convergence threshold. OPLS3⁴⁵ was used as force-field. No implicit solvation model was used.

Pharmacophore modeling.

The data sets used for the pharmacophores development are reported in table S3. Ligand conformations from the above reported conformational searches were used as input. Hypotheses A, B and C were developed using Phase²⁰ to find the best alignment and common features. Hypothesis were required to match at least half of the active molecules and to have a number of feature ranging between 3 and 7, with at least a hydrogen bond donor. For each training set, the best ranked model (by Phase Hypo Score) was retained, finally obtaining models A, B and C. Model D was built on the basis of the latter three models. Models B and C were both superimposed to model A by the shared features Ar1, Ar2, HY1, HBA and HBD. The three models were then merged to get the coordinates of features HY2 and HY3 from models B and C, respectively, while features HY1, Ar1, Ar2, HBA and HBD were inherited from model A.

Dihedral scans of linker moieties.

Dihedral scans reported in figure S1 were performed using MacroModel.⁴⁶ Linker moieties were capped using methyl groups. Dihedral angles were scanned from 0° to 360° with an increment of 10° and each rotamer was minimized, freezing the studied dihedral, through the Polak–Ribiere conjugate gradient method, using a maximum of 2500 minimization step and a 0.05 J/(Å mol) gradient convergence threshold. OPLS3⁴⁷ was used as force-field. For the molecules endowed with a second NH group (indicated with an asterisk in figure S1) a two coordinates scan was employed to find the absolute minimum for each dihedral angle. Molecular surfaces reported in Table S1 were calculated on the global minimum of each linker molecule. Electrostatic potential and electron densities were calculated using single-point DFT calculations (B3LYP/6-31G**) in vacuum, through the Jaguar software.⁴⁸ SCF spin treatment was set to automatic and grid density was set to medium. Accuracy level was set to quick and initial guesses for the molecular orbitals were constructed from atomic orbitals. SCF convergence (DIIS scheme) criteria were set as follows: maximum iterations=48; energy convergence= $5 \times 10^{-5} E_h$; RMS density matrix change= 5×10^{-6} ; SCF level shift 0.2 E_h

Homology modeling.

The sequence of human Kv7.2 (Swiss-Prot accession code O43526.2) was downloaded from the NCBI sequence database), and the region of our interest (residues 219-325) was extracted and aligned, using ClustalW,⁴⁹ to the CryoEM structure of Xenopus KCNQ1 channel (PDB id: 5VMS⁵⁰ – Score: 152 bits – Expect: 1e-44 – Identities: 70/112 – Positives 88/112 – Gaps: 5/112). Kv7.2₂₁₉₋₃₂₅ was modeled, as a homo-tetramer, by homology with the biological assembly 1 of 5VMS, using the energy-based method implemented in Prime.⁵¹ Side chains were optimized, with the exception of those belonging to conserved residues, whose rotamers were retained from the template structure. Residues not obtained from the templates were minimized. Residue deletions caused by query gaps were closed. No further optimization was carried on.

Photochemical Stability assay.

Compounds were dissolved in DMSO and then diluted in buffered aqueous solutions at pH 7.4 to a final concentration of 1 mM, 10 μ M and 1 μ M. 1cm quartz cells, filled with the above mentioned solutions were irradiated under natural daylight, or maintained at 37°C and irradiated by an UV lamp at 365 and 264 nm wavelength or an artificial daylight D65 lamp (Philips, Amsterdam, Nederland) inside a black box UV analyser. Control samples were maintained at 37°C and wrapped by aluminium foils to avoid light exposure. At predetermined intervals aliquots were withdrawn and analysed by HPLC (see below) in order to assess the concentration decrease of the starting materials.

***In vitro* drug metabolism using human liver microsomes**

2 μ L of Retigabine, **23a** and **24a** (1 mM) were incubated with 183 μ L of 100 mM phosphate buffer (pH 7.4), and 5 μ L of 20 mg/mL pooled human liver S9 fractions (Thermo Fisher Scientific, Bremen, Germany). After pre-incubation in water bath for 5 min, the mixture was incubated with 10 μ L of the 20 mM NADPH at 37°C for 60 min in a Thermomixer comfort (Eppendorf, Hamburg, Germany). For the measurement of uridine glucuronide transferases (UGT) activity, before the incubation with NADPH, were added to the reaction mixture 5 mM of the uridine 5'-diphospho-alpha-D-glucuronic acid (UDPGA), 50 micrograms of alamethicin/mg of microsomal protein and 1 mM MgCl. For the measurement of N-acetyl transferases (NAT) activity, before the incubation with NADPH, were added to the reaction mixture 2 mM of dithiothreitol, 60 micrograms of sulfamethazine/mg of microsomal protein, 4.5 mM of acetyl DL-carnitine, 0.1 Units/mL of carnitine acetyltransferase. The mixture were incubated at 37°C for 60 min. The reactions were stopped by the addition of 200 μ L of the ice-cold methanol and then samples were centrifuged at 10,000 rpm at 25°C for 5 min (Eppendorf microcentrifuge 5424, Hamburg, Germany). The supernatants were collected and injected in RP-UHPLC-DAD

The control at 0 min was obtained by addition of the organic solvent immediately after incubation with microsomes. As the positive control were used testosterone, 7-hydroxycoumarin and p-amino benzoic acid while the negative control was prepared by incubation up to 60 min without NADPH.

The extent of metabolism is expressed as a percentage of the parent compound turnover using the following equation:

$$\% \text{ Parent compound turnover} = 100 - \left[\frac{\text{concentration at 60 min}}{\text{concentration at 0 min}} \times 100 \right]$$

Analytical instrumentations and conditions

HPLC analysis

UHPLC analyses were performed on a Nexera UHPLC system (Shimadzu, Kyoto, Japan) consisting of a CBM-20A controller, two LC-30AD pumps, a DGU-20 A_{5R} degasser, an SPD-M20A photo diode array detector, a CTO-20AC column oven, a SIL-30AC autosampler.

The separation was carried out on a Kinetex™ C18 150 × 2.1 mm × 2.6 μm (100 Å) column (Phenomenex, Bologna, Italy). The optimal mobile phase consisted of 0.1% TFA/H₂O v/v (A) and 0.1% TFA/ACN v/v (B). Analysis was performed in gradient elution as follows: 0–13.0 min, 5–65% B; 13–14.0 min, 65–95% B; 14–15.0 min, isocratic to 95% B; 15–15.01 min, 95–5% B; then three minutes for column re-equilibration. Flow rate was 0.5 mL min⁻¹. Column oven temperature was set to 45°C. Injection volume was 7 μL of sample. The following PDA parameters were applied: sampling rate, 12.5 Hz; detector time constant, 0.160 s; cell temperature, 40°C. Data acquisition was set in the range 190–800 nm and chromatograms were monitored at 254 nm. To avoid overlapping of the compounds peak with the acetonitrile bump, derivatives **33a** and **33b** were analyzed using a Kinetex™ C8 150 × 2.1 mm × 2.6 μm (100 Å) column (Phenomenex, Bologna, Italy) using the following gradient elution: 0.01-13.00 min, 5-65% B; 13.01-14.00 min 65-95% B; 14.01-15.00 min, 95% isocratic B; and finally 5 minutes for column re-equilibration.

1
2
3 The calibration curves of were obtained in a concentration range of 10-0.6 μM with five concentration
4 levels and triplicate injection of each level were run. Peak areas were plotted against corresponding
5 concentrations and the linear regression was used to generate calibration curve (**retigabine**: $y =$
6 $0.00012x + 0.16116$, $R^2 = 0.9995$; **8a** $y = 0.00008x + 0.03642$, $R^2 = 0.9993$; **13a** $y = 0.00008x +$
7 0.06438 , $R^2 = 0.9995$; **13d** $y = 0.00007x + 0.09685$, $R^2 = 0.9994$; **23a**: $y = 0.00005x + 0.03559$, $R^2 =$
8 0.9999 ; **23c** $y = 0.00008x + 0.08246$, $R^2 = 0.9996$; **24a**: $y = 0.00005x + 0.07188$, $R^2 = 0.9998$).

16 **HPLC/MS analysis**

17
18 HPLC/MS analyses were conducted interfacing the UHPLC system described above with an IT-TOF
19 hybrid mass spectrometer (Ion Trap-Time of Flight) equipped with an electrospray source (ESI)
20 (Shimadzu, Kyoto, Japan). The LC-MS/MS data were processed by the LCMSsolution® software
21 (Version 3.50.346, Shimadzu). In detail, the analysis were conducted using a Kinetex® EVO C18
22 150×2.1 mm (100 Å) column, having a 2.6 μm core shell particulate (Phenomenex, Bologna, Italy).
23 The flow of the mobile phases was set at 0.5 mL/min and the oven temperature was set at 45°C. The
24 injection volume was 2 μL . The analysis were carried out employing as mobile phase: A) 10mM
25 HCOONH_4 in H_2O (pH=6.3) and B) ACN using the following elution gradient: 0.01-20.00 min, 5-
26 95% B; 20.01-22.00 min, 95% isocratic B; and finally 5 minutes for column re-equilibration. Data
27 acquisition was set in the range 190–800 nm and chromatograms were monitored at 254 nm and 550
28 nm. MS detection was operated in positive ionization mode with the following parameters: 1.75 kV;
29 CDL (curve desolvation line) temperature, 250°C; block heater temperature, 250°C; nebulizing gas
30 flow (N_2), 1.5 L/min; drying gas pressure, 98 kPa. Full scan MS data were acquired in the range of
31 150–2000 m/z (ion accumulation time, 25 ms; IT, repeat = 3). MS/MS experiments were conducted
32 in data dependent acquisition, precursor ions were acquired in the range 150–2000 m/z; peak width,
33 3 Da; ion accumulation time, 50 ms; CID energy, 55%; collision gas, 50%; repeat = 1; execution
34 trigger (BPC) intensity, at 70% stop level.

57 **GC/MS analysis**

GC-MS analysis were performed on Shimadzu GC-2010 Plus gas chromatograph coupled to a 2010 Plus single quadrupole mass spectrometer (Shimadzu Corp., Kyoto, Japan). Chromatographic separation was carried out on an CP-Sil 8 CB fused silica capillary GC column (30 m × 0.25 mm i.d, 1.0 μm film thickness, Agilent, Santa Clara, CA). The operating conditions of GC were: Helium (purity > 99.9999%) was used as carrier gas at linear velocity of 39 cm/s, 2 μL of sample was injected in splitless mode via autosampler (AOC-20s), and injector temperature (AOC-20i) was 280 °C. Oven temperature was programmed as follows: started from 100 °C (hold for 1 min), increased to 320 °C at the rate of 6 °C/min (hold for 2 min). The mass spectrometer was operated in electron-impact mode with 70 eV electrons. Interface and ion source temperatures were set at 320 °C and 200 °C, respectively. The quadrupoles were operated in scan mode over the *m/z* range of 35–600 *m/z* with a solvent cut time of 2.9 min. The complete GC program duration was 40 min.

Cell Culture and Transient Transfection.

Channel subunits were expressed in Chinese Hamster Ovary (CHO) cells by transient transfection, using plasmids containing cDNAs encoding human Kv7.1, Kv7.2, Kv7.3, and Kv7.4, all cloned in pcDNA3.1 vector. According to the experimental protocol, these plasmids were expressed individually or in combination, together with a plasmid-expressing enhanced green fluorescent protein (Clontech, Palo Alto, CA) used as a transfection marker. Total cDNA in the transfection mixture was kept at 4 μg. CHO cells were grown in 100-mm plastic Petri dishes in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum, nonessential amino acids (0.1 mM), penicillin (50 U/ml), and streptomycin (50 mg/ml) in a humidified atmosphere at 37°C with 5% CO₂. At 24 hours before transfection, the cells were plated on glass coverslips coated with poly-L-lysine, and were transfected on the next day with the appropriate cDNA using Lipofectamine 2000 (Life Technologies), according to the manufacturer's protocol. Electrophysiologic experiments were performed 24 hours after transfection.

Whole-cell electrophysiology.

Currents from CHO cells were recorded at room temperature (20–22°C) using the whole-cell configuration of the patch-clamp technique, with glass micropipettes of 3-5 MΩ resistance. During the recording, constant perfusion of extracellular solution was maintained. The extracellular solution contained (in mM): 138 NaCl, 2 CaCl₂, 5.4 KCl, 1 MgCl₂, 10 glucose, and 10 HEPES, at pH 7.4, with NaOH. The pipette (intracellular) solution contained (in mM): 140 KCl, 2 MgCl₂, 10 EGTA, 10 HEPES, 5 Mg²⁺-ATP, at pH 7.3-7.4, with KOH. Current were recorded using an Axopatch-200A amplifier, filtered at 5 kHz, and digitized using a DigiData 1440A (Molecular Devices). The pCLAMP software (version 10.2) was used for data acquisition and analysis (Molecular Devices). To evaluate the activity of each compound on Kv7.2 currents, the cells were clamped at -80 mV and currents were elicited by 3-s voltage ramps from -80 mV to +20 mV in the presence and absence of each compound.

The ΔV values, calculated as membrane potentials at which currents reached 20% of their peak value for controls and after drug exposure, were plotted versus log(concentration) of the compound, fitted to a four parameter logistic equation and EC₅₀ values were calculated with SigmaPlot (version 12.3). Indicated EC₅₀ values are the mean of at least three independent experiments ± standard deviation (SD).

CMC determination using fluorescence spectroscopy

A stock solution of compounds 23a and 24a and retigabine was prepared in DMSO. These solutions were, then, diluted in 0.9% w/v NaCl to obtain the tested concentrations in the range 0.7-100 μM. Residual DMSO was below 0.1% v/v in all tested concentration. Pyrene (Sigma Aldrich, Italy) was used as fluorescent probe. Pyrene spectra in presence of different concentrations of these compounds were recorded in the range between 200 nm and 700 nm with a 2.5 nm slits after excitation at 334 nm. Each recorded spectrum was the sum of ten acquisition. Analyses were performed at 25 °C using a Fluorescence Spectrometer LS 55 (PerkinElmer, Waltham, USA) equipped with a thermostatic bath

1
2
3 (HAAKE C25P). The ratio of peak intensity I ($\lambda=372$ nm) and peak intensity III ($\lambda=383$ nm) of the
4
5 emission spectrum of pyrene was plotted against concentrations. Data were the mean \pm standard
6
7 deviation of at least three independent measurements.
8
9
10
11
12
13
14
15
16

17 **Statistical analysis**

18
19 Statistically significant differences in electrophysiological data were evaluated with the Student t-
20
21 test, or with ANOVA followed by the Student- Newman-Keuls test when multiple groups were
22
23 compared, with the threshold set at $P < 0.05$. Data were analyzed using the Sigma Plot 12.3 for
24
25 Windows (Systat Software Inc, San Jose, CA). Values are expressed as the mean \pm standard deviation
26
27 of at least 3 cells recorded in at least 2 independent transfections as the mean \pm standard deviation of
28
29 three independent measurements
30
31
32
33
34

35 **ASSOCIATED CONTENT**

36
37
38 The Supporting Information is available free of charge on the ACS Publications website at DOI:

39
40
41 **Figure S1.** Relative potential energies for the rotation of the bond connecting the hydrogen bond
42
43 donor group to the hydrogen bond acceptor; **Table S1:** Relative electrostatic potential and relative
44
45 electron densities surfaces of the linker moieties N-X; **Table S2:** Effect of tested compounds on ramp-
46
47 evoked currents of Kv 7.2; **Figure S2.** CMC fluorescence measurements for **23a**, **24a** and retigabine;
48
49 **Figure S3:** Effect of retigabine and 23a on homomeric Kv7.1 channels; **Figure S4.** Superimposition
50
51 of models B (solid spheres) and C (transparent spheres); **Table S3:** Training sets of models A, B and
52
53 C; **Figure S5.** UHPLC profile of a retigabine batch after 6h visible light irradiation; **Figure S6.** Full
54
55 scan, MS/MS and predicted structure of a retigabine photooxidative byproduct; **Figure S7.** Retigabine
56
57 GC/MS profile; **Figure S8.** Overlapping HPLC traces of a 4-fluorobenzaldehyde standard solution
58
59
60

1
2
3 and a photodegraded retigabine batch; **Figure S9**. MS/MS profile for unknown compound #1 and the
4 corresponding putative molecular structures; **Figure S10**. HPLC, GC and MS profile for compound **8a**
5 after the photodegradation assay. **Figures S11-S12**. Blank RP-HPLC trace of the analytical method
6 used for purity determination; **NMR spectra** of synthesized compounds, **RP-HPLC traces** of
7 synthesized compounds (pdf). **Molecular Formula Strings** (CSV file)
8
9
10
11
12
13

14 **AUTHOR INFORMATION**

16 **Corresponding Authors**

17
18 * Pietro Campiglia, pcampiglia@unisa.it
19

20
21
22 * Maurizio Tagliatela, mtagliat@unina.it
23
24
25

26 **Author Contributions**

27
28 The manuscript was written through contributions of all authors. All authors have given approval to
29 the final version of the manuscript. # These authors contributed equally.
30
31
32
33

34 **Funding Sources**

35
36 The present work was also supported by the Telethon Foundation (grant number GGP15113) to MT,
37 the Italian Ministry for University and Research (MIUR) (PRIN 2017ALCR7C) to MT, MVS and
38 MM, MIUR (Projects Scientific Independence of Researchers 2014 RBSI1444EM and PRIN
39 2017YH3SXX) to FM, the University of Naples “Federico II” and Compagnia di San Paolo in the
40 frame of Program STAR “Sostegno Territoriale alle Attività di Ricerca” (project number 6-
41 CSPUNINA-120) to FM, and the Italian Ministry of Health (Project GR-2016-02363337) to MVS.
42
43
44
45
46
47
48
49
50
51
52
53

54 **ACKNOWLEDGMENT**

55
56 NVIDIA Corporation is gratefully acknowledged for its support with the donation of the Tesla K40
57 GPU used for this research. The authors thank Prof. Thomas J. Jentsch (Max-Delbrück-Center for
58
59
60

1
2
3 Molecular Medicine, Berlin, Germany) for Kv7.2, Kv7.3, Kv7.4, and Kv7.5 cDNAs in pcDNA3.1;
4
5 Prof. Mark Shapiro (University of Texas Health Science Center, San Antonio, TX) for Kv7.5 cDNA
6
7 in pcDNA3zeo; and Dr. Eckhard Ficker (Rammelkamp Center, Cleveland, OH) for Kv7.1 cDNA.
8
9
10
11
12
13
14
15
16

17 ABBREVIATIONS USED

18
19
20 DIPEA, diisopropylethylamine. TEA, triethylamine. CHO, Chinese hamster ovary cells. RET,
21
22 retigabine. APCI, atmospheric pressure chemical ionization. RP-HPLC, reverse phase-HPLC. PDA,
23
24 photodiode array. MOMCl, methoxymethyl chloride. ACN, acetonitrile. HEPES, 4-(2-
25
26 hydroxyethyl)-1-piperazineethanesulfonic acid; EGTA, ethylene glycol tetraacetic acid.
27
28
29
30
31

32 REFERENCES

- 33
34
35 1. Kwan, P.; Brodie, M.J., Early identification of refractory epilepsy. *N Engl J Med* **2000**, *342*,
36
37 314-319
38
39
40 2. Soldovieri, M. V.; Miceli, F.; Tagliatela, M., Driving with no brakes: molecular
41
42 pathophysiology of Kv7 potassium channels. *Physiology (Bethesda)* **2011**, *26* (5), 365-376.
43
44
45 3. Miceli, F.; Soldovieri, M.V.; Ambrosino, P.; Manocchio, L.; Mosca, I.; Tagliatela, M.,
46
47 Pharmacological targeting of neuronal Kv7.2/3 channels: a focus on chemotypes and receptor sites.
48
49 *Curr Med Chem* **2018**, *25* (23), 2637-2660.
50
51
52 4. Main, M. J.; Cryan, J. E.; Dupere, J. R.; Cox, B.; Clare, J. J.; Burbidge, S. A., Modulation of
53
54 KCNQ2/3 potassium channels by the novel anticonvulsant retigabine. *Mol Pharmacol* **2000**, *58* (2),
55
56 253-262.
57
58
59 5. (a) Kim, R. Y.; Yau, M. C.; Galpin, J. D.; Seebohm, G.; Ahern, C. A.; Pless, S. A.; Kurata, H.
60
T., Atomic basis for therapeutic activation of neuronal potassium channels. *Nat Commun* **2015**, *6*,

- 1
2
3 8116; (b) Schenzer, A.; Friedrich, T.; Pusch, M.; Saftig, P.; Jentsch, T. J.; Grotzinger, J.; Schwake,
4
5 M., Molecular determinants of KCNQ (Kv7) K⁺ channel sensitivity to the anticonvulsant retigabine.
6
7 *J Neurosci* **2005**, *25* (20), 5051-5060; (c) Wuttke, T. V.; Seebohm, G.; Bail, S.; Maljevic, S.; Lerche,
8
9 H., The new anticonvulsant retigabine favors voltage-dependent opening of the Kv7.2 (KCNQ2)
10
11 channel by binding to its activation gate. *Mol Pharmacol* **2005**, *67* (4), 1009-1017.
- 12
13
14 6. Barrese, V.; Miceli, F.; Soldovieri, M. V.; Ambrosino, P.; Iannotti, F. A.; Cilio, M. R.;
15
16 Tagliatela, M., Neuronal potassium channel openers in the management of epilepsy: role and
17
18 potential of retigabine. *Clin Pharmacol* **2010**, *2*, 225-236.
- 19
20
21 7. Zhou, P.; Zhang, Y.; Xu, H.; Chen, F.; Chen, X.; Li, X.; Pi, X.; Wang, L.; Zhan, L.; Nan, F.;
22
23 Gao, Z., P-retigabine: an N-propargyld retigabine with improved brain distribution and enhanced
24
25 antiepileptic activity. *Mol Pharmacol* **2015**, *87* (1), 31-38.
- 26
27
28 8. Jankovic, S.; Ilickovic, I., The preclinical discovery and development of ezogabine for the
29
30 treatment of epilepsy. *Expert Opin Drug Discov* **2013**, *8* (11), 1429-1437.
- 31
32
33 9. (a) Kumar, M.; Reed, N.; Liu, R.; Aizenman, E.; Wipf, P.; Tzounopoulos, T., Synthesis and
34
35 evaluation of potent KCNQ2/3-specific channel activators. *Mol Pharmacol* **2016**, *89* (6), 667-677;
36
37 (b) Bock, C.; Link, A., How to replace the lost keys? Strategies toward safer KV7 channel openers.
38
39 *Future Med Chem* **2019**, *11* (4), 337-355.
- 40
41
42 10. (a) Manville, R.W.; Abbott, G.W., Ancient and modern anticonvulsants act synergistically in
43
44 a KCNQ potassium channel binding pocket. *Nat Commun* **2018**, *9* (1), 3845; (b) Manville, R.W.;
45
46 Abbott, G.W., In silico re-engineering of a neurotransmitter to activate KCNQ potassium channels in
47
48 an isoform-specific manner. *Commun Biol* **2019**, *2*, 401; (c) Liu, R.; Tzounopoulos, T.; Wipf, P.
49
50 Synthesis and Optimization of Kv7 (KCNQ) Potassium Channel Agonists: The Role of Fluorines in
51
52 Potency and Selectivity. *ACS Med Chem Lett* **2019**, *10* (6), 929-935.
- 53
54
55 11. Vernier, J.M.; Chen, H.; Song, J. Derivatives of 5-Amino-4,6-Disubstituted Indole and 5-
56
57 Amino-4,6-Disubstituted Indoline as Potassium Channel Modulators. WO2009023677, 2009;
58
59 Valeant Pharmaceuticals (US)
60

- 1
2
3 12. (a) Fang, Z.; Song, Y.; Zhan, P.; Zhang, Q.; Liu, X., Conformational restriction: an effective
4 tactic in 'follow-on'-based drug discovery. *Future Med Chem* **2014**, *6* (8), 885-901; (b) Hempel, R.;
5
6 Schupke, H.; McNeilly, P. J.; Heinecke, K.; Kronbach, C.; Grunwald, C.; Zimmermann, G.;
7
8 Griesinger, C.; Engel, J.; Kronbach, T., Metabolism of retigabine (D-23129), a novel anticonvulsant.
9
10 *Drug Metab Dispos* **1999**, *27* (5), 613-622.
11
12
13
14
15 13. Ulmschneider, S.; Muller-Vieira, U.; Klein, C. D.; Antes, I.; Lengauer, T.; Hartmann, R. W.,
16
17 Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally
18
19 modified derivatives: potent and selective inhibitors of aldosterone synthase. *J Med Chem* **2005**, *48*
20
21 (5), 1563-1575.
22
23
24 14. (a) Wang, L.; Qiao, G.-H.; Hu, H.-N.; Gao, Z.-B.; Nan, F.-J., Discovery of novel retigabine
25
26 derivatives as potent KCNQ4 and KCNQ5 channel agonists with improved specificity. *ACS Med*
27
28 *Chem Lett* **2019**, *10* (1), 27-33; (b) Hu, H.-N.; Zhou, P.-Z.; Chen, F.; Li, M.; Nan, F.-J.; Gao, Z.-B.,
29
30 Discovery of a retigabine derivative that inhibits KCNQ2 potassium channels. *Acta Pharmacol Sin*
31
32 **2013**, *34*(10), 1359-1366.
33
34
35 15. Tatulian, L.; Delmas, P.; Abogadie, F. C.; Brown, D. A., Activation of expressed KCNQ
36
37 potassium currents and native neuronal M-type potassium currents by the anti-convulsant drug
38
39 retigabine. *J Neurosci* **2001**, *21* (15), 5535-5545.
40
41
42 16. Wickenden, A. D.; Yu, W.; Zou, A.; Jegla, T.; Wagoner, P. K., Retigabine, a novel anti-
43
44 convulsant, enhances activation of KCNQ2/Q3 potassium channels. *Mol Pharmacol* **2000**, *58* (3),
45
46 591-600.
47
48
49 17. (a) Martire, M.; Castaldo, P.; D'Amico, M.; Preziosi, P.; Annunziato, L.; Tagliatela, M., M
50
51 channels containing KCNQ2 subunits modulate norepinephrine, aspartate, and GABA release from
52
53 hippocampal nerve terminals. *J Neurosci* **2004**, *24*, 592-597. (b) Blom, S.M.; Schmitt, N.; Jensen,
54
55 H.S., Differential effects of ICA-27243 on cloned K(V)7 channels. *Pharmacology* **2010**, *86*, 174-181.
56
57
58 18. (a) Winnik, F.M., Photophysics of preassociated pyrenes in aqueous polymer solutions and in
59
60 other organized media. *Chem Rev* **1993**, *93* (2), 2587-614; (b) Salonen, A.; Knyazev, A.; von Bandel,

- 1
2
3 N.; Degrouard, J.; Langevin, D.; Drenckhan, W., A Novel Pyrene-Based Fluorescing Amphiphile
4 with Unusual Bulk and Interfacial Properties. *ChemPhysChem* **2011**, *12* (1), 150-160.
5
6
7
8 19. (a) Padilla, K.; Wickenden, A.D.; Gerlach, A.C.; McCormack, K., The KCNQ2/3 selective
9 channel opener ICA-27243 binds to a novel voltage-sensor domain site. *Neurosci Lett* **2009**, *465*,
10 138-142. (b) Wang, A.W.; Yang, R.; Kurata, H.T., Sequence determinants of subtype-specific actions
11 of KCNQ channel openers. *J Physiol* **2017**, *595*, 663-676.
12
13
14
15
16
17 20. (a) Dixon, S. L.; Smondyrev, A. M.; Knoll, E. H.; Rao, S. N.; Shaw, D. E.; Friesner, R. A.,
18 PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D
19 database screening: 1. Methodology and preliminary results. *J Comput Aid Mol Des* **2006**, *20* (10-
20 11), 647-671; (b) Dixon, S. L.; Smondyrev, A. M.; Rao, S. N., PHASE: a novel approach to
21 pharmacophore modeling and 3D database searching. *Chem Biol Drug Des* **2006**, *67* (5), 370-372.
22
23
24
25
26
27
28 21. Manville, R. W.; Papanikolaou, M.; Abbott, G. W., Direct neurotransmitter activation of
29 voltage-gated potassium channels. *Nat Commun* **2018**, *9* (1), 1847.
30
31
32
33 22. Dousa, M.; Srbek, J.; Radl, S.; Cerny, J.; Klecan, O.; Havlicek, J.; Tkadlecova, M.; Pekarek,
34 T.; Gibala, P.; Novakova, L., Identification, characterization, synthesis and HPLC quantification of
35 new process-related impurities and degradation products in retigabine. *J Pharm Biomed Anal* **2014**,
36 *94*, 71-76.
37
38
39
40
41
42 23. Meyer, A.; Fischer, K., Oxidative transformation processes and products of para-
43 phenylenediamine (PPD) and para-toluenediamine (PTD)—a review. *Environ Sci Eur* **2015**, *27* (1),
44 11.
45
46
47
48
49 24. Groseclose, M. R.; Castellino, S., An investigation into retigabine (ezogabine) associated
50 dyspigmentation in rat eyes by MALDI imaging mass spectrometry. *Chem Res Toxicol* **2019**, *32* (2),
51 294-303.
52
53
54
55
56 25. (a) Lai, J.; Chang, L.; Yuan, G., I₂/TBHP Mediated C–N and C–H bond cleavage of tertiary
57 amines toward selective synthesis of sulfonamides and β -arylsulfonyl enamines: the solvent effect on
58 reaction. *Org Lett* **2016**, *18*, 3194–3197; (b) Gong, J.L.; Qi, X.; Wei, D.; Feng, J.B.; Wu X.F.,
59
60

- 1
2
3 Oxidative cleavage of benzylic C–N bonds under metal-free conditions. *Org Biomol Chem* **2014**, *12*,
4 7486–7488; (c) Yang, Z.K.; Xu, N.X.; Wang, C.; Uchiyama, M., Photoinduced C(sp₃)-N bond
5
6 7486–7488; (c) Yang, Z.K.; Xu, N.X.; Wang, C.; Uchiyama, M., Photoinduced C(sp₃)-N bond
7
8 cleavage leading to the stereoselective syntheses of alkenes. *Chem Eur J* **2019**, *25*, 5433 – 5439
9
- 10 26. (a) Boger, D. L.; Zarrinmayeh, H., Regiocontrolled nucleophilic addition to selectively
11
12 activated p-quinone diimines: alternative preparation of a key intermediate employed in the
13
14 preparation of the CC-1065 left-hand subunit. *J Org Chem* **1990**, *55* (4), 1379-1390; (b) Boger, D.
15
16 L.; Coleman, R. S., Total synthesis of (+)-CC-1065 and ent-(-)-CC-1065. *J Am Chem Soc* **1988**, *110*
17
18 (4), 1321-1323.
19
- 20
21 27. Hubbard, T. D.; Murray, I. A.; Perdew, G. H., Indole and tryptophan metabolism: endogenous
22
23 and dietary routes to Ah receptor activation. *Drug Metab Dispos* **2015**, *43* (10), 1522-1535.
24
25
- 26 28. Lewis, D. F.; Jacobs, M. N.; Dickins, M., Compound lipophilicity for substrate binding to
27
28 human P450s in drug metabolism. *Drug Discov Today* **2004**, *9* (12), 530-537.
29
- 30 29. (a) Borlak, J.; Gasparic, A.; Locher, M.; Schupke, H.; Hermann, R., N-Glucuronidation of the
31
32 antiepileptic drug retigabine: results from studies with human volunteers, heterologously expressed
33
34 human UGTs, human liver, kidney, and liver microsomal membranes of Crigler-Najjar type II. *Metab*
35
36 *Clin Exp* **2006**, *55* (6), 711-721; (b) Perez, H. L.; Boram, S. L.; Evans, C. A., Development and
37
38 validation of a quantitative method for determination of retigabine and its N-acetyl metabolite;
39
40 overcoming challenges associated with circulating labile N-glucuronide metabolites. *Anal Methods*
41
42 **2015**, *7* (2), 723-735.
43
44
- 45
46 30. Jentsch, T. J.; Schroeder, B. C.; Kubisch, C.; Friedrich, T.; Stein, V., Pathophysiology of
47
48 KCNQ channels: neonatal epilepsy and progressive deafness. *Epilepsia* **2000**, *41* (8), 1068-1069.
49
- 50
51 31. Munro, G.; Dalby-Brown, W., Kv7 (KCNQ) channel modulators and neuropathic pain. *J Med*
52
53 *Chem* **2007**, *50* (11), 2576-2582.
54
- 55
56 32. Wainger, B. J.; Kiskinis, E.; Mellin, C.; Wiskow, O.; Han, S. S.; Sandoe, J.; Perez, N. P.;
57
58 Williams, L. A.; Lee, S.; Boulting, G.; Berry, J. D.; Brown, R. H., Jr.; Cudkowicz, M. E.; Bean, B.
59
60

1
2
3 P.; Eggan, K.; Woolf, C. J., Intrinsic membrane hyperexcitability of amyotrophic lateral sclerosis
4 patient-derived motor neurons. *Cell Rep* **2014**, *7* (1), 1-11.

5
6
7
8 33. (a) Korsgaard, M. P.; Hartz, B. P.; Brown, W. D.; Ahring, P. K.; Strobaek, D.; Mirza, N. R.,
9 Anxiolytic effects of Maxipost (BMS-204352) and retigabine via activation of neuronal Kv7
10 channels. *J Pharmacol Exp Ther* **2005**, *314* (1), 282-292; (b) Dencker, D.; Dias, R.; Pedersen, M. L.;
11 Husum, H., Effect of the new antiepileptic drug retigabine in a rodent model of mania. *Epilepsy*
12 *Behav* **2008**, *12* (1), 49-53; (c) Delmas, P.; Brown, D. A., Pathways modulating neural KCNQ/M
13 (Kv7) potassium channels. *Nat Rev Neurosci* **2005**, *6* (11), 850-862.

14
15
16
17
18
19
20
21 34. (a) Lange, W.; Geissendorfer, J.; Schenzer, A.; Grotzinger, J.; Seebohm, G.; Friedrich, T.;
22 Schwake, M., Refinement of the binding site and mode of action of the anticonvulsant Retigabine on
23 KCNQ K⁺ channels. *Mol Pharmacol* **2009**, *75* (2), 272-280; (b) Manville, R. W.; Abbott, G. W.,
24 Gabapentin is a potent activator of KCNQ3 and KCNQ5 potassium channels. *Mol Pharmacol* **2018**,
25 *94* (4), 1155-1163.

26
27
28
29
30
31
32 35. Kalappa, B. I.; Soh, H.; Duignan, K. M.; Furuya, T.; Edwards, S.; Tzingounis, A. V.;
33 Tzounopoulos, T., Potent KCNQ2/3-specific channel activator suppresses in vivo epileptic activity
34 and prevents the development of tinnitus. *J Neurosci* **2015**, *35* (23), 8829-8842.

35
36
37
38
39
40 36. (a) Surur, A. S.; Bock, C.; Beirow, K.; Wurm, K.; Schulig, L.; Kindermann, M. K.; Siegmund,
41 W.; Bednarski, P. J.; Link, A., Flupirtine and retigabine as templates for ligand-based drug design of
42 KV7.2/3 activators. *Org Biomol Chem* **2019**, *17*, 4512-4522; (b) Bock, C.; Surur, A. S.; Beirow, K.;
43 Kindermann, M. K.; Schulig, L.; Bodtke, A.; Bednarski, P. J.; Link, A., Sulfide analogues of flupirtine
44 and retigabine with nanomolar KV 7.2/KV 7.3 channel opening activity. *ChemMedChem* **2019**, *14*
45 (9), 952-964.

46
47
48
49
50
51
52
53 37. Musella, S.; di Sarno, V.; Ciaglia, T.; Sala, M.; Spensiero, A.; Scala, M. C.; Ostacolo, C.;
54 Andrei, G.; Balzarini, J.; Snoeck, R.; Novellino, E.; Campiglia, P.; Bertamino, A.; Gomez-Monterrey,
55 I. M., Identification of an indol-based derivative as potent and selective varicella zoster virus (VZV)
56 inhibitor. *Eur J Med Chem* **2016**, *124*, 773-781.
57
58
59
60

- 1
2
3 38. Bertamino, A.; Iraci, N.; Ostacolo, C.; Ambrosino, P.; Musella, S.; Di Sarno, V.; Ciaglia, T.;
4
5 Pepe, G.; Sala, M.; Soldovieri, M. V.; Mosca, I.; Gonzalez-Rodriguez, S.; Fernandez-Carvajal, A.;
6
7 Ferrer-Montiel, A.; Novellino, E.; Tagliatela, M.; Campiglia, P.; Gomez-Monterrey, I.,
8
9 Identification of a potent tryptophan-based TRPM8 antagonist with in vivo analgesic activity. *J Med*
10
11 *Chem* **2018**, 61 (14), 6140–6152
12
13
14 39. Quast, H.; Ross, K.-H.; Philipp, G.; Hagedorn, M.; Hahn, H.; Banert, K., Syntheses and ¹⁵N
15
16 NMR spectra of iminodiaziridines - ring-expansions of 1-aryl-3-iminodiaziridines to 1H- and 3aH-
17
18 benzimidazoles, 2H-indazoles, and 5H-dibenzo[d,f][1,3]diazepines. *Eur J Org Chem* **2009**, 23, 3940-
19
20 3952.
21
22
23 40. Plsikova, J.; Janovec, L.; Koval, J.; Ungvarsky, J.; Mikes, J.; Jendzelovsky, R.; Fedorocko,
24
25 P.; Imrich, J.; Kristian, P.; Kasarkova, J.; Brabec, V.; Kozurkova, M., 3,6-Bis(3-
26
27 alkylguanidino)acridines as DNA-intercalating antitumor agents. *Eur J Med Chem* **2012**, 57, 283-
28
29 295.
30
31
32 41. Bertamino, A.; Ostacolo, C.; Ambrosino, P.; Musella, S.; Di Sarno, V.; Ciaglia, T.; Soldovieri,
33
34 M. V.; Iraci, N.; Fernandez Carvajal, A.; de la Torre-Martinez, R.; Ferrer-Montiel, A.; Gonzalez
35
36 Muniz, R.; Novellino, E.; Tagliatela, M.; Campiglia, P.; Gomez-Monterrey, I., Tryptamine-based
37
38 derivatives as transient receptor potential melastatin type 8 (TRPM8) channel modulators. *J Med*
39
40 *Chem* **2016**, 59 (5), 2179-2191.
41
42
43 42. Thuo, M. M.; Reus, W. F.; Nijhuis, C. A.; Barber, J. R.; Kim, C.; Schulz, M. D.; Whitesides,
44
45 G. M., Odd-even effects in charge transport across self-assembled monolayers. *J Am Chem Soc* **2011**,
46
47 133 (9), 2962-2975
48
49
50 43. Madabhushi, S.; Jillella, R.; Sriramoju, V.; Singh, R., Oxyhalogenation of thiols and disulfides
51
52 into sulfonyl chlorides/bromides using oxone-KX (X = Cl or Br) in water. *Green Chem.* **2014**, 16 (6),
53
54 3125-3131
55
56
57 44. Maestro, S. R.-. *Schrödinger, LLC*, New York, NY, 2018.
58
59
60 45. LigPrep, S. R.-. *Schrödinger, LLC*, New York, NY, 2018.

- 1
2
3 46. MacroModel, S. R.-. *Schrödinger, LLC*, New York, NY, 2018.
- 4
5 47. Jorgensen, W. L.; Maxwell, D. S.; TiradoRives, J., Development and testing of the OPLS all-
6 atom force field on conformational energetics and properties of organic liquids. *J Am Chem Soc* **1996**,
7 *118* (45), 11225-11236.
- 8
9
10
11 48. Bochevarov, A.D.; Harder, E.; Hughes, T.F.; Greenwood, J.R.; Braden, D.A.; Philipp, D.M.;
12 Rinaldo, D.; Halls, M.D.; Zhang, J.; Friesner, R.A., Jaguar: A high-performance quantum chemistry
13 software program with strengths in life and materials sciences. *Int. J. Quantum Chem.*, **2013**, 113(18),
14 2110-2142.
- 15
16
17 49. Thompson, J. D.; Higgins, D. G.; Gibson, T. J. CLUSTAL W: improving the sensitivity of
18 progressive multiple sequence alignment through sequence weighting, position-specific gap penalties
19 and weight matrix choice. *Nucleic Acids Res* **1994**, 22 (22), 4673–4680.
- 20
21
22 50. Sun, J.; MacKinnon. R., Cryo-EM structure of a KCNQ1/CaM complex reveals insights into
23 congenital long QT syndrome. *Cell* **2017**, 169 (6), 1042-1050.e9
- 24
25
26 51. (a) Jacobson, M. P.; Pincus, D. L.; Rapp, C. S.; Day, T. J. F.; Honig, B.; Shaw, D. E.; Friesner,
27 R. A., A hierarchical approach to all-atom protein loop prediction. *Proteins* **2004**, 55 (2), 351-367;
28 (b) Jacobson, M. P.; Friesner, R. A.; Xiang, Z. X.; Honig, B., On the role of the crystal environment
29 in determining protein side-chain conformations. *J Mol Biol* **2002**, 320 (3), 597-608.
- 30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60






Figure 1. Structures of retigabine and its newly synthesized analogues

54x25mm (300 x 300 DPI)




Scheme 1: Synthesis of 1-(4-fluorobenzyl)-5-substituted indoline derivatives 4a-b, 5a-b, 6, 7, 8a-i and 9a-c.

89x48mm (300 x 300 DPI)




Scheme 2: Synthesis of 1-benzyl-5-cyclohexanesulfonamido indoline derivatives 13a-g.

85x35mm (300 x 300 DPI)




Scheme 3: Synthesis of 1-acyl-5-cyclohexanesulfonamido (16a-b) and 1-alkyl-5-cyclohexanesulfonamido (19) indoline derivatives.

72x31mm (300 x 300 DPI)



Scheme 4: Synthesis of 1-benzyl-5-amido (23a-25a, 23b-24b, 28a-29a) and 1-benzyl-5-cyclohexanesulfonamido (23c-23d, 26a-27a) indole derivatives.

95x60mm (300 x 300 DPI)



Scheme 5: Synthesis of (R,S)-N-(5-(4-(trifluoromethyl)benzyl)-5,6,7,8-tetrahydronaphthalen-2-yl)heptanamide (34).

88x23mm (300 x 300 DPI)




Figure 2. Effect of synthesized compounds on Kv7.2 current in comparison with retigabine. a-b. Representation of the ratio between current amplitude in the presence (A_2 , B_2) and absence (A_1 , B_1) of each of the indicated compounds ($10 \mu\text{M}$) calculated at 0 mV (a) and at -40 mV (b). The inset shows the protocol used to evaluate drug activity on Kv7.2 currents. Current scale, 400 pA ; time scale, 0.2 s . Histograms are colored according to the following scheme: blue represents available Kv7 activators, such as retigabine (RET) at 1 and $10 \mu\text{M}$, Flupirtine (FLU) at $10 \mu\text{M}$, and ICA27243 (ICA43) at $10 \mu\text{M}$; red represents indoline derivatives, yellow represents indole derivatives and green represents tetrahydronaphthalene derivatives. Each data point is expressed as the mean \pm standard error of the mean (SEM) of at least 3 cells recorded in at least 2 independent transfections; the precise number of cells included in the analysis for each compound is specified in Table S2. * indicates values significantly different ($p < 0.05$) from retigabine ($10 \mu\text{M}$).

51x29mm (300 x 300 DPI)




Figure 3. Effect of retigabine, 23a and 24a on ramp-evoked Kv7.2 current. a. Representative whole-cell current traces from Kv7.2 channels activated by the indicated ramp protocol recorded in control conditions and upon exposure to 0.01-10 μM retigabine (RET), 23a and 24a. b. Time courses of Kv7.2 current potentiation by retigabine (RET), 23a and 24a. The steady-state amplitudes of the peak currents at -40 mV were plotted as a function of time. The bars on top of the plot indicate the duration of drug application. Current scale, 200 pA; time scale, 0.2 s. c. Protocol used to calculate ΔV (V_2-V_1) at 20% of current peak value for controls (V_1) and after RET exposure (V_2). d. Dose-response curve for RET-, 23a-, and 24a-induced ΔV shift.

119x137mm (300 x 300 DPI)




Figure 4. Effect of retigabine and 23a on the activation curve of Kv7.2 channels expressed in CHO cells. a-b. Representative macroscopic current traces recorded from a CHO cell expressing Kv7.2 homomeric channels in response to the indicated voltage protocol before (left) and after (right) application of 0.03 μ M RET (a) and 23a (b). Current scale, 100 pA; time scale, 0.2 s. c. Current/voltage curves for Kv7.2 currents before and after application of RET or 23a. d. Normalized I/V curves for Kv7.2 currents before and after application of RET or 23a. Continuous lines represent fits of the experimental data to a double Boltzmann distribution.

80x49mm (300 x 300 DPI)




Figure 5. The W236 residue in Kv7.2 exerts a critical influence on 23a and 24a ability to activate Kv7.2 currents. a-b. Representative traces of whole-cell ramp-evoked currents from Kv7.2 W236L (a) and Kv7.2 F168L (b) channels upon applicatio of 10 μM retigabine (RET), ICA 27243 (ICA43), 23a and 24a. c. Quantification of the effects of the indicated compounds on Kv7.2, W236L and Kv7.2 F168L currents; data are expressed as the ratio between current amplitude at -40 mV in the presence and absence of 10 μM drugs (I_{DRUG}/I_{CTL}). Each data point is expressed as the mean ± standard error of the mean (SEM) of at least 3 cells recorded in at least 2 independent transfections. * indicates values significantly different (p < 0.05) from respective controls.

119x99mm (300 x 300 DPI)





Figure 6. Pharmacophore models developed on the basis of our novel Kv7 channel activators. Pharmacophore features are color-coded as follows: Hydrophobic (HY – cyan), Aromatic (Ar – orange), Hydrogen Bond Donor (HBD – green), Hydrogen Bond Acceptor (HBA – red). Panel a) Model A with compounds 24a and 8a depicted in magenta and cyan sticks, respectively. Panel b) Model B with compound 24a depicted in magenta sticks. Panel c) Model C with compound 8a depicted in cyan sticks. Panel d) Model D with compounds 24a and 8a depicted in magenta and cyan sticks, respectively. Retigabine is depicted as reference, in every panel, in green sticks.

40x24mm (300 x 300 DPI)



35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 7. Compounds 23a (green sticks) and 8a (cyan sticks) fitting feature HY2 (panel a) and HY3 (panel b). Pharmacophore features are color-coded as follows: Hydrophobic (HY – cyan), Aromatic (Ar – orange), Hydrogen Bond Donor (HBD – green), Hydrogen Bond Donor (HBA – red).

30x36mm (300 x 300 DPI)




Figure 8. Kv modulators binding region modeled by homology with the CryoEM structure of Xenopus KCNQ1 channel (PDB id: 5vms). W236 (magenta sticks) is surrounded by several hydrophobic residues (cyan sticks) that could host chemical features HY1 and HY2/3.

39x33mm (300 x 300 DPI)




Table of contents graphic

131x55mm (300 x 300 DPI)